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The pulsatile secretion of growth hormone (GH) by pituitary somatotrophs is 
regulated by two antagonistic hypothalamic peptides: GH-releasing hormone (GHRH) and 
somatostatin. In addition, GH release can be stimulated by synthetic GH secretagogues 
(GHSs), such as growth hormone-releasing peptide-6 (GHRP-6), by acting through receptors 
different from those for GHRH. In 1999, the endogenous ligand for this GHS-receptor was 
purified and characterized from rat and human stomach and was called ‘ghrelin’. Ghrelin has 
also been identified in the fundus of the canine stomach. The general aim of Part I of this 
thesis was to document spontaneous, GHS-, and ghrelin-induced GH release in healthy dogs 
and dogs with a pituitary disorder. In addition, ghrelin secretion was studied in healthy dogs. 
The pituitary gland is not the only site of GH production. Under the influence of 
endogenous progesterone or the administration of progestins, the canine mammary gland is 
also able to secrete considerable amounts of GH into the systemic circulation. This mammary-
derived GH is identical to pituitary GH. Part II of this thesis concentrates on several aspects 
of this progestin-induced mammary-derived GH in dogs. 
The first part of the general introduction is an overview of pituitary GH secretion and 
its regulation, and of the diverse endocrine and nonendocrine effects of synthetic GHSs and 
ghrelin (Chapter 2, part I). The second part of the general introduction (Chapter 2, part II) 
concentrates on the effects of progesterone and synthetic progestins in the bitch. 
Besides the physiological effects of several hormones on pituitary GH secretion, the 
secretion pattern of GH may also change as a result of pathological hypersecretion of 
hormones such as, for example, cortisol. In Chapter 3 and Chapter 4 the effects of pituitary-
dependent hyperadrenocorticism on the plasma GH profile and the GH response to various 
GHSs (ghrelin, GHRP-6, and GHRH) are reported. 
In humans, not only diseases such as hypercortisolism, but also ageing and obesity 
affect pituitary GH secretion and cause a reduced response to GH stimulating factors. In dogs, 
little is known about the effect of age on the plasma GH response to GH-releasing stimuli. 
Chapter 5 reports on the effects of several GHSs (ghrelin, GHRP-6, and GHRH) on the 
release of GH in young and old healthy Beagle dogs. In a search for the specificity of these 
stimulations, the effects of GHRP-6 and ghrelin administration on plasma 
adrenocorticotrophic hormone (ACTH), cortisol, thyroid-stimulating hormone (TSH), 
luteinizing hormone (LH), and prolactin (PRL) release were also studied. 
Ghrelin is a potent stimulator of GH release. The option of using ghrelin in the 
diagnosis of congenital GH deficiency was studied by measuring the effect of ghrelin 
administration on the plasma GH concentration in German shepherd dogs with pituitary 
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dwarfism. The dwarfism in German shepherd dogs is a combined pituitary hormone 
deficiency. Therefore, also the plasma concentrations of ACTH, cortisol, TSH, LH, and PRL 
were determined before and after ghrelin administration (Chapter 6). 
Through activation of pathways distinct from those involved in the stimulation of GH 
secretion, ghrelin also functions as a potent orexigenic peptide. Ghrelin induces weight gain 
by increasing food intake and reducing fat utilization. In several mammalian species it also 
plays a role in meal initiation. Chapter 7 reports on the physiological effects of food intake 
and fasting on the circulating concentrations of ghrelin, GH, glucose, insulin, and insulin-like 
growth factor-I (IGF-I) in healthy Beagle dogs.  
 
In Part II of this thesis several aspects of progestin-induced mammary-derived GH in 
dogs are presented. Cystic endometrial hyperplasia (CEH) is frequently seen in bitches treated 
repeatedly with progestins for prevention of oestrus. The condition may also develop 
spontaneously in the luteal phase of the oestrous cycle of middle-aged or elderly bitches, i.e. 
bitches that have gone through several luteal phases. Because of the similarity of the 
progestin-induced epithelial changes in both the mammary gland and the uterus, it was 
hypothesized that mammary GH is involved in the pathogenesis of progestin-induced CEH. 
Therefore, the effect of chronic administration of a synthetic progestin on the development of 
CEH was investigated in bitches with surgically excised mammary glands and in healthy 
control bitches (Chapter 8).  
It is not clear whether the oestrus-preventing properties of progestins in the bitch are 
due to effects at the level of the hypothalamus, the pituitary gland, or the ovary. In Chapter 9 
the effects of chronic administration of a synthetic progestin on adenohypophyseal function 
are reported, including the effects on the GH-IGF-I axis.  
The presence of progesterone receptors in mammary gland tissue of dogs allows for a 
targeted endocrine therapy with progesterone receptor blockers in dogs with progestin-
induced mammary-derived GH overproduction. The effects of treatment with the 
progesterone receptor blocker aglépristone in Beagle dogs with progestin-induced mammary-
derived GH excess are reported in Chapter 10. 
In Chapter 11 the results of the studies are summarized and discussed. 
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General introduction - Part I 
 
Pituitary growth hormone secretion and its regulation,  
and the diverse endocrine and nonendocrine effects 
of synthetic growth hormone secretagogues and ghrelin 
 
1. Nomenclature of the canine pituitary gland 
 According to the Nomina Anatomica Veterinaria, the canine pituitary gland is 
composed of two main parts 1) the adenohypophysis and 2) the neurohypophysis (Hullinger, 
1993). The pituitary gland is suspended from the midline of the hypothalamus by a cylindrical 
stalk. This stalk is an extension of the median eminence of the hypothalamus, and is called the 
pars proximalis neurohypophysis (also called the infundibulum). The third ventricle continues 
as an invagination into the infundibulum. The pars proximalis neurohypophysis is continuous 
with the distal enlargement, the pars distalis neuohypophysis, which is the major portion of 
the neurohypophysis (Figure 1). 
 The adenohypophysis can be divided into two functional units 1) the anterior lobe 
(pars infundibularis adenohypophysis and pars distalis adenohypophysis) and 2) the pars 
intermedia (pars intermedia adenohypophysis). In the dog, the largest portion of the anterior 
lobe (AL) lays ventrorostral to the pars distalis neurohypophysis, which is almost entirely 
surrounded by the AL. The canine AL also extends as a cuff or collar around the pars 
proximalis neurohypophysis and even envelops part of the median eminence (Figure 1). 
 The pars intermedia (PI) is in direct contact with the pars distalis neurohypophysis and 
is separated from the AL by the hypophyseal cleft or cavity, which is a remnant of the 
embryonic Rathke’s pouch. 
 The AL is populated by at least five highly differentiated types of endocrine cells, 
which are classified according to the trophic hormones they produce: somatotrophic cells 
secreting growth hormone (GH), lactotrophic cells secreting prolactin (PRL), thyrotrophic 
cells secreting thyroid-stimulating hormone (TSH), gonadotrophic cells secreting luteinizing 
hormone (LH) and follicle-stimulating hormone (FSH), and corticotrophic cells synthesizing 
the precursor molecule pro-opiomelanocortin (POMC), which gives rise to 
adrenocorticotrophic hormone (ACTH) and related peptides. Somatotrophic cells account for 
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50 % or more of the endocrine AL cells, with the other cell types each representing about 5-
15 % of the AL cell population (Rijnberk, 1996; Meij, 1997). 
 
 
 
 
Figure 1. Schematic illustration of the median sagittal section through the canine pituitary gland (adapted from 
Meij, 1997). Left is rostral, right is caudal. 1 = sphenoid bone, 2 = tuberculum sellae, 3 = dorsum sellae, 4 = 
pituitary fossa, 5 = pars distalis adenohypophysis, 6 = pars infundibularis adenohypophysis, 7 = transitional 
zone, 8 = hypophyseal cleft or cavity, 9 = pars intermedia adenohypophysis, 10 = third ventricle, 11 = 
hypothalamus (median eminence), 12 = pars proximalis neurohypophysis, 13 = pars distalis neurohypophysis. 
  
2. The hypothalamic-pituitary axis 
 The hypothalamic-pituitary axis constitutes the main axis of the neuroendocrine 
system of the body. In this axis, the pituitary is an essential regulatory interface integrating 
signals from the periphery and brain to control vital functions such as growth, reproduction, 
lactation, basal metabolism and the stress response (Treier and Rosenfeld, 1996). Hormonal 
control of pituitary gene expression and cellular proliferation is initiated during 
embryogenesis and continues through adulthood. At all stages, the cells of the pituitary have a 
remarkable ability to proliferate in response to demand for a specific hormone. 
 The hypothalamic-pituitary axis consists of three major systems: 1) a neuroendocrine 
system connected to an endocrine system by a portal circulation, 2) a neurosecretory pathway, 
and 3) a direct neural pathway that regulates endocrine secretion. The neuroendocrine system 
connects clusters of peptide- and monoamine-secreting cells in the anterior and middle 
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portion of the ventral hypothalamus to the AL (Swanson, 1987). Releasing and inhibiting 
factors such as GH-releasing hormone (GHRH), somatostatin (SS), thyrotrophin-releasing 
hormone (TRH), corticotrophin-releasing hormone (CRH), and gonadotrophin-releasing 
hormone (GnRH), are transported along nerve fibres from the hypothalamus to the median 
eminence. From the median eminence these factors are released into the capillary vessels of 
the hypothalamic-pituitary portal system and are transported to the pituitary to regulate the 
secretion of hormones from the AL (Figure 2). Specificity is achieved by the presence of 
specific receptors on individual types of AL cells. In addition to the hypothalamic 
hypophysiotrophic hormones, the secretion of AL hormones is regulated by feedback from 
target organs such as the thyroid, adrenals, and gonads (Figure 2). 
 The neurosecretory pathway is involved in osmoregulation through the production of 
vasopressin, and in parturition and nursing through the secretion of oxytocin. The two 
neurohypophyseal hormones are synthesised by populations of magnocellular neurons 
grouped in the paraventricular and supraoptic nuclei of the hypothalamus (Swanson, 1987), 
from which axons extend through the pituitary stalk and terminate in the neurohypophysis on 
fenestrated blood vessels. Vasopressin and oxytocin are stored in secretory granules within 
these nerve terminals and are released by exocytosis into the bloodstream in response to 
appropriate stimuli.  
 The pituitary PI is poorly vascularized and is directly innervated by predominantly 
dopaminergic nerve fibres from the hypothalamus. This direct neural control is mainly 
inhibitory in nature. Despite high levels of bioactive ACTH in the canine PI (Halmi et al., 
1981), the main hormone secreted by the PI is α-melanocyte-stimulating hormone (α- MSH) 
(Figure 2). 
 
3. Regulation of growth hormone secretion 
3.1 Secretion and effects of growth hormone 
 In mammals, secretion of GH from the adenohypophysis is regulated by two 
hypothalamic hormones with antagonistic actions: a stimulatory GHRH that is produced in 
the arcuate nucleus, and an inhibitory hormone, SS, synthesized in the paraventricular nucleus 
(Figure 3) (Plotsky and Vale, 1985). 
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Figure 2. Simplified diagram of the hypophysiotrophic regulation of the secretion of hormones in the 
adenohypophysis, and with some target glands. Modified from Meij (1997). 
 
Both hormones are transported from the hypothalamus to target cells in the pituitary gland via 
the hypothalamo-hypophyseal portal system in the median eminence. Alternation in secretion 
of GHRH and SS is responsible for the pulsatile pattern of GH release (Tannenbaum and 
Ling, 1984; Kooistra et al., 2000a). Measurement of GHRH and SS in hypophyseal-portal 
blood in humans and animals reveals that the episodic pattern of secretion of GHRH and SS 
does not fully account for all pulses of GH secretion (Frohman et al., 1992). The amplitude 
and frequency of GH secretory pulses are regulated by a complex array of external and 
internal stimuli, including body compostion, age, sleep, gender, disease status, menstrual 
cycle phase, genetic background, and nutritional status (Vigneri et al., 1976; Ho et al., 1988; 
Van Cauter et al., 1998). Furthermore, the secretion of GH is influenced by several hormones, 
such as progesterone, thyroid hormones, and glucocorticoids. 
 Growth hormone, a 191 amino acid single-chain polypeptide, mediates growth and 
metabolic functions through binding with the GH receptor. Growth hormone forms complexes 
with two peripheral GH-receptor components, leading to dimerization of the receptor, an 
event that is necessary for subsequent GH signalling (Hoech and Mukku, 1994). Growth 
hormone receptor dimerization elicits an intracellular phosphorylation cascade involving the 
JAK (Janus kinase)/STAT (signal transducers and activators of transcription) pathway (Xu et 
al., 1996).  
 The liver contains abundant GH receptors. Several other peripheral tissues, including 
muscle and fat, also express modest amounts of GH receptors (Barnard and Waters, 1997). In 
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contrast to most other pituitary hormones, the action of GH is not confined to a single target 
tissue and the hormone has both slow anabolic and rapid catabolic activities (Eigenmann et 
al., 1984). The catabolic effects are exerted via direct interaction with target cells, resulting in 
enhanced lipolysis in fat cells, and restriction of glucose transport across the cell membrane, 
caused by anti-insulin activity (Eigenmann et al., 1984; Casanueva, 1992; Carrel and Allen, 
2002). The anabolic effects (i.e., growth and cell proliferation) of GH are exerted indirectly, 
mainly mediated by growth factors known as insulin-like growth factors (IGFs) or 
somatomedins (Figure 3) (Daughaday et al., 1972). The liver is the primary source of 
circulating IGFs. Growth hormone also promotes the production of IGFs in peripheral tissues 
(e.g., muscle, bone, cartilage, kidney, and skin), where they appear to have autocrine and 
paracrine effects (Daughaday et al., 1972). 
 Insulin-like growth factors have approximately 50 % sequence similarity with insulin 
(Tamura et al., 1989). In contrast to free circulating insulin, IGFs are bound to plasma 
proteins, which prolongs their half-life and contributes to their long-term growth-promoting 
effects. Circulating IGFs are important determinants of body size, because they stimulate 
protein synthesis, chondrogenesis, and body growth. Insulin-like growth factor-I has an 
inhibitory effect on GH secretion, most likely by stimulating the release of SS and by a 
directly inhibitory influence at the level of the pituitary gland (Figure 3) (Ceda et al., 1987). 
Additionally, GH has a negative feedback effect on its own production at the level of the 
hypothalamus (Figure 3) (Pelligrini et al., 1996). 
  
3.2 Effects of gender and age on growth hormone secretion 
 Gender- and age-related differences in GH secretion have been established in various 
mammalian species. It appears that the sexually dimorphic pattern of GH secretion differs 
considerably between species. Before puberty, there is no apparent difference in GH secretion 
patterns between males and females in both humans (Zadik et al., 1985) and rats (Eden, 1979; 
Gabriel et al., 1992). In sheep, however, the plasma profiles of GH are already sexually 
dimorphic before puberty (Gatford et al., 1996). In humans (Zadik et al., 1985) and rats 
(Eden, 1979; Gabriel et al., 1992), GH secretion increases gradually till puberty. After 
puberty, GH release differs between males and females in most mammalian species. Mean 
concentrations of GH and IGF-I in blood are higher in adult males than in adult females in 
rats (Eden, 1979; Gabriel et al., 1992), mice (MacLeod et al., 1991), cattle (Plouzek and 
Trenkle, 1994), and horses (Thompson et al., 1994). In contrast, in primates mean circulating 
concentrations of IGF-I are higher in females than in males (Zadik et al., 1985; Ho et al., 
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1987). Also the characteristics of GH pulses differ after puberty between males and females, 
albeit with some variation between species (Plouzek and Trenkle, 1994; Thompson et al., 
1994). 
 In adulthood, the plasma GH concentration declines with increasing age in both 
primates (Finkelstein et al., 1972; Zadik et al., 1985; Ho et al., 1987; Corpas et al., 1993; 
Arvat et al., 1997a) and rodents (Sonntag et al., 1980; Crew et al., 1987). In humans it has 
been estimated that plasma GH decreases by 14 % with each decade (Iranmanesh et al., 
1991). In both humans (Ho et al., 1987; Veldhuis et al., 1995) and rats (Sonntag et al., 1980) 
the amplitude of GH pulses is significantly lower in old individuals than in young individuals, 
whereas the frequency of GH pulses does not change with age. Several factors affect GH 
secretion in the elderly, such as age-related changes in body composition, reduced physical 
fitness, and medication use. Obesity is probably the strongest inhibitor of GH secretion 
(Veldhuis et al., 1995). Information on the effects of gender and age on the plasma profile in 
dogs is scarce. A recent study demonstrates that, in agreement with many other mammalian 
species, ageing in dogs is associated with a reduction in GH secretion. However, in contrast 
with findings in other mammalian species, no sex-related differences were detected in the 
pulsatile plasma profile in dogs (Lee, 2004). 
 
3.3 Growth hormone secretion in endocrine disease 
 The pattern of GH secretion may also change in hyper- or hyposecretion syndromes, 
such as pituitary-dependent hyperadrenocorticism and pituitary dwarfism. 
 
3.3.1 Pituitary-dependent hyperadrenocorticism 
 Cushing’s disease or pituitary-dependent hyperadrenocorticism (PDH) is the most 
common endocrine disorder in the dog. Pituitary-dependent hyperadrenocorticism is most 
often caused by a corticotroph adenoma that may originate in the AL or the PI (Peterson et al., 
1986). These corticotroph tumours produce an excessive amount of ACTH, resulting 
primarily in hypersecretion of glucocorticoids and in hyperplasia of the two inner zones of the 
adrenal cortices.  
 Glucocorticoids are important physiological regulators of GH synthesis and secretion. 
In humans and rats, glucocorticoids enhance GH gene transcription (Evans et al., 1982; Karin 
et al., 1990) and increase the number of pituitary GHRH receptors (Seifert et al., 1985; 
Ohyama et al., 1997). Consequently, both spontaneous and GHRH-induced GH secretion are 
stimulated by acute administration of dexamethasone (Casanueva et al., 1990). A minimum 
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level of cortisol is essential for normal GH production. Individuals with hypoadrenocorticism 
(Addison’s disease) may become GH-deficient because of diminished GH synthesis (Allen, 
1996). In humans with persistently elevated secretion of glucocorticoids, as in Cushing’s 
disease, both the spontaneous and the stimulated GH secretion are blunted (Takahashi et al., 
1992). Pituitary-dependent hyperadrenocorticism in dogs has many similarities to Cushing’s 
disease in humans (Kemppainen and Peterson, 1993). Consequently, changes in spontaneous 
and stimulated pituitary GH secretion may also be expected in dogs with PDH. 
  
3.3.2 Pituitary dwarfism 
 In dogs, congenital GH deficiency or pituitary dwarfism is the most striking example 
of adenohypophyseal hormone deficiency. Congenital GH deficiency has been mentioned to 
occur in different dog breeds, including Saarloos Wolfshounds and Carelian bear dogs. 
However, the condition is encountered most often as a simple, autosomal, recessive inherited 
abnormality in the German shepherd dog (Andresen and Willeberg, 1976). 
 Functionally, German shepherd dwarf dogs have a combined pituitary hormone 
deficiency. An absolute deficiency of GH, PRL, and TSH is associated with an impaired 
release of gonadotrophins, whereas ACTH secretion is preserved (Kooistra et al., 1998; 
Kooistra et al., 2000b). The abnormality in these dwarfs is most likely caused by a mutation 
in a developmental transcription factor that precludes effective expansion of a pituitary stem 
cell after the differentiation of the corticotroph cells (Kooistra et al., 2000b). To date, 
sequence analysis of genomic DNA from German shepherd dwarfs has not revealed causative 
mutations in candidate genes (Lantinga-van Leeuwen et al., 2000a; Lantinga-van Leeuwen et 
al., 2000b; Van Oost et al., 2002). 
 
4. Ultradian pulsatile hormone secretion 
4.1 Biological relevance of ultradian pulsatile hormone secretion 
 It is now generally accepted that all adenohypophyseal hormones are secreted in an 
ultradian pulsatile fashion and that this pattern of secretion represents an important 
component of neuroendocrine signalling (Negro-Vilar et al., 1987; Brabant et al., 1992). The 
ultradian patterns of adenohypophyseal hormone release are primarily driven by hypothalamic 
signals acting on responsive pituitary cells, which are modulated in turn by intrapituitary 
paracrine and autocrine factors, and also by systemic feedback of hormones derived of target 
organs. 
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 Pulsatile hormone secretion allows for encoding information not only in the absolute 
concentration of the ligand but also in a time-dependent fashion. The pulsatile secretion of 
adenohypophyseal hormones is essential for target-cell regulation and is reproducible under 
comparable environmental conditions (Brabant et al., 1990). Physiological and 
pathophysiological situations may modulate pulsatile secretion patterns by altering the pulse 
amplitude, pulse frequency, or both (Brabant et al., 1992). 
  
4.2 Analysis of pulsatile growth hormone secretion 
 The pulsatile pattern of GH secretion can be determined by collecting blood samples 
serially over a period of hours or days. The samples are assayed and the results are plotted 
graphically to enable recognition of the pulsatile secretion pattern. Different methods can be 
used to analyse the data. Traditionally, the graphs have been given to a blinded scorer who 
identifies the peaks by visual inspection. With this technique it is difficult to state precisely 
the criteria used for pulse identification, which complicates communicating among different 
centres studying similar problems and points to the need for more objective methods 
(Merriam and Wachter, 1982). Nowadays, a number of computer programmes are available 
for computer-assisted analysis of pulsatile secretion patterns. Commonly used detection 
methods such as the Pulsar programme (Merriam and Wachter, 1982) employ mathematical 
assumptions to identify pulses in time series of hormone concentrations. The statistical 
parameters used have to be adjusted for each hormone and different sampling frequencies. 
 Several methodological aspects should be borne in mind when interpreting patterns of 
pulsatile hormone secretion. Analysis of the profile of pulsatile hormone secretion requires 
that detection methods are precise and sensitive. A high intra-assay coefficient of variation 
will make it difficult to distinguish significant hormone pulses from assay noise. Secondly, 
hormone-specific responses are determined by the bioactivity of the hormone. However, 
plasma GH concentrations are measured by an immunoassay rather than by a bioassay. 
Thirdly, pulsatile plasma profiles are measured as a relatively small number of points, 
because “on-line” measurement of GH is not yet available. The shorter the sampling interval 
the higher the chance that significant GH pulses are detected. Therefore, the Pulsar 
programme is not able to extract the “true” underlying pattern of information. Nevertheless, 
the method is an objective way to compare different data sets (Brabant et al., 1992). 
 
5. Synthetic growth hormone secretagogues 
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 In 1975, before the discovery of GHRH, the GH-releasing properties of enkephalins 
were reported (Bowers et al., 1977). Chemical modification of the structure of met-enkephalin 
led to development of a highly potent GH-releasing hexapeptide, GHRP-6 [(His-D-Trp-Ala-
Trp-D-Phe-Lys-NH2)3] in 1980 (Bowers et al., 1984). One of the most remarkable properties 
of GHRP-6 was the strong GH-releasing activity induced following oral administration 
(Bowers et al., 1984). The hexapeptide was the basic structure from which synthetic GH 
secretagogues (GHSs), of either peptidergic structure such as hexarelin or non-peptidergic 
structure such as MK-0677 (Ghigo et al., 1994; Chapman et al., 1996), were subsequently 
produced. Current synthetic GHSs are highly bioavailable and may be administered via 
intravenous, intramuscular, intranasal, subcutaneous, oral, and transdermal routes (Casanueva 
and Dieguez, 1999). Because GH is a large protein that must be administered via injection or 
inhalation, administration of synthetic GHSs is often preferred over administration of GH. In 
addition, GHSs induce a more physiologic pulsatile profile of GH release (Laron, 1995; 
Casanueva and Dieguez, 1999). For example, a single orally administered dose of MK-0677 
increases mean 24-h plasma GH concentrations (Chapman et al., 1996; Jacks et al., 1996; 
Smith et al., 1997).  
 The synthetic GHSs have potent GH-releasing activity in several species, including 
humans, mice, rats, swine, goats, cows, and dogs (Hayashida et al., 2001; Bhatti et al., 2002; 
Bhatti et al., 2006 in press). In humans, nearly all synthetic GHSs induce the release of more 
GH than GHRH (Casanueva and Dieguez, 1999). However, the hormone-releasing action of 
synthetic GHSs is not specific in all instances (Casanueva and Dieguez, 1999). In humans, 
synthetic GHSs such as GHRP-6 also have a stimulatory effect on the secretion of PRL, 
ACTH, and cortisol (Massoud et al., 1996; Casanueva and Dieguez, 1999; Arvat et al., 2001). 
Newer selective GHSs, such as ipamorelin, do not have ACTH- or PRL-releasing actions 
(Raun et al., 1998; Broglio et al., 2002). 
 Interest in GHSs faded after the isolation and characterization of GHRH in 1982 
(Guillemin et al., 1982; Rivier et al., 1982), but was later revived when it was discovered that 
GHSs operated through receptors that are different from those for GHRH (Howard et al., 
1996; Guan et al., 1997; Casanueva and Dieguez, 1999). Growth hormone secretagogues and 
GHRH have strongly synergistic actions, which indicates that synthetic GHSs are not 
physiologic surrogates of GHRH (Bowers et al., 1990). In 1996, the GHS-receptor (GHS-R), 
a G-protein-coupled seven-transmembrane receptor, was identified (Pong et al., 1996). This 
receptor has been cloned from cells of the pituitary gland in humans (Howard et al., 1996; 
McKee et al., 1997a) and rats (McKee et al., 1997b).  
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 Two types of GHS-Rs, which are presumably the result of alternate processing of pre-
mRNA, have been identified and designated as receptors 1a and 1b (Howard et al., 1996; 
Smith et al., 1997). The human GHS-R 1a shares 96 and 93 % sequence identity with rat and 
pig receptors, respectively. The existence of this receptor can be traced to animals in the pre-
Cambrian era because amino acid sequences highly similar to those in the human GHS-R 1a 
have been detected in teleost fish (Palyha et al., 2000). These observations indicate that the 
GHS-R 1a is highly conserved across species and likely has an essential biological function. 
This receptor is largely confined to somatotroph cells in the pituitary gland and to several 
hypothalamic nuclei (e.g., the supraoptic, arcuate, and paraventricular nuclei) in humans and 
rats (Howard et al., 1996; Guan et al., 1997; Smith et al., 1997; Shuto et al 2001). The 
presence in the pituitary gland of mRNA coding for GHS-R 1a indicates that GHSs can act 
directly on somatotrophs to stimulate GH release. This is in accordance with an earlier 
observation (Cheng et al., 1993) that GHSs are able to directly stimulate GH release from rat 
pituitary cells in vitro. The hypothalamic localization of the GHS-R 1a, especially in the 
supraoptic and paraventricular nuclei, supports the notion that GHSs may also indirectly 
regulate GH release by interacting with GHRH-producing neurons, SS-producing neurons, or 
both, in the hypothalamus (Dickson et al., 1995). The GHS-R 1a is also expressed in other 
areas of the brain and certain peripheral tissues (Papotti et al., 2000), indicating that GHSs 
may also be involved in other physiologic functions (Guan et al., 1997; Kojima et al., 2001). 
The importance of the widespread expression of GHS-R 1b in endocrine and non-endocrine 
tissues has not been determined (Howard et al., 1996; Gnanapavan et al., 2002). 
 The GHS-Rs are distinct from the GHRH receptor (Howard et al., 1996; Guan et al., 
1997; McKee et al., 1997a). Although binding of GHRH to the GHRH receptor increases 
cAMP in somatotroph cells and stimulates GH release via activation of the kinase A pathway, 
the binding of ghrelin and synthetic GHSs to the GHS-R 1a activates the phospholipase C 
signalling pathway, leading to an increase in inositol triphosphate and protein kinase C 
activation, followed in turn by release of calcium from intracellular stores (Pong et al., 1996). 
Unlike GHS-R 1a, GHS-R 1b does not bind ghrelin or synthetic GHSs, and its function awaits 
clarification (Howard et al., 1996; McKee et al., 1997a; Gnanapavan et al., 2002). 
 
6. Ghrelin 
 The 1999 discovery of the endogenous or natural ligand of the GHS-R, termed ghrelin 
(ghre is the proto-Indo-European root of the word grow, and relin indicates release), provided 
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a new dimension to GH research (Figure 3) (Kojima et al., 1999). The usual sequence of 
discovery in endocrinology is isolation of a hormone, cloning of its receptor, and 
development of analogues of the hormone for clinical use. With ghrelin, this sequence was 
reversed: first, analogues were synthesized, then the receptor was cloned, and lastly, the 
natural ligand of the orphan receptor was isolated.  
 Ghrelin releases GH in vitro and in vivo. The 28-amino acid peptide was isolated from 
the stomach, where its expression is higher than in any other tissue (Kojima et al., 1999). 
Although this source may initially seem strange, it should be remembered that most 
circulating SS is synthesized primarily in the gut and pancreas and that GHRH was first 
isolated not from the hypothalamus but from a pancreatic tumour (Casanueva and Dieguez, 
2002). Thus, the 3 neurohormones (i.e., SS, GHRH, and ghrelin) responsible for regulation of 
GH secretion are highly expressed in gastrointestinal tissues.  
 In humans, rats, and domestic animals, expression of ghrelin mRNA and the ghrelin 
peptide have been primarily detected in the entero-endocrine or X/A-like cells of the fundic 
gland in the stomach (Hayashida et al., 2001; Tomasetto et al., 2001) and have now been 
renamed Ghr-cells. The cells containing ghrelin do not communicate with the lumen of the 
fundic gland. Like all entero-endocrine cells, they are positioned adjacent to capillaries, 
indicating that their primary action is secretion of hormone into plasma and not into the 
intestinal lumen (Date et al., 2000).  
 The degree of structural heterogeneity of ghrelin among species appears to be minor, 
suggesting that there is little functional heterogeneity. Such preservation of structure 
throughout evolution reflects the physiologic relevance of the peptide (Tomasetto et al., 2001; 
Casanueva and Dieguez, 2002). For example, human and rat ghrelin differ in only two amino 
acids (Table 1) (van der Lely et al., 2004). Alternative splicing of mRNA segments encoding 
ghrelin yields two different peptides, ghrelin and des-Gln14-ghrelin (Hosoda et al., 2000). 
The latter is homologous with ghrelin except for the absence of a single glutamine residue. 
Des-Gln14-ghrelin is expressed in the stomach in low quantities (Kojima et al., 2001), but, 
like ghrelin, it increases the intracellular concentration of calcium in cells that express the 
GHS-R 1a and increases plasma GH concentrations (Kojima et al., 1999; Hosoda et al., 
2000).
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Figure 3. Regulation of the hypothalamic-pituitary-growth hormone (GH) axis. Growth hormone secretion by 
the pituitary gland is stimulated by growth hormone releasing hormone (GHRH) and is inhibited by somatostatin 
(SS). Negative feedback control of GH secretion is exerted at the pituitary and hypothalamic level by insulin-like 
growth factor-I (IGF-I). Growth hormone itself exerts a short-loop negative feedback by activation of SS 
neurons. The gastric peptide ghrelin is the natural ligand for the GH secretagogue receptor that stimulates GH 
secretion at the pituitary level. 
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Table 1. Primary structure of ghrelin from domestic mammalian species. Adapted from van der Lely et al. 
(2004) with permission (Copyright 2004, The Endocrine Society). Bold indicates sites at which a residue is 
different from that in the human peptide.  
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 Species
G S S F L S P E H Q R V Q Q R K E S K K P P A K L Q P R Human
G S S F L S P E H Q K T Q Q R K E S K K P P A K L Q P R Gerbil
G S S F L S P E H Q K A Q Q R K E S K K P P A K L Q P R Mouse
G S S F L S P E H Q K A Q Q R K E S K K P P A K L Q P R Rat
G S S F L S P E H Q K L Q Q R K E S K K P P A K L Q P R Dog
G S S F L S P E H Q K V Q Q R K E S K K P A A K L K P R Pig
G S S F L S P E H Q K L Q Q R K E A K K P S G R L K P R Cattle
G S S F L S P E H Q K L Q Q R K E P K K P S G R L K P R Sheep
G S S F L S P T Y K N I Q Q Q K D T R K P T A R L H R R Chicken  
 
 Before being secreted, n-octanoic acid is added to the third serine residue of ghrelin 
and des-Gln14 ghrelin (Figure 4) (van der Lely et al., 2004). This acylation step, unique in 
mammalian species, is essential for binding to and activating the GHS-R 1a (Bednarek et al., 
2000) and hence for the peptide’s GH-releasing action. The acylation is most likely also 
necessary for the other endocrine actions of the ghrelin molecule (Kojima et al., 2001; Broglio 
et al., 2003). Addition of the n-octanoyl group confers a hydrophobic property to the N 
terminus of the peptide. It has been suggested that the octanoylation of ghrelin is critical to 
the peptide’s ability to cross the blood-brain barrier. It may also facilitate distribution of the 
peptide in the brain although there are presently no data to support this speculation (Horvath 
et al., 2001). Non-acylated ghrelin is found in far greater quantities in human serum than 
acylated ghrelin, but it seems to be devoid of any endocrine activity. However, this peptide 
does have certain nonendocrine actions, such as cardiovascular and anti-proliferative effects 
and these are probably mediated through binding to a novel, as yet unidentified, GHS-R 
subtype (Cassoni et al., 2004). Non-acylated ghrelin is able to inhibit proliferation of human 
prostate cancer cell lines and neoplastic cell growth in thyroid, breast and lung tumours. Also, 
cardioprotective and negative inotropic effects have been described (Date et al., 2000; 
Cassoni et al., 2004). 
 Lower amounts of ghrelin have been detected in various other tissues, including the 
intestines (Date et al., 2000), the pituitary gland (Korbonits et al., 2001), the hypothalamus 
(Kojima et al., 1999; Date et al., 2000), the kidney (Mori et al., 2000), the placenta (Gualillo 
et al., 2001), the heart (Casanueva and Dieguez, 2002), the testes (Barreiro et al., 2002), the 
thyroid gland (Kanamoto et al., 2001), the pancreas (Volante et al., 2002a), the lung (Volante, 
2002b), the ovary (Gyatan et al., 2003), the immune system (Hattori et al., 2001), and 
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neoplastic tissue (Papotti et al., 2000). The physiologic importance of ghrelin as a paracrine 
factor in these tissues is the subject of current research. An endocrine role for non-stomach-
derived ghrelin is thought to be unlikely. Removal of the stomach in humans and rats 
decreases the plasma concentration of ghrelin by approximately 65 % and 80 %, respectively 
(Date et al., 2000; Ariyasu et al., 2001). However, plasma ghrelin concentrations gradually 
increase after gastrectomy (Hosoda et al., 2003). Taken together, these findings indicate that 
the stomach is the major source of circulating ghrelin but other tissues may contribute to the 
secretion of ghrelin in a compensatory manner (Moller et al., 2003).  
 
6.1 Endocrine effects of ghrelin 
 Ghrelin has pronounced, dose-related GH-releasing actions that are more marked in 
humans than in animals (Smith et al., 1997; Kojima et al., 1999; Arvat et al., 2000; Date et al., 
2000; Seoane et al., 2000; Takaya et al., 2000; Arvat et al., 2001; Ghigo et al., 2001; 
Hayashida et al., 2001; Bhatti et al., 2002; Bhatti et al., 2006 in press). The GH-releasing 
activity of ghrelin is greater in vivo than in vitro, because ghrelin and GHRH act 
synergistically, consistent with the fact that their actions are at least partially mediated via 
different mechanisms (Smith et al., 1997; Tannenbaum and Bowers, 2001). Nevertheless, 
GHRH activity is required for full expression of ghrelin’s GH-releasing activity (Smith et al., 
1997; Tannenbaum and Bowers, 2001). The GH response to ghrelin is inhibited, although not 
completely, by GHRH receptor antagonists and by hypothalamo-pituitary disconnection 
(Hickey et al., 1996; Popovic et al., 2003). This supports the assumption that the effect of 
ghrelin on GH secretion is primarily mediated by GHRH-secreting neurons at the level of the 
hypothalamus (Bowers et al., 1991; Smith et al., 1997; Tannenbaum and Bowers, 2001; 
Popovic et al., 2003). 
 In anaesthetized rats, intravenously administered ghrelin stimulates GH release 
without affecting the secretion of other adenohypophyseal hormones (Kojima et al., 1999). 
Also, in cultured rat pituitary cells, ghrelin stimulates GH release in a dose-dependent manner 
without affecting the release of other pituitary hormones, even at high concentrations (Kojima 
et al., 1999). However, in healthy humans, ghrelin is not fully specific for GH release, 
because it also has stimulatory effects on lactotroph and corticotroph cells (Arvat et al., 
1997b; Peino et al., 2000; Takaya et al., 2000; Arvat et al., 2001). The effect of ghrelin on 
PRL secretion is independent of gender and age, and likely results from direct stimulation of 
somatomammotrophs (Renner et al., 1994; Arvat et al., 1997b; Takaya et al., 2000; Muccioli 
et al., 2002). 
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Figure 4. Acylation of the ghrelin molecule. A hydroxyl group on the serine residue at position 3 of the ghrelin 
molecule is octanoylated. This esterification is unique to mammals and is essential for ghrelin binding to and 
activating the growth hormone secretagogue receptor type 1a and, consequently, for the growth hormone-
releasing action of ghrelin. The other endocrine actions of ghrelin are also likely dependent on the acylation of 
the peptide. Figure adapted from van der Lely et al. (2004) with permission (Copyright 2004, The Endocrine 
Society). 
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In rats (Kojima et al., 1999), synthetic GHSs do not stimulate PRL release. This species-
related difference may be explained by differences in the number of somatomammotrophs in 
various species, with humans having a high proportion of those cells (Frawley and Boockfor, 
1991; Raun et al., 1998). The mechanism by which ghrelin stimulates the pituitary-
adrenocortical axis is still unknown, but may be mediated via the hypothalamus, because the 
stimulatory effect is lost after sectioning of the pituitary stalk (Loche et al., 1995). Ghrelin 
may also interact with hypothalamic peptides that control ACTH release, probably via 
arginine vasopressin (Thomas et al., 1997; Korbonits et al., 1999; Broglio et al., 2003). 
 
6.2 Orexigenic actions and role in energy homeostasis 
 Evidence for the involvement of ghrelin in the regulation of appetite was first 
described in humans. Healthy human volunteers reported hunger after administration of 
ghrelin in a clinical study in which GH release was analyzed (Arvat et al., 2000). In rodents, 
ghrelin stimulates food intake and increases body weight while reducing mobilization of 
adipose stores (Tschop et al., 2000; Wren et al., 2000; Shintani et al., 2001). The effects of 
ghrelin on food intake are likely mediated through mechanisms other than those implicated in 
GH regulation, compatible with the concept of distinct GHS-R subtypes (Tschop et al., 2000; 
Toogood and Thorner, 2001).  
 Traditionally, adipocytes have been viewed as energy depots that store triglycerides 
during feeding and release fatty acids during fasting to provide fuel for other tissues. 
However, it has become clear that adipose tissue has major integrative physiologic functions, 
including the secretion of numerous proteins (Friedman an Halaas, 1998; Miner, 2004). The 
realization that adipose tissue functions as an endocrine organ has important implications for 
our understanding of the associations between excess body fat and pathologic states like 
insulin resistance and type-2 diabetes mellitus (Miner, 2004).  
 An important finding that linked central regulation of metabolism to peripheral energy 
stores was the discovery of the adipose hormone, leptin (from the Greek root leptos, meaning 
thin). Leptin, a peptide hormone discovered in 1994, is produced principally by white adipose 
tissue (Zhang et al., 1994). Leptin crosses the blood-brain barrier to act via receptors in the 
arcuate nucleus of the hypothalamus to inhibit the release of orexigenic neuropeptides and 
stimulate the release of anorexigenic neuropeptides (Friedman and Halaas, 1998; Neary et al., 
2003). There is a direct relationship between plasma leptin concentrations and percentage 
body fat. Plasma leptin levels in humans are generally proportional to adipose mass. A 
reduction in leptin levels occurs because of loss of adipose mass such as anorexia nervosa, 
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diet- or exercise-induced weight loss, or starvation. Concentrations of circulating leptin 
decrease rapidly within 12h after initiation of starvation, whereas concentrations increase in 
response to overfeeding. Thus, plasma leptin concentrations reflect adipose tissue mass and 
provide a signal that informs the central nervous system about the body’s energy reserves 
(Friedman and Halaas, 1998). 
 The similarities and complementary interplay of actions between leptin and ghrelin are 
intriguing. The effects of ghrelin on metabolism appear to be the opposite to those of leptin 
(Tschop et al., 2000; Bowers, 2001; Kojima et al., 2001; Spiegelman and Flier; 2001). Leptin 
reduces food intake and selectively reduces fat mass without altering lean body mass (Farooqi 
et al., 1999). Ghrelin, in contrast, increases food intake and selectively enhances fat mass 
(Tschop et al., 2000). 
 Ghrelin stimulates food intake in rodents when administered via central 
(intracerebroventricular) or peripheral (subcutaneous) routes, although the effect is more 
powerful after central administration (Tschop et al., 2000). There is evidence that the appetite-
stimulating effects of ghrelin are mediated by secretion of 2 potent orexigenic hypothalamic 
hormones (neuropeptide Y and agouti-related peptide) and by inhibition of pro-
opiomelanocortin and α-melanocyte-stimulating hormone (α-MSH) (Dickson et al., 1997; 
Hewson and Dickson, 2000; Kamegai et al., 2001; Cowley et al., 2003). Furthermore, the 
orexigenic action of ghrelin is eliminated when neuropeptide Y and agouti-related peptide are 
antagonized (Kamegai et al., 2001). By stimulating the release of orexigenic peptides and 
neurotransmittors, ghrelin mediates a novel regulatory circuit regulating energy homeostasis 
(Cowley et al., 2003; Kohno et al., 2003; Olszewski et al., 2003; Riediger et al., 2003; Seoane 
et al., 2003).  
 In humans and rats, concentrations of circulating ghrelin decrease in chronic (obesity) 
(Tschop et al., 2001) and acute (caloric intake) (Cummings et al., 2001) states of positive 
energy balance, whereas ghrelin levels increase in states of negative energy balance (e.g., 
fasting) (Tschop et al., 2000). In cattle, plasma ghrelin concentrations are low 1h after feeding 
and then return to the pre-feeding concentration (Hayashida et al., 2001). In sheep, the 
preprandial ghrelin surge is higher in animals fed twice daily than in animals fed four times 
daily, highlighting the influence of different feeding regimens on ghrelin concentrations 
(Sugino et al., 2002). The preprandial rise and postprandial fall in plasma ghrelin 
concentrations suggest a possible role for ghrelin as a hunger signal, triggering meal initiation 
(Cummings et al., 2001). Because ghrelin is a potent stimulator of GH release, these 
observations are in accordance with the low plasma GH concentrations associated with 
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obesity (Bowers, 1993) and the high concentrations observed in the malnutrition and fasting 
states (Dieguez and Casanueva, 1995).  
 It may be concluded that nutritional state is an important determinant of plasma 
ghrelin concentration (Tolle et al., 2002). Ghrelin peptide reaches ghrelin receptors in the 
hypothalamo-pituitary region via the general circulation, where it stimulates GH release and 
regulates energy homeostasis. It is unclear whether ghrelin must cross the blood-brain barrier 
to influence the activity of these central structures (van der Lely et al., 2004). In the general 
circulation, ghrelin is bound to high-density lipoproteins in the serum and presumably to other 
proteins, such as albumin, as well. Ghrelin may also signal the brain directly, by activating the 
afferent portion of the vagal nervous system as either an endocrine or a paracrine signal, at the 
level of the stomach. Ghrelin-responsive GHS-Rs are expressed on gastric vagal nerves, and 
vagotomy prevents some of the effects of ghrelin on energy balance. On the other hand, the 
extent and direction of ghrelin transport across the blood-brain barrier may be determined by 
its unique primary structure (Banks et al., 2002). There is still debate on the routes by which 
ghrelin in the peripheral circulation activates receptors in the central nervous system of 
different species.  
 
6.3 Gastric prokinetic action 
 Ghrelin induces strong prokinetic activity in the stomach (Masuda et al., 2000; 
Asakawa et al., 2001). The peptide dramatically accelerates gastric and intestinal emptying in 
rats, and circulating ghrelin concentrations are correlated with gastric emptying time in 
humans (Masuda et al., 2000). In addition, ghrelin stimulates gastric acid secretion (Asakawa 
et al., 2001).  
 In this context, it is interesting to consider the structural and functional similarities 
between ghrelin and motilin (Folwaczny et al., 2001). In addition to their prokinetic effect on 
the gastrointestinal tract, both peptides have orexigenic properties (Garthwaite, 1985) and 
stimulatory effects on pituitary GH release (Samson et al., 1984). Also, the G-protein-coupled 
receptors of ghrelin and motilin have a high degree of structural homology (Feighner et al., 
1999). In contrast to ghrelin, motilin is primarily expressed in the small intestine (Brown et 
al., 1971). Motilin stimulates motor activity in the gastric antrum and proximal portion of the 
duodenum, and plays a key role in the regulation of interdigestive motility (Itoh, 1997).  
 The gastrokinetic effects of ghrelin and motilin may prove beneficial in the treatment 
of postoperative gastric ileus. In humans and other mammalian species, abdominal surgery 
and attendant manipulation of the viscera inhibit gastric emptying and digestive motor 
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activity, which may result in postoperative ileus. Attempts to stimulate smooth muscle 
activity with various prokinetics (eg, cisapride and acetylcholine) are often unsuccessful 
(Asakawa et al., 2001). In rats, ghrelin reverses postoperative gastric ileus (Masuda et al., 
2000). Further studies may elucidate the pharmacologic potential of ghrelin and motilin in 
gastroenterologic applications. 
 
6.4 Effects on the endocrine pancreas 
 Ghrelin and GHS-R 1a mRNA are expressed in endocrine cells of the pancreas (Guan 
et al., 1997; Date et al., 2002; Gnanapavan et al., 2002; Rindi et al., 2002). Expression of 
ghrelin has been reported in the pancreatic α-cells (Date et al., 2002), although other 
investigators have reported that ghrelin is expressed in the pancreatic β-cells (Volante et al., 
2002a). Ghrelin is not co-expressed with any known islet-derived hormone; thus, ghrelin-
producing cells may be a newly recognized type of islet cell (Wierup et al., 2002).  
 Published information regarding the effect of ghrelin on insulin secretion in humans 
and rats is conflicting (Caixas et al., 2002; Date et al., 2002; Lee et al., 2002). However, most 
findings suggest a negative association between ghrelin concentrations and insulin secretion 
(Broglio et al., 2001; Cummings et al., 2001; Tschop et al., 2001; Adeghate and Ponery, 2002; 
Date et al., 2002). In humans, ghrelin induces a significant increase in plasma glucose 
concentrations and a decrease in insulin secretion (Broglio et al., 2001; Broglio et al., 2003). 
Coupled with the observation that treatment with GHSs, particularly the non-peptidyl 
derivatives, induces hyperglycaemia and insulin resistance in the elderly and in obese human 
patients, those findings suggest that ghrelin has an important role in the regulation of insulin 
secretion and glucose metabolism (Svensson et al., 1998; Muller et al., 2001). 
 In healthy humans, hyperglycaemia suppresses both baseline plasma concentrations of 
GH and GH release induced by GHRH (Masuda et al., 1985). The mechanism of the 
hyperglycaemia-induced decrease in circulating GH is unclear. Acute hyperglycaemia 
substantially decreases plasma ghrelin concentrations in healthy humans (Nakagawa et al., 
2002). Because ghrelin markedly stimulates GH secretion, the hyperglycaemia-induced 
suppression of GH release may be caused, at least partly, by the decrease in plasma ghrelin 
concentrations (Casanueva, 1992). 
 
6.5 Cardiovascular effects 
 Ghrelin receptors are widely distributed in cardiovascular tissues. In humans and rats, 
GHS-R 1a mRNA has been detected primarily in the heart, coronary arteries, and aorta 
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(Nagaya et al., 2001, Gnanapavan et al., 2002). Ghrelin is synthesized and secreted by 
isolated human cardiomyocytes, in which it likely has paracrine or autocrine effects and may 
protect the cells from apoptosis (Iglesias et al., 2004).  
 Growth hormone improves cardiac performance in experimentally induced heart 
failure (Yang et al., 1995; Fazio et al., 1996). In one study, prolonged treatment with GHSs 
protected aged rats against cardiovascular damage and improved cardiac performance after 
myocardial infarction, and enhanced left ventricular contractility in pigs with dilated 
cardiomyopathy (Muccioli et al., 2002). Long-term ghrelin administration improves cardiac 
contractility and cardiac output and reduces systemic vascular resistance in humans with 
chronic heart failure (Nagaya et al., 2001). Furthermore, it induces myocardial growth, 
improving the structure and function of the left ventricle (Nagaya et al., 2003; Nagaya et al., 
2004). Interestingly, hexarelin, acylated ghrelin, and even unacylated ghrelin all prevent 
doxorubicin-induced death in cultured cardiomyocytes (Filigheddu et al., 2001). Because 
unacylated ghrelin does not activate the GHS-R 1a (Bednarek et al., 2000), these data indicate 
that another subtype of GHS-R exists in cardiac tissue and that unacylated ghrelin has some 
biological activity (Muccioli et al., 2002). Thus, long-term administration of ghrelin may 
become a treatment strategy for patients with heart failure (Nagaya et al., 2003). 
 
6.6 Anti-proliferative effects 
 GHS-Rs are also found in human neoplastic tissues, such as mammary gland tumours 
and thyroid carcinoma cells (Cassoni et al., 2001; Kanamoto et al., 2001). Ghrelin and GHSs 
inhibit cell proliferation in thyroid tumour cells (Kanamoto et al., 2001; Cassoni et al., 2002) 
and breast cancer cells (Cassoni et al., 2001). Nonacylated ghrelin also exerts anti-
proliferative actions (Cassoni et al., 2001). Because unacylated ghrelin is unable to bind to the 
GHS-R 1a, these data suggest that the anti-proliferative effects of acylated and unacylated 
ghrelin on cancer cells are mediated via a GHS-R subtype that is different from GHS-R 1a 
(Muccioli et al., 2001). 
 
6.7 Conclusion 
 The isolation and characterization of ghrelin are landmarks in GH research and 
represent a major advancement in our understanding of GH regulation. Ghrelin is a gastric 
peptide that is active in the central nervous system, where it is involved in regulation of GH 
secretion and control of food intake. The widespread expression of GHS-Rs in central and 
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peripheral tissues suggests that ghrelin may have many endocrine, paracrine, and possibly 
autocrine effects.  
 Future challenges lie in improving our ability to diagnose and treat the different 
diseases associated with altered GH secretion. For example, the potential use of ghrelin in GH 
deficiency requires investigation. In addition, ghrelin or ghrelin analogues may be useful in 
pathologic catabolic states such as wound and fracture healing, osteoporosis, severe burns, 
sepsis, excessive inflammation, multiple organ failure, and weakness in critically ill patients, 
all conditions in which the administration of moderate doses of GH has been effective (Van 
den Berghe 2000; Petersenn 2002). The orexigenic actions of ghrelin and its analogues may 
be harnessed to treat the pathologic forms of anorexia that accompany cancer and ageing 
(Torsello et al., 1998). Whether ghrelin antagonists can be used to reduce food intake and be 
developed as a treatment for obesity remains to be investigated. 
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General introduction - Part II 
 
Progesterone and synthetic progestins  
used for oestrus prevention in the bitch  
and their systemic effects 
 
1. Progesterone and synthetic progestins 
 Natural progesterone is biosynthesized and secreted by partial luteinized granulosa 
cells during the preovulatory LH peak and consequently the corpus luteum during the luteal 
phase of the oestrous cycle and serves to prepare the genital tract for the reception and 
development of the fertilized ovum. The name progesterone comes from pro, gestation, sterol, 
and one, indicating this first recognized function of the steroid hormone. However, apart from 
the genital tract and ovaries, also brain, bone, and especially the mammary gland (Lantinga-
van Leeuwen et al., 2000c) are important target organs for progesterone action. The terms 
progestin, progestagen, and progestogen are used interchangeably to refer to any of the 
manufactured steroids with progestational activity and derived from progesterone or related 
steroids. Progestins are widely used in companion animal medicine and the main use involves 
the control of the reproductive cycle (Briggs, 1983; Romagnoli and Concannon, 2003). 
 A progestational agent, capable of maintaining pregnancy in ovariectomized animals 
and of causing endometrial gland secretion, was identified, isolated, and eventually 
synthesized in the first decades of the 20th century. In the 1930s, it was discovered that 
progesterone administered by intramuscular injection was capable of blocking ovulation in 
rabbits. A quest for progesterone-like substances that could control reproduction ensued, 
leading to the synthesis and characterization of a number of progestins with potential 
contraceptive application. These included medroxyprogesterone acetate (MPA), melengestrol 
acetate, megestrol acetate, and others. In the 1960s, some progestins being evaluated for use 
in humans were found to induce mammary tumours in Beagle bitches during toxicity studies 
(Frank et al., 1979; Gräf and El Etreby, 1979; Edgren, 1994). Thereafter, long-term animal 
studies became a requirement by the Food and Drug Administration and the World Health 
Organization for any progestin to be marketed for human use (Johnson, 1989; Jordan, 1994). 
In veterinary medicine, depot-injectable MPA rapidly became, and remained for a few 
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decades, the most widely used progestin in Europe. In the United States, however, it was 
quickly withdrawn from the veterinary market because of a high incidence of uterine disease 
reported in dogs administered MPA. Other progestins that were developed as potential human 
contraceptives have also been marketed for contraceptive use in dogs and/or cats e.g. oral 
megestrol acetate, oral MPA, oral delmadinone acetate, oral clormadinone acetate, and depot-
injectable proligestone (Romagnoli and Concannon, 2003). In a variety of in vivo and in vitro 
assays in various species, such compounds have been examined for relative biopotency, 
bioavailability, oestrogenic activity, and androgenic activity. Often, however, different 
compounds have not been evaluated in the same way, and therefore relative differences are 
not clear-cut. Species differences in potency and efficacy are also known to exist. 
  
2. Mechanism of action of progestins 
 In most if not in all target tissues, progesterone and synthetic progestins diffuse 
through the cell membrane, and bind to intracellular receptors. In most mammalian species 
two progesterone receptor (PR) variants are known, the 51-94 kDa PR-A and the larger 116-
120 kDa PR-B form. PR-A and PR-B share the same hormone- and DNA-binding domains 
and differ only in the length of the amino terminus (Graham and Clarke, 1997). After binding 
of progesterone, the progesterone-PR complex binds to a progesterone-response-element in 
the nuclear genome, resulting in suppression or activation of transcription and eventual 
translation of specific gene sequences regulated by progesterone. The translation products 
include structural and secretory proteins, enzymes, and other regulatory proteins. It is also 
likely that in some tissues, progesterone, similar to oestradiol, can bind to membrane 
receptors and has cellular effects in response to binding to membrane receptors (Graham and 
Clarke, 1997; Romagnoli and Concannon, 2003). 
 
3. Reproductive effects of progestins  
 In addition to its progestational activity in maintaining pregnancy, progesterone was 
initially characterized and assayed based on its ability to increase uterine weight (acting 
synergistically with oestrogen) and its ability to increase endometrial glandularity and 
endometrial secretory activity (Nelson et al., 1982). Numerous studies on progesterone and 
progestins have demonstrated that their administration can have actions that can be classified 
General introduction – Part II 
  
 
49 
as progestational, anti-oestrogenic, anti-androgenic, anti-gonadotrophic, and/or contraceptive 
(Romagnoli and Concannon, 2003).  
 The pregnancy supporting or progestational actions of progesterone and synthetic 
progestins include the following: stimulation of endometrial gland development and secretion, 
promotion of cervical closure, suppression of uterine motility by depressing myometrial 
sensitivity and contractility directly and by decreasing the availability of myometrial oxytocin 
receptors, and stimulating proliferation of mammary tissue, especially lobulo-alveolar tissue 
(Nelson et al., 1982; Mol et al., 1995a,b). Prior progestin administration reduces or prevents 
oestrogen-induced phenomena including vaginal bleeding, oestrus behaviour, and ciliation of 
the oviduct by suppressing the synthesis of oestrogen receptors normally stimulated by 
exposure to oestrogens. Progestin administration reduces, inhibits, or reverses some effects of 
androgens, including libido, possibly by interfering with androgen or other steroid receptors’ 
reponses to their own hormone ligands. Progestin administration can also suppress follicle 
development and prevent ovulation. The exact mechanism of the contraceptive activity of 
progestins is still unclear. In many species there is evidence that contraceptive progestins 
reduce serum concentrations of gonadotrophins. However, there is little information about the 
effects of progestins on gonadotrophin secretion in dogs. In one study high doses of MPA 
administered to Beagle bitches for several months did not reduce the increased concentrations 
of LH in ovariectomized bitches nor did it lower LH concentrations in intact bitches (McCann 
et al., 1987). In another study high doses of megestrol acetate did not suppress basal 
gonadotrophin secretion during anoestrus, nor was the pituitary hypersecretion of LH and 
FSH in ovariectomized bitches suppressed (Colon et al., 1993). The contraceptive activity of 
progestins may involve the prevention of increases in gonadotrophin secretion above basal 
values. In addition, there may be a direct negative effect on follicle development in the ovary 
(Colon et al., 1993).  
 The progestins most frequently used for oestrus prevention in the dog are proligestone 
and MPA. Because the drug cannot be rapidly withdrawn after injection of the depot 
progestin, care must be taken to use the lowest possible effective dosing regimen. The single 
injection dosage recommended by the manufacturer for proligestone ranges from 10 mg/kg 
for a dog of about 60 kg, to 30 mg/kg for one of 3 kg, s.c., and for MPA the single injection 
dose is 2 mg/kg (maximum 60 mg), s.c. (Schaefers-Okkens, 1996). They should be 
administered during anoestrus about one month before the expected follicular phase. The first 
oestrus after the use of proligestone in the majority of bitches can be expected within 9-12 
months; after MPA administration it may be up to 2-3 years. Medroxyprogesterone acetate 
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can also be administered orally, 5 mg once daily (10 mg for large dogs during the first 5 days) 
for as long as oestrus prevention is wanted or for a maximum of 21 days. The recurrence of 
oestrus may vary from 2-9 months (Schaefers-Okkens, 1996). In the United States the advise 
dosage for megestrol acetate, a progestin which probably has a stronger progestagenic effect 
than MPA, is 0.5 mg/kg orally once daily for 32 days starting during anoestrus, or 2 mg/kg for 
8 days starting at the onset of pro-oestrus (Schaefers-Okkens, 1996). 
  
4. Additional effects of progestins  
 Side effects have been observed after prolonged (6-12 months or longer), chronic use 
of progestins such as during the course of chronic toxicity studies. They are also reported with 
varying severity and varying or unknown frequency during the course of treatment with 
recommended contraceptive doses. 
 
4.1 Induction of mammary growth hormone secretion 
 In the 1970s acromegalic features were reported to occur in some dogs used in 
toxicological studies on long-term treatment with progestins (Tucker, 1971; Sloan et al., 
1975). Initially it was denied that GH might be involved in the development of the physical 
features reminiscent of acromegaly (Hansel et al., 1977). In 1980 confirmation that progestin 
administration can lead to increased circulating GH concentrations was obtained (Concannon 
et al., 1980). The elevated plasma GH levels declined after cessation of progestin 
administration (Rijnberk et al., 1980). This phenomenon appeared not to be confined to 
exogenous progestins, as an excess of GH was also found in bitches during the luteal phase of 
the oestrous cycle (Concannon et al., 1980; Eigenmann et al., 1983; Rutteman et al., 1987). 
The absence of a pulsatile pattern in plasma GH concentrations after progestin treatment 
pointed to autonomous GH production, which only could be inhibited by treatment with the 
antiprogestin RU 38486 (Watson et al., 1987). This autonomous release was further 
substantiated by the fact that GHRH did not stimulate and SS did not inhibit GH expression 
and release (Selman et al., 1991). The progestin-induced increase of plasma GH concentration 
was associated with elevated plasma concentrations of IGF-I (Selman et al., 1994a).  
 Because the GH overproduction could not be attributed to a pituitary tumour or an 
ectopic neoplastic production of GHRH, as in other species, and because cessation of 
progestin administration resulted in gradual normalization of the circulating GH levels, an 
extra-pituitary site of GH production was looked for. Measurement of GH concentrations in 
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tissue homogenates revealed that the progestin-induced GH excess in the dog originated from 
foci of hyperplastic ductular epithelium of the mammary gland (Selman et al., 1994a; van 
Garderen et al., 1997). Further evidence came from the arterio-venous gradient over the 
mammary gland and the fast decrease of plasma GH concentrations after complete 
mastectomy (Selman et al., 1994a). RT-PCR analysis revealed the expression of the gene 
encoding GH in normal mammary tissue and in benign and malignant mammary tumours 
(Mol et al., 1995b). The expression of the GH gene was also documented for feline and 
human mammary tissue, indicating that the phenomenon of mammary GH expression is not 
unique for the dog (Mol et al., 1995a; Mol et al., 1996). Immunohistochemical analysis and in 
situ hybridization revealed that both immunoreactive GH and GH mRNA were present in 
normal and tumourous mammary epithelial cells. Growth hormone-containing secretory 
granules could also be demonstrated in epithelial cells by immunoelectron microscopy (van 
Garderen et al., 1997). Sequence analysis has revealed that the gene encoding GH in the 
mammary gland is identical to the pituitary GH gene (Mol et al., 1995a; Mol et al., 1995b). 
The regulation of extra-pituitary GH gene expression is largely unknown. There are at least 
two differences between the regulation of GH expression in the mammary gland and that in 
the pituitary gland. First of all, the synthesis and release of mammary GH are highly 
dependent upon progesterone (Selman et al., 1994a; Lantinga-Van Leeuwen et al., 1999). 
Secondly, expression of mammary GH is independent of the transcription factor Pit-1, as is 
GH expression in bone marrow (Lantinga-Van Leeuwen et al., 1999). 
 The co-localization of GH and the progesterone receptor in the canine mammary gland 
supports the concept that ligand-activated progesterone receptors may play a direct role in GH 
gene promotor activation (Lantinga-van Leeuwen, 2000c). The presence of progesterone 
receptors in mammary gland tissue of dogs opens possibilities for a targeted endocrine 
therapy with progesterone receptor blockers in dogs with progestin-induced mammary-
derived GH overproduction. 
 
4.2 Increased incidence of mammary tumours 
 The role of progestins in the pathogenesis of human breast cancer has been highly 
debated (van Leeuwen 1991; Pike et al., 1993). Several epidemiologic studies have linked the 
use of contraceptive agents during adolescence or before a full-term pregnancy to a higher 
risk of developing breast cancer at a young age (Pike et al., 1981; van Leeuwen et al., 1991). 
The question of whether this increased risk is attributable to the oestrogen or progestin 
content of the contraceptives has not been answered satisfactorily, but there is good reason to 
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assume that this increased risk is due to the progestin component (Lee et al., 1987; Kay and 
Hannaford, 1988). This assumption is supported by observations that the highest proliferation 
rates of mammary epithelium are found in the progesterone-dominated luteal phase of the 
menstrual cycle and in women receiving progestin-only formulations of contraceptives, 
indicating a strong mitogenic action of progestins upon mammary epithelium (Horwitz, 1991; 
Clarke and Sutherland, 1990). 
 In the dog, prolonged administration of oestrogens does not increase the incidence of 
mammary tumours (Rutteman, 1992), but treatment of female dogs with progestins at high 
dosages induces a dose-dependent mammary tumour development (Casey et al., 1979; 
Misdorp 1991; Rutteman, 1992). Also, endogenous ovarian steroids appear to promote 
mammary tumourigenesis in dogs, as ovariectomy, even performed at an advanced age, 
protects against mammary tumour formation (Misdorp 1988). As mentioned above, GH gene 
expression has been demonstrated in neoplastic mammary tissue of the dog (Mol et al., 
1995b). The expression in normal tissue is stimulated by progestins and might mediate the 
progestin-stimulated development of canine mammary tumours. Progestin-induced GH 
probably participates in the cyclic development of the mammary gland but may promote 
mammary tumourigenesis by stimulating proliferation of susceptible, and sometimes 
transformed, mammary epithelial cells. Progestin-induced mammary GH might function as an 
autocrine or paracrine growth factor, in view of the presence of the GH receptor that has been 
demonstrated in the normal canine mammary gland and in mammary tumours of dogs (van 
Garderen and Schalken, 2002).  
 In young queens exogenous progestins, but also endogenous progesterone, may cause 
extensive proliferation of mammary duct epithelium and stroma, leading to the so-called 
fibroadenomatous hyperplasia (Hayden and Johnson, 1986). Growth hormone mRNA has 
been demonstrated in mammary tissues of cats with progestin-induced fibroadenomatous 
changes (Mol et al., 1995b). 
 
4.3 Increased incidence of uterine pathology 
 Teunissen (1952) reported that progestins may induce the development of cystic 
endometrial hyperplasia (CEH) in bitches. In line with this observation CEH is frequently 
seen in bitches treated repeatedly with progestins for prevention of oestrus (Sokolowski and 
Zimbelman 1974; Goyings et al., 1977). Cystic endometrial hyperplasia may also develop 
spontaneously in the luteal phase of the oestrous cycle of middle-aged or elderly bitches, i.e., 
bitches that have gone through several luteal phases (Dow, 1958). The luteal phase of the 
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oestrous cycle of the bitch differs from that of most other mammals because it is characterized 
by a prolonged increase of plasma concentrations of progesterone, irrespective of pregnancy 
(Concannon et al., 1975).  
Uterine pathology involves proliferation of the glandular endometrium and cystic dilatation of 
the endometrial glands with endometrial fluid accumulated in their lumen. Cystic endometrial 
hyperplasia may be an incidental finding and the natural incidence of CEH is not known. 
Cystic endometrial hyperplasia predisposes the uterus to infection and can result in pyometra. 
 From studies in which CEH was induced experimentally in the dog (Dow, 1959), it 
has become clear that metoestrus or progesterone influence in general seems to be required or 
at least predisposes to development of CEH. This is remarkable because in women, cows, 
ewes, mares, and sows endometrial hyperplasia is associated only with excess stimulation by 
oestrogen from cystic follicles, oestrogenic implants or granulosa cell tumours (Potter et al., 
1991). In women it is well known that progesterone induces endometrial atrophy (Seidman et 
al., 1997), while in dogs progestin treatment has been associated with endometrial hyperplasia 
(Anderson et al., 1965; Fidler, 1966). The exposure of captive wild felids to progestins is a 
strong risk factor for development of uterine carcinoma (Harrenstien et al., 1996). In contrast, 
endometrial carcinomas in dogs, even under progestin treatment, are rare (Kennedy, 1993). 
This suggests that the canine endometrium responds in a different way to progesterone 
compared to other species.  
 As mentioned before, locally produced mammary GH most likely plays a autocrine 
and/or paracrine role in the progestin-induced proliferation of mammary epithelium (Mol et 
al., 1995b). Because of the similarity of the progestin-induced epithelial changes in both the 
mammary gland and the uterus, it is reasonable to assume that GH is also involved in the 
development of progestin-induced CEH. Although immunoreactive GH was found in the 
uterine epithelial cells of progestin treated dogs, the absence of mRNA encoding GH in 
uterine tissue as shown by RT-PCR suggests that this immunoreactive GH does not originate 
in the uterus (Kooistra et al., 1997). This finding refutes the hypothesis that local production 
of GH is involved in the pathogenesis of progestin-induced CEH. However these findings do 
not exclude the possibility that GH plays a role in the pathogenesis of progestin-induced 
CEH, whereby progestins promote the expression of membrane-bound GH receptors of 
uterine epithelial cells. In combination with the increase in progestin-induced circulating 
mammary-derived GH this would explain the presence of GH in uterine epithelial cells. The 
presence of mRNA encoding the GH receptor has already been demonstrated in the human 
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uterus (Sharara and Nieman, 1995). The possible role of progestin-induced mammary-derived 
GH in the pathogenesis of CEH warrants further investigation.  
 
4.4 Prolonged pregnancy 
 This occurs if progestins are administered subcutaneously at the onset of the follicular 
phase and the bitch or queen is mated. The gestation will be prolonged and a caesarean 
section may be needed, unless a progesterone receptor antagonist, such as mifepristone or 
aglépristone, is given (Schaefers-Okkens, 1996). 
 
4.5 Insulin resistance and diabetes mellitus 
 The progestin-induced GH excess may give rise to glucose intolerance, which may 
lead to “exhaustion” of the pancreatic β-cells and subsequently diabetes mellitus (Eigenmann 
et al., 1983). Diabetes mellitus is a common finding in acromegaly in humans, cats and dogs 
and can be explained by the diabetogenic properties of GH, leading to insulin resistance 
(Eigenmann and Rijnberk, 1981).  
 
 The occurrence of the afore mentioned side-effects is, with the exception of 
‘prolonged pregnancy’, largely dependent upon total progestin exposure. With the advised 
dosage regimens the exposure may be higher with MPA and megestrol acetate than with 
proligestone, the latter being a rather weak progestagen (Schaefers-Okkens, 1996). 
 
4.6 Suppression of the hypothalamic-pituitary-adrenal axis 
 Besides an effect on the progesterone receptor, MPA also has intrinsic glucocorticoid 
properties due to the relatively high affinity of MPA for the glucocorticoid receptor (Selman 
et al., 1996). Suppression of the hypothalamic-pituitary-adrenocortical axis by MPA has been 
reported in both humans (Willemse et al., 1990) and dogs (Selman et al., 1994b; Selman et al., 
1996). In man the use of high doses of MPA may even lead to Cushing’s syndrome 
(Simononski et al., 1989).  
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Abstract 
The amplitude and frequency of growth hormone (GH) secretory pulses are influenced 
by a variety of hormonal signals, among which glucocorticoids play an important role. The 
aim of this study was to investigate the pulsatile secretion pattern of GH in dogs in which the 
endogenous secretion of glucocorticoids is persistently elevated, i.e., in dogs with pituitary-
dependent hyperadrenocorticism (PDH). Blood samples for the determination of the pulsatile 
secretion pattern of GH were collected at 10-min intervals between 0800h and 1400h in 
sixteen dogs with PDH and in six healthy control dogs of comparable age. The pulsatile 
secretion patterns of GH were analyzed using the Pulsar programme.  
Growth hormone was secreted in a pulsatile fashion in both dogs with PDH and 
control dogs. There was no statistical difference between the mean (± SEM) basal GH level in 
dogs with PDH (0.7 ± 0.1 µg/l) and the control dogs (0.6 ± 0.1 µg/l). The mean area under the 
curve above the zero-level (AUC0) for GH in dogs with PDH (4.6 ± 0.6 µg/lx6h) was 
significantly lower than that in the control dogs (7.3 ± 1.0 µg/lx6h). Likewise, the mean area 
under the curve above the baseline (AUCbase) for GH in dogs with PDH (0.6 ± 0.1 µg/lx6h) 
was significantly lower than that in the control dogs (3.7 ± 1.0 µg/lx6h). The median GH 
pulse frequency in the dogs with PDH (2 pulses/6h, range 0 to 7 pulses/6h) was significantly 
lower (P = 0.04) than that (5 pulses/6h, range 3 to 9 pulses/6h) in the control group 
The results of this study demonstrate that PDH in dogs is associated with less GH 
secreted in pulses than in control dogs, whereas the basal plasma GH concentrations were 
similarly low in both groups. It is discussed that the impaired pulsatile GH secretion in dogs 
with PDH is the result of alterations in function of pituitary somatotrophs and changes in 
supra-pituitary regulation. 
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Introduction 
Like the other hormones of the canine pituitary anterior lobe, growth hormone (GH) 
secretion is pulsatile in nature (Takahashi et al., 1981; Kooistra et al., 2000; Lee et al., 2001). 
Pituitary GH secretion is regulated predominantly by the opposing actions of the stimulatory 
hypothalamic peptide GH-releasing hormone (GHRH) and the inhibitory hypothalamic 
peptide somatostatin (SS). Each GH secretory episode seems to be initiated by a burst of 
GHRH into the hypophyseal portal system, preceded by a reduction of somatostatinergic 
input to the pituitary (Plotsky and Vale, 1985). In addition to these hypothalamic hormones, a 
recently identified GH-releasing peptide, called ghrelin, is likely to play a role in the 
regulation of pituitary GH secretion (Kojima et al., 1999). The amplitude and frequency of 
GH secretory pulses are influenced by a variety of hormonal signals, among which 
glucocorticoids play an important role (Devesa et al., 1992). 
Glucocorticoids are important physiological regulators of GH synthesis and secretion. 
In humans and rats, glucocorticoids enhance GH gene transcription (Evans et al., 1982; Karin 
et al., 1990) and increase pituitary GHRH receptor numbers (Seifert et al., 1985; Miller and 
Mayo, 1997; Ohyama et al., 1998). Consequently, both spontaneous and GHRH-induced GH 
secretion are stimulated by acute administration of dexamethasone (Wehrenberg et al., 1983; 
Casanueva et al., 1990; Veldhuis et al., 1992). A minimum level of cortisol is essential for 
normal GH production. Individuals with hypoadrenocorticism (Addison’s disease) may be 
GH-deficient because of poor GH synthesis (Allen, 1996). In line with this observation, 
humans with idiopathic adrenocorticotrophic hormone (ACTH) deficiency need appropriate 
glucocorticoid replacement to re-establish the normal pattern of GH response to stimulatory 
tests (Giustina et al., 1989). However, when in humans the endogenous secretion of 
glucocorticoids is persistently elevated, as in Cushing’s disease, the spontaneous and 
stimulated GH secretion are blunted (Takahashi et al., 1992; Magiakou et al., 1994; Borges et 
al., 1997). 
In dogs, pituitary-dependent hyperadrenocorticism (PDH) is one of the most common 
endocrine diseases and has many similarities with Cushing’s disease in humans (Kemppainen 
and Peterson, 1994). Consequently, changes in pituitary GH secretion may also be expected in 
dogs with PDH. Indeed, it has been reported that basal plasma GH levels are lower and 
stimulated GH secretion is blunted in dogs with PDH (Peterson and Altszuler, 1981; Regnier 
and Garnier, 1995; Meij et al., 1997). However, information on changes in the spontaneous 
pulsatile secretion pattern of GH in dogs with PDH is lacking. Therefore, we investigated the 
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6-h pulsatile secretion pattern of GH in sixteen dogs with PDH and compared the 
characteristics of these secretory profiles with those of six healthy control dogs of comparable 
age. 
 
Materials and methods 
Dogs 
A total of six female and ten male dogs with PDH and six healthy Beagle bitches were 
used in this study. The mean (± SEM) age (8.3 ± 0.5 years; median 8 years, range 5-12 years) 
and the mean (± SEM) body weight (15.7 ± 1.7 kg, median 14 kg, range 7-30 kg) of the dogs 
with PDH did not differ significantly from those of the control dogs (7.8 ± 0.2 years, median 
8 years, range 7-8.5 years, and 14.7 ± 0.6 kg, median 15 kg, range 12-17 kg, respectively). 
The suspicion of hyperadrenocorticism was based upon medical history, physical 
examination, and results of routine haematological and biochemical testing. 
Hyperadrenocorticism was diagnosed when the mean corticoid/creatinine (C/C) ratio in two 
consecutive morning urine sample exceeded 10 x 10-6 (Rijnberk et al., 1988). Differentiation 
between PDH and hyperadrenocorticism due to an adrenocortical tumour was accomplished 
by administering, after collection of the second urine sample, three oral doses of 
dexamethasone 0.1 mg/kg body weight at 8-h intervals. When the C/C ratio in the third urine 
sample was less than 50 % of the mean of the first two samples, the dog was categorized as 
being responsive to dexamethasone and PDH was diagnosed (Rijnberk et al., 1988). In the 
dogs with less suppression of the third urinary C/C ratio, pituitary dependency was 
established by the finding of non-suppressed plasma ACTH levels (≥10 ng/l). The latter is 
justified because ectopic ACTH- or CRH-producing tumours have not been reported in dogs. 
In addition to these biochemical function tests, the diagnosis of PDH was supported by 
visualization of the adrenals by ultrasonography (Voorhout et al., 1990) and computed 
tomography of the pituitary gland (Kooistra et al., 1997; Meij et al., 1998). 
 
Blood sample collection 
Blood samples for the determination of the plasma concentration of GH were collected 
at 10-min intervals between 0800h and 1400h. Blood samples were collected by jugular 
venipuncture and immediately placed in chilled EDTA-coated tubes, and centrifuged. Plasma 
was stored at -20° C until assayed. 
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Hormone determination 
Plasma ACTH concentrations were measured using a commercially available two-site 
immunoradiometric assay (IRMA) (Nichols Institute, Wijchen, The Netherlands). The intra- 
and interassay coefficients of variation were 3.2 % and 7.8 %, respectively, and the sensitivity 
was 1 ng/l. There was no cross-reaction between the antiserum and α-melanocyte-stimulating 
hormone or ACTH precursors (Findling and England, 1990). 
Urinary corticoid concentrations were measured by radioimmunoassay (RIA) as 
described previously (Rijnberk et al., 1988). The intra- and interassay coefficients of variation 
were 6 % and 8 %, respectively, and the sensitivity was 1 nmol/l. The urinary corticoid 
concentration was related to the urinary creatinine concentration (Jaffé kinetic method, initial 
rate reaction) and the C/C ratio was calculated (Stolp et al., 1983; Rijnberk et al., 1988). 
Plasma GH concentrations were measured by a homologous RIA as described by 
Eigenmann and Eigenmann (1981). The intra- and interassay coefficients of variation were 
3.8 % and 7.2 %, respectively. The sensitivity of the assay was 0.3 µg/l.  
 
Statistical analysis 
The 6-h secretion patterns of GH were analyzed using the Pulsar programme 
developed by Merriam and Wachter (1982). The programme identifies secretory peaks by 
height and duration from a smoothed baseline, using the assay standard deviation (SD) as a 
scale factor. The cut-off parameters G1-G5 of the Pulsar programme were set at 3.98, 2.4, 
1.68, 1.24, and 0.93 times the assay SD as criteria for accepting peaks 1, 2, 3, 4, and 5 points 
wide, respectively, resulting in a false-positive error rate of less than 5 %. The smoothing 
time, a window used to calculate a running mean value, was set at 5h. The weight assigned to 
peaks was 0.05. The A, B, and C values of the Pulsar programme used to calculate the 
variance of the assay, were set at A=0, B=7.2, and C=5. The values extracted from the Pulsar 
analyses included the overall mean of the smoothed baseline, the number of peaks, the area 
under the curve above the zero level (AUC0), and the AUC above the baseline (AUCbase). 
Differences in parameters between control dogs and dogs with PDH were evaluated by 
the unpaired Student’s t-test (two-tailed). Since the data were not assumed to be normally 
distributed, differences in GH pulse frequency were determined by non-parametric analysis, 
using Wilcoxon-Mann-Whitney test. Values are expressed as mean ± SEM or range or as 
median and range. P < 0.05 was considered significant. 
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Ethics of the study 
The experiments in this study were approved by the Ethical Committee of the Faculty 
of Veterinary Medicine, Utrecht University. 
 
Results 
The mean basal urinary C/C ratio ranged from 23 to 301 x 10-6 in the dogs with PDH. 
In thirteen of the sixteen dogs with PDH oral dexamethasone suppressed the urinary C/C ratio 
to less than 50 % of the mean basal urinary C/C ratio of the first two days (range 3 to 33 %). 
In the remaining three dogs the urinary C/C ratios after oral dexamethasone were 57 %, 85 %, 
and 105 % of the mean basal urinary C/C ratio of the first two days. The plasma ACTH 
concentrations in these three dogs were 90 ng/l, 111 ng/l, and 129 ng/l, respectively.  
Growth hormone was secreted in a pulsatile fashion in both dogs with PDH and 
control dogs (Figure 1). There was no statistical difference (P = 0.57) between the mean (± 
SEM) basal GH level in dogs with PDH (0.7 ± 0.1 µg/l) and the control group (0.6 ± 0.1 
µg/l). The mean AUC0 for GH in dogs with PDH (4.6 ± 0.6 µg/lx6h) was significantly lower 
(P < 0.05) than that in the control group (7.3 ± 1.0 µg/lx6h). Likewise, the mean AUCbase for 
GH in dogs with PDH (0.6 ± 0.1 µg/lx6h) was significantly lower (P = 0.03) than that in the 
control group (3.7 ± 1.0 µg/lx6h). The median GH pulse frequency in the dogs with PDH (2 
pulses/6h, range 0 to 7 pulses/6h) was significantly lower (P = 0.04) than that (5 pulses/6h, 
range 3 to 9 pulses/6h) in the control group (Table 1). 
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Figure 1. The 6-h secretory profile of GH in a healthy Beagle dog (●) and a dog with pituitary-dependent 
hyperadrenocorticism (○). Significant pulses, calculated by the Pulsar programme, are indicated with an asterisk. 
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Table 1. Characteristics of the 6-h secretory profiles of GH in sixteen dogs with pituitary-dependent 
hyperadrenocorticism and in six control dogs of comparable age. Basal GH = mean basal plasma GH level; 
AUC0 = area under the curve above the zero-level for GH; AUCbase = area under the curve above the baseline for 
GH; Frequency = number of GH pulses per 6h. 
 Basal GH  
(µg/l) 
AUC0 
 (µg/lx6h) 
AUCbase 
(µg/lx6h) 
Frequency 
(pulses/6h) 
Dog with PDH     
Dog 1 1.2 7.5 0.2 0 
Dog 2 0.5 4.1 1.2 5 
Dog 3 0.3 3.0 1.1 6 
Dog 4 0.3 2.2 0.4 2 
Dog 5 0.5 2.9 0.1 0 
Dog 6 0.5 3.4 0.3 2 
Dog 7 0.6 3.6 0.4 2 
Dog 8 0.4 4.2 1.8 7 
Dog 9 1.2 7.9 0.6 3 
Dog 10 0.8 5.6 0.8 5 
Dog 11 0.3 2.0 0.2 1 
Dog 12 0.5 4.9 1.8 5 
Dog 13 0.5 3.3 0.4 2 
Dog 14 1.2 7.2 0.2 0 
Dog 15 0.3 2.5 0.6 3 
Dog 16 1.6 9.8 0.2 0 
 
Control dogs 
    
Dog 1 0.5 7.5 4.6 5 
Dog 2 0.5 3.2 0.4 3 
Dog 3 0.6 6.3 2.7 3 
Dog 4 0.8 7.5 2.6 9 
Dog 5 0.7 8.7 4.3 7 
Dog 6 0.5 10.5 7.7 5 
 
Discussion 
The results of this study demonstrate that GH is secreted in a pulsatile fashion in both 
healthy dogs and dogs with PDH. However, the low AUC for GH, both above the zero-level 
and above the baseline, and the low GH pulse frequency compared with healthy dogs indicate 
that less GH is secreted in pulses in dogs with PDH. Spontaneous pulsatile GH secretion has 
also been reported to be suppressed in humans with PDH and rats treated for four weeks with 
high doses of glucocorticoids (Magiakou et al., 1994; Wajchenberg et al., 1996; Ohyama et 
al., 1997). The impaired pulsatile GH secretion may be the result of alterations in supra-
pituitary regulation and changes at the level of the somatotroph. 
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The inhibitory effect of chronic hypercorticism on pituitary GH secretion involves, at 
least in part, enhancement of hypothalamic SS release (Wehrenberg et al., 1990; Wajchenberg 
et al., 1996; Terzolo et al., 2000). Support for the concept of the enhancement of SS tone by 
glucocorticoids comes from observations in rats that the hypothalamic content of 
immunoreactive SS (Nakagawa et al., 1987) and hypothalamic SS mRNA levels (Nakagawa 
et al., 1992) are increased following chronic dexamethasone administration. Further evidence 
for a regulatory role of glucocorticoids on GH secretion acting at the hypothalamic level is 
derived from in vivo studies in rats after passive immunization with anti-SS antibodies. This 
immunization reverses the inhibitory effect of high levels of circulating glucocorticoids on 
stimulated GH response (Wehrenberg et al., 1990; Mallo et al., 1993). However, 
pyridostigmine, which activates cholinergic synapses and thus suppresses hypothalamic SS 
release, does not modify plasma GH levels in humans with Cushing’s syndrome (Leal-Cerro 
et al., 1990). Thus enhancement of hypothalamic SS release is not the only factor suppressing 
pituitary GH secretion in chronic hypercorticism. Inhibition of pituitary GH secretion may 
also be explained by a decrease in hypothalamic GHRH synthesis and secretion. 
Hypothalamic GHRH mRNA levels were indeed reduced in rats treated with high doses of 
glucocorticoids (Miell et al., 1991; Senaris et al., 1996; Ohyama et al., 1997). 
In addition to their effect at the hypothalamic level, glucocorticoids may also influence 
GH secretion by acting directly at the pituitary level. Studies in humans, rats, and dogs have 
demonstrated that chronic glucocorticoid excess inhibits the GH response to GH-releasing 
stimuli, such as GHRH (Peterson and Altszuler, 1981; Wehrenberg et al., 1983; Hotta et al., 
1988; Burguera et al., 1990; Voltz et al., 1995; Ohyama et al., 1997; Meij et al., 1997; Watson 
et al., 2000). In humans with Cushing’s syndrome, blunted GH responses were also found to a 
synthetic hexapeptide (GHRP-6) which releases GH by a direct effect at the pituitary level 
through receptors other than GHRH receptors (Leal-Cerro et al., 1994). These observations 
suggest that chronic hypercorticism may also have a direct effect on pituitary somatotrophs, 
although the impaired response might also be the result of the persisting inhibitory effect of 
SS.  
Although the GH response to GHRH is markedly impaired, an increase in the number 
of pituitary GHRH receptors has been reported in rats treated for four weeks with high doses 
of dexamethasone (Ohyama et al., 1997). The increase in the number of pituitary GHRH 
receptors may be caused by decreased GHRH secretion, since Miki et al. (1996) reported an 
increase in pituitary GHRH receptor mRNA levels in rats after immunoneutralization for 
GHRH. Therefore it may be hypothesized that post GHRH receptor signalling is impaired in 
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somatotrophs exposed to high doses of dexamethasone for long periods (Ohyama et al., 
1997). The decrease in hypothalamic GHRH secretion may result in a lack of priming of the 
somatotrophs and, subsequently, in reduced GH synthesis and secretion and decreased 
responsiveness to exogenously administered GHRH (Thakore and Dinan, 1994). This concept 
is supported by the observation that there was a clear GH response to GHRH plus 
pyridostigmine in humans with Cushing’s disease treated for one week with GHRH (Leal-
Cerro et al., 1993). This suggests that blunted GH secretion in patients with Cushing’s 
syndrome is at least partially mediated by decreased priming of the somatotrophs with 
endogenous GHRH. In addition, it has been demonstrated in young rats that administration of 
cortisone acetate decreases the number of somatotrophs in the pituitary gland (Niimi et al., 
1993). 
The suppressed pulsatile GH secretion in dogs with PDH may also be ascribed to 
obesity. Under the influence of glucocorticoid excess energy derived from protein catabolism 
is increased and the contribution from lipid oxidation is decreased. This effect leads to 
characteristic changes in body habitus that are frequently associated with glucocorticoid 
excess. Indeed, one of the cardinal physical features of dogs with hyperadrenocorticism is 
centripetal obesity (Rijnberk, 1996). Like chronic hypercorticism, obesity is associated with 
insulin-like growth factor-I (IGF-I)-mediated GH suppression (Magiakou et al., 1994) and 
blocked GH response to GH-releasing stimuli (Cordido et al., 1993). Elevated plasma free 
fatty acid levels (Leal-Cerro et al., 1997) and changes in circulating leptin levels (Pombo et 
al., 1999) may be contributing factors to the deranged GH secretion observed in humans with 
Cushing’s syndrome. Leal-Cerro et al. (1998) demonstrated that in humans with Cushing’s 
syndrome hyporesponsiveness of the somatotrophic cells to GHRH is improved after a short-
term hypocaloric diet. However, in contrast to chronic hypercorticism (Leal-Cerro et al., 
1994) intravenous administration of a combination of GHRH and GHRP-6 resulted in an 
elevated GH response in obese humans (Cordido et al., 1993), indicating that obesity is not 
the only explanation for the blocked GH response in chronic hypercorticism. 
In contrast to observations of Meij et al. (1997), in the present study the basal plasma 
GH concentrations were not different in the dogs with PDH compared to the control dogs. 
However, the basal plasma GH levels in the study of Meij et al. (1997) were derived from 
only three blood samples collected at 15-min intervals. Therefore, it is possible that pulses 
may have contributed to the higher basal plasma GH levels in the control dogs in the study of 
Meij et al. (1997). In addition, in the study of Meij et al. (1997) the basal plasma GH levels in 
dogs with PDH (median age 10 years) were compared with those of control dogs with a 
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median age of two years. The significantly lower basal plasma GH levels in dogs with PDH 
may therefore have been caused by the effects of ageing. Indeed, it has been reported that GH 
secretion is decreased in elderly humans (Finkelstein et al., 1972; Zadik et al., 1985; Wilshire 
et al., 1995) and aged rats (Sonntag et al., 1980; De Gennaro Colonna et al., 1994). Also in 
the dog there are indications that ageing is associated with impaired GH secretion. The basal 
plasma GH levels in the control dogs in the present study were lower than those in young 
adult bitches (Kooistra et al., 2000; Lee et al., 2001) employing the same GH assay. The 
decreased GH secretion in elderly humans has been ascribed to the blunted response of GH to 
GHRH (Shetty and Duthie, 1995) and feedback disruption of the regulatory GH-IGF-I system 
(Veldhuis, 1997). The decreased GH secretion in elderly rats is associated with decreased 
pituitary GH content (Sonntag et al., 1980), reduced pituitary GH mRNA (Takahashi et al., 
1990), and reduction of hypothalamic GHRH mRNA levels (De Gennaro Colonna et al., 
1994). 
With regard to the similar basal plasma GH levels in dogs with PDH and control dogs, 
it is important to notice that these values were close to the sensitivity of the GH assay used in 
the present study. Although the results of this study indicate that the basal plasma GH levels 
were similarly low in both groups, an ultrasensitive GH assay may be needed to confirm this 
observation. 
In conclusion, the results of this study demonstrate that PDH in dogs is associated with 
less GH secreted in pulses, whereas the basal plasma GH concentrations were similarly low in 
both groups. The impaired pulsatile GH secretion in dogs with PDH may be the result of 
alterations in function of pituitary somatotrophs and changes in supra-pituitary regulation. 
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Abstract 
The aim of this study was to investigate the effects of ghrelin and growth hormone-
releasing peptide-6 (GHRP-6) on the release of growth hormone (GH), adrenocorticotrophic 
hormone (ACTH), cortisol, thyroid-stimulating hormone (TSH), luteinizing hormone (LH), 
and prolactin (PRL) in dogs with pituitary-dependent hyperadrenocorticism (PDH) and in 
healthy dogs of comparable age. In eight healthy dogs, the responses to ghrelin and GHRP-6 
were compared to those of GH-releasing hormone (GHRH) and NaCl 0.9 % (control). In 
seven dogs with PDH, the effects of ghrelin and GHRP-6 were compared with their effects in 
healthy dogs. 
In the healthy dogs, GHRH, GHRP-6, and ghrelin caused a significant rise in plasma 
GH concentrations. Administration of GHRH elicited significantly higher plasma GH 
concentrations than administration of ghrelin and GHRP-6. In the dogs with PDH, the GHRP-
6-induced release of GH was significantly lower than in healthy dogs. Administration of 
ghrelin elicited a GH release that did not differ significantly between dogs with PDH and 
healthy dogs. Ghrelin and GHRP-6 did not cause a significant rise in plasma ACTH, cortisol, 
TSH, LH, and PRL concentrations in either the healthy dogs or the dogs with PDH. 
It is concluded that in comparison with GHRH, GHRP-6 and ghrelin have a low GH-
releasing potency in healthy dogs. In dogs with PDH, the GH release in response to GHRP-6 
is impaired. Neither GHRP-6 nor ghrelin activates the pituitary-adrenocortical axis or 
stimulates TSH, LH, and PRL release in healthy elderly dogs and dogs with PDH. 
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Introduction 
For many years it was thought that the pulsatile secretion of growth hormone (GH) by 
pituitary somatotrophs was controlled by the two antagonistic hypothalamic peptides GH-
releasing hormone (GHRH) and somatostatin (SS) (Plotsky and Vale, 1985). However, GH 
release can also be elicited by synthetic GH secretagogues (GHSs) (Bowers et al., 1977, 
Momany et al., 1981). Synthetic GHSs exert their effect on GH release by acting through 
receptors different from those for GHRH (Casanueva and Dieguez, 1999). Growth hormone-
releasing peptide-6 (GHRP-6) was the first powerful GHS used in humans and rats. 
Nowadays, GHRP-6 is the gold standard against which all so-called non-classic GHSs are 
compared (Korbonits and Grossman, 1995). After the introduction of GHRP-6, a new 
generation of peptidyl and non-peptidyl GHSs was developed (Casanueva and Dieguez, 
1999). Interestingly, most of the GHSs were constructed well before the isolation of GHRH in 
1982 (Guillemin et al., 1982, Rivier et al., 1982). In 1996, the GHS-receptor (GHS-R), a 
specific G-protein-coupled seven-transmembrane receptor, was identified by Pong et al. The 
GHS-R is present in various tissues (e.g. pituitary, hypothalamus, heart, lung, pancreas, 
intestine, adipose tissue). The demonstration of a hypothalamic and pituitary localization of 
the human GHS-R is consistent with its role in regulating GH release. The expression of this 
receptor in other central and peripheral regions may imply that it is involved in additional yet 
undefined physiological functions (Guan et al., 1997; Papotti et al., 2000; Kojima et al., 
2001). 
In 1999, Kojima et al. purified and characterized the endogenous ligand for the GHS-
R from rat and human stomach and called it ‘ghrelin’. Ghrelin has since been identified in the 
fundus of the stomach of dogs and appears to be highly conserved (Tomasetto et al., 2001). 
Unlike the digestive enzymes, ghrelin is not secreted into the gastrointestinal tract but 
released into the bloodstream to act - among other possible functions - on the pituitary to 
release GH. Ghrelin is a peptide of 28 amino acids, in which the hydroxyl group of the serine 
3 residue is esterified by n-octanoic acid. This octanoylation is essential for its GH-releasing 
activity (Kojima et al., 1999).  
In healthy humans, the endocrine effects of GHSs are not specific for GH. 
Administration of synthetic GHSs also significantly increases the secretion of prolactin 
(PRL), adrenocorticotrophic hormone (ACTH), and cortisol (Massoud et al., 1996, Arvat et 
al., 2001). According to Kojima et al. (1999), ghrelin specifically stimulates GH release and 
does not affect the secretion of other adenohypophyseal hormones in rats. In contrast, Arvat et 
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al. (2001) demonstrated that intravenous administration of ghrelin, apart from stimulating GH 
secretion, also increases circulating PRL, ACTH, and cortisol levels in healthy humans. 
Several pathological (e.g. obesity and chronic hypercortisolism) and non-pathological 
(e.g. ageing) states in humans are characterized by a reduction in pituitary GH secretion 
(Leal-Cerro et al., 1994). Chronic hypercortisolism is not only associated with reduced 
pituitary GH release (Hartog et al., 1964) but also with an impaired GH response to various 
stimuli (Casanueva, 1992). Even a combination of GHRH and GHRP-6, which is a very 
powerful GH-releasing stimulus, is unable to induce significant GH release in humans with 
Cushing’s syndrome (Leal-Cerro et al., 1994). So far, there are no reports on the effects of 
ghrelin on GH release in patients with hyperadrenocorticism. 
The aim of this study was to investigate the effects of ghrelin and GHRP-6 on the 
release of GH, ACTH, cortisol, thyroid-stimulating hormone (TSH), luteinizing hormone 
(LH), and PRL in dogs with pituitary-dependent hyperadrenocorticism (PDH) and in healthy 
dogs of comparable age.  
 
Materials and methods 
Dogs 
For the first study, eight healthy Beagle dogs (four males and four females) with ages 
ranging from 7 to 12 years (median age: 10 years) were used. In the second study, seven dogs 
of different breeds (seven males, two intact females and one spayed female), aged 9 to 13 
years (median age: 10 years), with PDH were studied.  
Diagnosis of hyperadrenocorticism was based upon elevated (> 10 x 10-6) 
corticoid/creatinine (C/C) ratios in two consecutive morning urine samples (Rijnberk et al., 
1988). After collection of the second urine sample, the dogs received three oral doses of 
dexamethasone (0.1 mg/kg body weight) at 8-h intervals. Then a third urine sample was 
collected. If the C/C ratio in this third urine sample was less than 50 % of the mean of the first 
two samples, PDH was diagnosed (Galac et al., 1997). In one dog in which the urinary C/C 
ratio was suppressed less than 50 %, the diagnosis of PDH was confirmed by an elevated 
plasma ACTH concentration, bilaterally enlarged adrenal glands on ultrasonographic 
examination, and an abnormal pituitary gland on computed tomography (Voorhout, 1990, 
Voorhout et al., 1990).  
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Study design and blood sample collection 
The first study was a randomized clinical trial in which the eight healthy Beagle dogs 
were randomly allocated to four groups. According to a Latin-square design, the dogs 
received an intravenous injection of either human GHRH (2 µg per kg body weight), GHRP-6 
[(His-D-Trp-Ala-Trp-D-Phe-Lys-NH2)3] (2 µg per kg body weight), human ghrelin (2 µg per 
kg body weight) (Peninsula Laboratories Inc. Belmont, CA, USA), or 0.9 % NaCl (control). 
In order to avoid carry-over effects, washout periods of at least 4 days were included in the 
protocol. 
In the second study, the seven dogs with PDH received an intravenous injection of 
either GHRP-6 (2 µg per kg body weight) or ghrelin (2 µg per kg body weight). One week 
later, the other compound was administered.  
Blood samples for the determination of plasma concentrations of GH, ACTH, cortisol, 
TSH, LH, and PRL were collected by jugular venipuncture at -15 and 0, 5, 10, 20, 30, and 45 
min and immediately transferred to ice-chilled EDTA-coated tubes (GH, ACTH, cortisol, LH 
and PRL) or heparin-coated tubes (TSH). Samples were centrifuged at 4o C for 10 min. 
Plasma was stored at -25o C until assayed. 
 
Hormone determination 
The urinary corticoid concentrations were measured with a non-commercial 
radioimmunoassay (RIA). The urinary corticoid concentration was related to the urinary 
creatinine concentration and the corticoid/creatinine ratio was calculated (Stolp et al., 1983; 
Rijnberk et al., 1988).  
Plasma GH concentrations were determined with a homologous RIA (Eigenmann and 
Eigenmann, 1981). The intra- and interassay coefficients of variation were 3.8 % and 7.2 % 
respectively, and the sensitivity of the assay was 0.3 µg/l. The degree of cross-reaction with 
canine PRL was 2 %.  
Plasma ACTH concentrations were measured with an immunoradiometric assay 
(Nichols Institute, Wijchen, The Netherlands). The interassay coefficient of variation was 7.8 
% and the sensitivity was 0.2 pmol/l.  
Plasma cortisol concentrations were measured with a commercially available RIA 
(Diagnostic Products Corporation, Los Angeles, CA, USA), validated for the dog. The intra- 
and interassay coefficients of variation ranged from 3.0 % to 5.1 % and from 4.0 % to 6.4 %, 
respectively. The sensitivity of the assay was 5.5 nmol/l.  
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Plasma TSH concentrations were determined with a homologous solid-phase, two-site 
chemiluminescent enzyme immunometric assay (Immulite canine TSH, Diagnostic Products 
Corporation [DPC]) according to the instructions of the manufacturer. The intra-assay 
coefficients of variation were 5.0 %, 4.0 %, and 3.8 % at TSH levels of 0.20, 0.50, and 2.60 
µg/l, respectively. The interassay coefficients of variation were 6.3 % and 8.2 % at TSH 
levels of 0.16 and 2.80 µg/l, respectively. The sensitivity of the assay was 0.03 µg/l. Cross-
reactivity with FSH and LH was negligible.  
Plasma LH concentrations were determined with a heterologous RIA as described 
previously by Nett et al. (1975). A rabbit antiserum raised against ovine LH (CSU-204; kindly 
supplied by G.D. Niswender, Colorado State University), radioiodinated NIAMDD-bLH-4, 
and canine pituitary standard LER 1985-1 (a gift from Dr. L.E. Reichert, Albany Medical 
College, NY) were used in this assay. The intra- and interassay coefficients of variation for 
values higher than 0.5 µg/l were 2.3 % and 10.5 % respectively. The sensitivity of the assay 
was 0.3 µg/l. 
Plasma concentrations of PRL were determined with a previously validated 
heterologous RIA (Okkens et al., 1985). The intra-assay and interassay coefficients of 
variation were 3.5 % and 11.5 %, respectively. The sensitivity of the assay was 0.8 µg/l. 
 
Statistical analysis 
The plasma concentrations of GH, ACTH, cortisol, TSH, LH, and PRL at -15 and 0 
min were averaged per dog and used in all analyses as the basal plasma hormone 
concentration (basal). 
Statistical analyses were performed using the MIXED procedure (SAS Version 8.02, 
SAS Institute Inc., Cary, NC, USA) with dog within group as the unit of analysis. Dog was 
considered a random effect. A first-order autoregressive covariance structure was used to 
model the autocorrelation in the repeated measures of the response variables. All data were 
log-transformed for further analysis to correct for non-normality.  
For the first study, models were fitted for GH, ACTH, cortisol, TSH, LH, and PRL 
respectively, with compound (ghrelin, GHRP-6, GHRH, and 0.9 % NaCl), group of dogs (1 to 
4), day of compound administration (day 1 to 4), and time (repeated measurement of 
hormones starting with the basal concentration), included as fixed effects. It was assumed 
there were no interactions between effects. For the second study, models were fitted 
separately for the responses of GH, ACTH, cortisol, TSH, LH, and PRL respectively, after 
ghrelin or GHRP-6 administration. Group (healthy dogs versus dogs with PDH), time 
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(repeated measurement of hormones starting with the basal concentration), and the interaction 
between group and time, allowing different slopes for both groups over time, were included as 
fixed effects. Values are expressed as mean ± SEM concentrations. Statistical significance 
was defined at P ≤ 0.05.  
 
Ethics of the study 
This study was approved by the Ethics Committee of the Faculty of Veterinary 
Medicine, Utrecht University. 
 
Results 
No side effects were observed during or after administration of the GH-releasing 
agents. In the healthy dogs, administration of ghrelin, GHRP-6, and GHRH resulted in a mean 
plasma GH concentration of 1.8 ± 0.5 µg/l, 2.7 ± 1.0 µg/l, and 5.5 ± 1.0 µg/l, respectively, 
which was significantly higher than that after administration of NaCl 0.9 % (0.9 ± 0.2 µg/l). 
GHRH administration caused a significantly higher mean plasma GH concentration (5.5 ± 1.0 
µg/l) than administration of ghrelin (1.8 ± 0.5 µg/l) or GHRP-6 (2.7 ± 1.0 µg/l) (Table 1 and 
Figure 1).  
Administration of the GH secretagogues did not cause stimulation of the pituitary-
adrenocortical axis. Administration of ghrelin (25 ± 5 ng/l), GHRP-6 (30 ± 6 ng/l), and 
GHRH (21 ± 4 ng/l) resulted in mean plasma ACTH concentrations that did not differ 
significantly from those measured after administration of NaCl 0.9 % (25 ± 5 ng/l). 
Furthermore, administration of ghrelin (64 ± 19 nmol/l), GHRP-6 (80 ± 24 nmol/l), or GHRH 
(55 ± 8 nmol/l) resulted in mean plasma cortisol concentrations that were not significantly 
higher than those measured after administration of NaCl 0.9 % (73 ± 13 nmol/l) (Table 1 and 
Figure 1). 
In the healthy dogs, the mean plasma TSH, LH, and PRL concentrations did not differ 
significantly when treated with the GH-releasing agents or NaCl 0.9 % (Table 1 and Figure 
1). 
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Table 1. Mean (± SEM) plasma concentrations of GH, ACTH, cortisol, TSH, LH, and PRL in eight healthy dogs 
treated with different GH secretagogues (GHSs) (ghrelin, GHRP-6, GHRH) and NaCl 0.9 % (control). 
 Ghrelin GHRP-6 GHRH Control 
GH (µg/l) 1.8 ± 0.5 a,b 2.7 ± 1.0 a,c 5.5 ± 1.0 a,b,c 0.9 ± 0.2 
ACTH (ng/l) 25 ± 5 30 ± 6 b 21 ± 4 b 25 ± 5 
Cortisol (nmol/l) 
TSH (µg/l) 
LH (µg/l) 
PRL (µg/l) 
64 ± 19 a 
0.26 ± 0.07 
3.8 ± 1.2 
3.4 ± 0.9 
80 ± 24 b 
0.24 ± 0.06 
5.5 ± 1.5 
2.5 ± 0.5 
55 ± 8 a,b 
0.28 ± 0.09 
3.5 ± 1.0 
2.8 ± 0.6 
73 ± 13 
0.23 ± 0.05 
4.1 ± 1.6 
3.0 ± 0.4 
a: significant difference in hormone concentrations between GHS and control group.  
b, c: significant difference in hormone concentrations between indicated GHSs. 
 
Administration of GHRP-6 to the healthy dogs elicited a mean plasma GH 
concentration of 2.7 ± 1.0 µg/l, which was significantly higher than the level in the dogs with 
PDH (0.8 ± 0.2 µg/l). Administration of ghrelin (1.8 ± 0.5 µg/l) led to a mean plasma GH 
concentration in the healthy dogs that did not differ significantly from that in the dogs with 
PDH (1.5 ± 0.7 µg/l). Neither GHRP-6 nor ghrelin caused a significant rise in plasma ACTH 
and cortisol concentrations in dogs with PDH. (Table 2, Figures 2 and 3). The mean plasma 
TSH, LH, and PRL concentrations in the healthy dogs after GHRP-6 or ghrelin administration 
did not differ significantly from that in the dogs with PDH and these hormone concentrations 
were not stimulated by the GHSs (Table 2, Figures 2 and 3). 
 
Table 2. Mean (± SEM) plasma concentrations of GH, ACTH, cortisol, TSH, LH, and PRL in seven dogs with 
pituitary-dependent hyperadrenocorticism (PDH) and eight healthy dogs treated with GHRP-6 and ghrelin. 
 GHRP-6  Ghrelin 
 PDH Healthy  PDH Healthy 
GH (µg/l) 0.8 ± 0.2 a    2.7 ± 1.0 a  1.5 ± 0.7 1.8 ± 0.5 
ACTH (ng/l) 120 ± 30 a   30 ± 6 a  114 ± 24 a 25 ± 5 a 
Cortisol (nmol/l) 
TSH (µg/l) 
LH (µg/l) 
PRL (µg/l) 
246 ± 53 a 
0.21 ± 0.06 
6.3 ± 2.6 
3.6 ± 0.9 
        80 ± 24 a 
      0.24 ± 0.06 
        5.5 ± 1.5 
        2.5 ± 0.5 
 
174 ± 26 a 
0.24 ± 0.05 
7.3 ± 2.7 
4.1 ± 1.3 
64 ± 19 a 
0.26 ± 0.07 
3.8 ± 1.2 
3.4 ± 0.9  
a: significant difference in hormone concentrations between dogs with PDH and healthy dogs  
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Figure 1. Mean (+ SEM) plasma concentrations of GH, ACTH, cortisol, TSH, LH, and PRL after intravenous 
administration of ghrelin (♦), GHRP-6 (▲), GHRH (■), or NaCl 0.9 % (○) in eight healthy dogs. 
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Figure 2. Mean (+ SEM) plasma concentrations of GH, ACTH, cortisol, TSH, LH, and PRL after administration 
of GHRP-6 in eight healthy dogs (□) and in seven dogs with pituitary-dependent hyperadrenocorticism (PDH) 
(■). 
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Figure 3. Mean (+ SEM) plasma concentrations of GH, ACTH, cortisol, TSH, LH, and PRL after intravenous 
administration of ghrelin in eight healthy dogs (□) and in seven dogs with pituitary-dependent 
hyperadrenocorticism (PDH) (■). 
 
0
2
4
6
8
10
basal 5 10 15 20 25 30 35 40 45
Time (min) 
G
H
 (µ
g/
l) 
  .
0
50
100
150
200
250
basal 5 10 15 20 25 30 35 40 45
Time (min) 
A
CT
H
 (n
g/
l) 
  ,
0
100
200
300
400
basal 5 10 15 20 25 30 35 40 45
Time (min) 
Co
rti
so
l (
nm
ol
/l)
   
.
0.0
0.1
0.2
0.3
0.4
0.5
basal 5 10 15 20 25 30 35 40 45
Time (min)
TS
H
 (µ
g/
l) 
  ,
0
2
4
6
8
10
12
14
basal 5 10 15 20 25 30 35 40 45
Time (min)
LH
 (µ
g/
l) 
  ,
0
1
2
3
4
5
6
7
basal 5 10 15 20 25 30 35 40 45
Time (min)
PR
L 
(µ
g/
l) 
  ,
Chapter 4 
 
 
102 
Discussion 
The results of this study demonstrate that both the natural and a synthetic ligand of the 
GHS-R (ghrelin and GHRP-6, respectively) stimulate GH release in healthy dogs. The results 
also underline the existence of intriguing species differences with regard to the GH-releasing 
potency of GHSs. In rats, the GH-releasing potency of ghrelin is similar to that of GHRH 
(Kojima et al., 1999), whereas in humans, ghrelin is a more potent stimulus of GH secretion 
than GHRH or the synthetic GHS hexarelin (Arvat et al., 2001). The results of the present 
study indicate that, compared with the GH-releasing effect of GHRH, ghrelin and GHRP-6 
are not very potent stimulators of GH release in elderly dogs. 
The GH response to stimulation with GHRH in the healthy dogs was considerably 
lower than that reported previously in healthy Beagle dogs (Meij et al., 1996). This may at 
least partly be due to the effects of ageing, because the healthy Beagle dogs in the study of 
Meij et al. (1996) had a median age of two years. It has been reported that GH secretion 
decreases in humans with increasing age (Finkelstein et al., 1972; Zadik et al., 1985; Wilshire 
et al., 1995) and in aged rats (Sonntag et al., 1980; De Gennaro Colonna et al., 1994). The 
decreased GH secretion in elderly humans has been ascribed to a blunted response of GH to 
GHRH (Shetty and Duthie, 1995) and feedback disruption of the regulatory GH-insulin-like 
growth factor-I system (Veldhuis, 1997). The decreased GH secretion in elderly rats is 
associated with a decreased pituitary GH content (Sonntag et al., 1980), reduced pituitary GH 
mRNA (Takahashi et al., 1992), and reduction of hypothalamic GHRH mRNA levels (De 
Gennaro Colonna et al., 1994). Also in the dog there are indications that ageing is associated 
with an impaired GH secretion. Cella et al. (1995) have demonstrated that the GH 
responsiveness to hexarelin, a synthetic GHS, decreases with ageing in the dog. This was 
previously shown for GH-releasing peptides in humans (Bowers et al., 1992) and rats (Walker 
et al., 1990). Data for aged dogs reinforce the idea that the pituitary mechanisms subserving 
GH secretion are, at least partially, preserved during ageing. Thus, the reduced GH secretion 
is mainly due to inadequate hypothalamic stimulation rather than a primary pituitary 
hypofunction (Franchimont et al., 1989; Walker et al., 1991; Cella et al., 1993). Because of 
the effects of ageing on GH secretion, in the present study dogs with PDH were compared 
with healthy dogs of comparable age. 
Chronic hypercortisolism is associated with impaired somatic growth, reduced GH 
release (Hartog et al., 1964), and a blocked GH response to various GH stimuli (Casanueva, 
1992). Even a combination of GHRH and GHRP-6, which is a very powerful GH-releasing 
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stimulus, is unable to induce significant GH release in humans with Cushing’s syndrome 
(Leal-Cerro et al., 1994). The results of the present study demonstrate that administration of 
GHRP-6 also results in a blunted GH response in dogs with PDH. The GH response after 
administration of ghrelin to dogs with PDH and healthy dogs was low and not significantly 
different. The mechanism by which chronic glucocorticoid excess inhibits GH secretion is not 
yet fully understood. Several hypotheses have been proposed, the most important of which are 
GHRH hyposecretion, enhancement of hypothalamic SS release, or a combination of these 
(Leal-Cerro et al., 1998). In addition to the effect at the hypothalamic level, chronic 
glucocorticoid excess may also influence GH secretion by acting directly at the pituitary level 
(Leal-Cerro et al., 1994).  
Polyphagia, polyuria, polydipsia, thin coat, alopecia, and muscular atrophy are the 
classical clinical manifestations of PDH in dogs (Rijnberk et al., 1968). Another cardinal 
physical feature is centripetal obesity with abdominal enlargement. As not only chronic 
hypercortisolism but also obesity is associated with an impaired GH response to GH-releasing 
stimuli (Bowers, 1993), it can be hypothesized that the suppressed GH release in Cushing’s 
syndrome is related to obesity as well. Indeed, Leal-Cerro et al. (1998) demonstrated that in 
humans with Cushing’s disease the hyporesponsiveness of somatotrophs to GHRH is 
improved after a short-term (3 days) hypocaloric diet. Indeed, GH secretion is increased after 
fasting in healthy humans (Ho et al., 1988) and healthy dogs (Arce et al., 1991), indicating 
that caloric restriction exerts an important stimulatory effect on GH secretion. This may be 
explained by two concurrently operating mechanisms, an increase in hypothalamic GHRH 
and a decrease in hypothalamic somatostatin, leading to increased plasma GH levels (Ho et 
al., 1988). However, in contrast to the situation of chronic hypercortisolism (Leal-Cerro et al., 
1994), intravenous administration of the combination of GHRH and GHRP-6 resulted in an 
elevated GH response in obese humans (Bowers, 1993). This indicates that the impaired GH 
response in individuals with Cushing’s syndrome cannot be explained solely by obesity.  
Administration of ghrelin and GHRP-6 did not cause a stimulation of the pituitary-
adrenocortical axis and did not stimulate TSH, LH, and PRL release in either the healthy dogs 
or the dogs with PDH. These results are in line with observations for anaesthetized rats 
reported by Kojima et al. (1999), who found that intravenous administration of ghrelin 
specifically stimulated GH release but did not affect other adenohypophyseal hormones. In 
contrast, Arvat et al. (2001) demonstrated that intravenous administration of ghrelin, apart 
from stimulating GH release, also increased circulating levels of PRL, ACTH, and cortisol in 
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healthy humans. So far, there is no explanation for this discrepancy other than species 
differences. 
In conclusion, the results of this study demonstrate that, in comparison with GHRH, 
GHRP-6 and ghrelin have a low GH-releasing potency in healthy dogs. In dogs with PDH, the 
GH response to GHRP-6 is impaired. Neither GHRP-6 nor ghrelin activates the pituitary-
adrenocortical axis or stimulates TSH, LH, and PRL release in healthy elderly dogs and dogs 
with PDH.  
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Abstract 
The effects of three growth hormone secretagogues (GHSs), ghrelin, growth hormone- 
releasing peptide-6 (GHRP-6), and growth hormone-releasing hormone (GHRH), on the 
release of adenohypophyseal hormones, growth hormone (GH), adrenocorticotrophic 
hormone (ACTH), thyroid-stimulating hormone (TSH), luteinizing hormone (LH), prolactin 
(PRL) and on cortisol were investigated in young and old healthy Beagle dogs.  
Ghrelin proved to be the most potent GHS in young dogs, whereas in old dogs, GHRH 
administration was associated with the highest plasma GH concentrations. The mean plasma 
GH response after administration of ghrelin was significantly lower in the old dogs compared 
with the young dogs. The mean plasma GH concentration after GHRH and GHRP-6 
administration was lower in the old dogs compared with the young dogs, but this difference 
did not reach statistical significance. In both age groups, the GHSs were specific for GH 
release as they did not cause significant elevations in the plasma concentrations of ACTH, 
cortisol, TSH, LH, and PRL.  
It is concluded that in young dogs, ghrelin is a more powerful stimulator of GH release 
than either GHRH or GHRP-6. Ageing is associated with a decrease in GH-releasing capacity 
of ghrelin, whereas this decline is considerably lower for GHRH or GHRP-6.  
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Introduction 
In 1977, Bowers and co-workers reported the growth hormone (GH)-releasing 
properties of enkephalin-derived peptides (Bowers et al., 1977). Among these synthetic 
peptides, GH-releasing peptide-6 (GHRP-6) proved to be a potent releaser of GH, both in 
vitro and in vivo, in several species (Bowers et al., 1984; Casanueva and Dieguez, 1999). 
After the synthesis of GHRP-6, new peptydil (e.g. hexarelin) and non-peptydil (e.g. MK-
0677) GH secretagogues (GHSs) with a higher bioavailability and a longer life span were 
produced (Ghigo et al., 1994; Patchett et al., 1995). These synthetic GHSs have a potent GH-
releasing activity in humans, mice, rats (Bowers et al., 1977; Bowers et al., 1984; Ghigo et al., 
1994; Casanueva and Dieguez, 1999), swine, goats, and cows (Hayashida et al., 2001).  
In humans, nearly all synthetic GHSs are more powerful than growth hormone-
releasing hormone (GHRH) in terms of GH release (Casanueva and Dieguez, 1999). Studies 
in dogs have shown that orally (e.g. MK-0677, capromorelin) and intravenously (e.g. 
hexarelin) administered GHSs are effective GH releasers as well (Cella et al., 1995; Jacks et 
al., 1996; Rigamonti et al., 1999; Carpino et al., 2003). However, the action of the synthetic 
GHSs is not always confined to the promotion of GH release (Smith et al., 1997; Casanueva 
and Dieguez, 1999; Lamberts, 1999). For instance, in man, synthetic GHSs such as GHRP-6 
stimulate the secretion of PRL, ACTH, and cortisol as well (Massoud et al., 1996; Smith et 
al., 1997; Casanueva and Dieguez, 1999; Lamberts, 1999; Arvat et al., 2001). Additionally in 
rats, GHRP-6 activates the pituitary-adrenocortical axis (Thomas et al., 1997).  
GHSs stimulate GH release from the pituitary somatotrophs by acting on receptors 
different from those for GHRH (Momany et al., 1981). In the mid-nineties, the GHS-receptor 
(GHS-R), a G-protein-coupled seven-transmembrane receptor was first detected in the 
anterior pituitary and hypothalamus of rats and humans (Pong et al., 1996). In 1999, Kojima 
et al. purified and characterized the endogenous ligand for the GHS-R in rats and humans. 
The 28-amino-acid peptide with an n-octanoyl modification at its third Serine residue was 
called ‘ghrelin’. Surprisingly, its expression was found to be much higher in the stomach than 
in any other tissue. Tomasetto and coworkers (2001) identified cDNA encoding ghrelin from 
the fundus of the canine stomach as well, and found that it is highly conserved with man, 
mouse and rat. Thus, structural heterogeneity of ghrelin among species seems minor, and we 
could probably expect a rather functional homogeneity in various mammalian species. 
Ghrelin’s expression is restricted to the X/A- like cells, or Ghr-cells, of the oxyntic gland 
(Date et al., 2000; Rindi et al., 2002).  
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The GH-releasing activity of ghrelin is more marked in humans than in animals (Smith 
et al., 1997; Kojima et al., 1999; Seoane et al., 2000; Takaya et al., 2000). In humans, the GH 
response to ghrelin is considerably greater than that observed following administration of 
GHRH or synthetic GHSs (Seoane et al., 2000; Takaya et al., 2000; Arvat et al., 2001; 
Bowers, 2001), whereas in rats, the GH-releasing potency of ghrelin is similar to that of 
GHRH (Kojima et al., 1999). In both isolated pituitary cells and intact (anaesthetized) rats, 
ghrelin solely stimulates GH release and does not affect the secretion of other 
adenohypophyseal hormones (Kojima et al., 1999). However, in humans, ghrelin significantly 
increases circulating concentrations of adrenocorticotrophic hormone (ACTH), cortisol, and 
prolactin (PRL), without affecting the release of luteinizing hormone (LH), follicle-
stimulating hormone (FSH) or thyroid-stimulating hormone (TSH) (Massoud et al., 1996; 
Arvat et al., 2001).  
The ageing process of organisms may be regarded as a progressive fall in bodily 
functions associated with a diminished ability to maintain homeostasis (Everitt and Meites, 
1989). Both basal and stimulated GH secretion and circulating insulin-like growth factor-I 
(IGF-I) concentrations decline with age in several mammalian species (Finkelstein et al., 
1972; Rudman, 1985; Zadik et al., 1985; Corpas et al., 1992; Wilshire et al., 1995; Muller et 
al., 2002). Also in dogs, the GH responsiveness to GH stimuli, such as GHRH and hexarelin, 
decreases with ageing (Cella et al., 1989; Cella et al., 1995). Until now, the effect of ageing 
on the GH responsiveness to ghrelin has not been studied in dogs. Preliminary results on the 
effects of GHSs on GH, ACTH, and cortisol concentrations in old dogs have been reported 
earlier (Bhatti et al., 2002). 
The aim of this study was to compare the effects of ghrelin, GHRP-6, and GHRH on 
the release of GH, ACTH, cortisol, TSH, LH, and PRL in both young and old healthy dogs.  
 
Materials and methods 
Dogs 
Four young female and four young male Beagle dogs aged between 13-17 months 
(median 15 months) and four old female and four old male Beagle dogs aged between 7-12 
years (median 10 years) were used. The mean body weight of the young dogs (11.8 kg) was 
significantly lower (P = 0.01, Mann-Whitney test) than that of the old dogs (17.9 kg). The 
dogs were accustomed to the laboratory environment and procedures such as collection of 
blood samples. They were housed in pairs in indoor-outdoor runs, had free access to tap water 
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and were fed on a commercial dog food. They were healthy and had no history of illnesses or 
treatments. All studies were carried out in conscious animals after an overnight fast. The 
bitches were in anoestrus during the study.  
 
Study design and blood sample collection 
Two 4x4 cross-over studies (young and old dogs, respectively) were conducted at 
different times. Each dog received four treatments sequentially on four different days (day 1 
to 4) with a washout period of at least four days in between. The dogs were two by two 
randomly assigned to one of the four treatment sequences. The four treatments consisted of an 
intravenous injection of either human ghrelin (MW 3370.9) in a dose of 2 µg/kg body weight 
(Peninsula Laboratories Inc), GHRP-6 [(His-D-Trp-Ala-Trp-D-Phe-Lys-NH2)3] (MW 872.4) 
in a dose of 2 µg/kg body weight, human GHRH (MW 5036.6) in a dose of 2 µg/kg body 
weight (hGHRF; Peninsula Laboratories Inc), or NaCl 0.9 % (control).  
Blood samples for the determination of plasma concentrations of GH, ACTH, cortisol, 
TSH, LH, and PRL were collected by jugular venipuncture at 15 min before and 0, 5, 10, 20, 
30, and 45 min after intravenous administration of the treatments and immediately transferred 
to ice-chilled EDTA-coated tubes (GH, ACTH, cortisol, LH, and PRL) or heparin-coated 
tubes (TSH). Samples were centrifuged at 4o C for 10 min. Plasma was stored at -25o C until 
assayed.  
 
Hormone determination  
Plasma GH concentrations were determined with a homologous radioimmunoassay 
(RIA) (Eigenmann and Eigenmann, 1981). The intra- and interassay coefficients of variation 
were 3.8 % and 7.2 %, respectively, and the sensitivity of the assay was 0.3 µg/l. The degree 
of cross-reaction with canine PRL was 2 %.  
Plasma ACTH concentrations were determined with an immunoradiometric assay 
(Nichols Institute, Wijchen, The Netherlands). The inter-assay coefficient of variation was 7.8 
% and the sensitivity was 0.2 pmol/l.  
Plasma cortisol concentrations were determined with a commercially available RIA 
(Diagnostic Products Corporation), validated for the dog. The intra- and interassay 
coefficients of variation ranged from 3.0 to 5.1 % and from 4.0 to 6.4 %, respectively. The 
sensitivity of the assay was 5.5 nmol/l.  
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Plasma TSH concentrations were determined with a homologous solid-phase, two-site 
chemiluminescent enzyme immunometric assay (Immulite canine TSH, Diagnostic Products 
Corporation [DPC]) according to the instructions of the manufacturer. The intra-assay 
coefficients of variation were 5.0 %, 4.0 %, and 3.8 % at TSH levels of 0.20, 0.50, and 2.60 
µg/l, respectively. The interassay coefficients of variation were 6.3 % and 8.2 % at TSH 
levels of 0.16 and 2.80 µg/l, respectively. The sensitivity of the assay was 0.03 µg/l. Cross-
reactivity with FSH and LH was negligible.  
Plasma LH concentrations were determined with a heterologous RIA as described 
previously by Nett et al. (1975). A rabbit antiserum raised against ovine LH (CSU-204; kindly 
supplied by G.D. Niswender, Colorado State University), radioiodinated NIAMDD-bLH-4, 
and canine pituitary standard LER 1985-1 (a gift from Dr. L.E. Reichert, Albany Medical 
College, NY) were used in this assay. The intra- and interassay coefficients of variation for 
values higher than 0.5 µg/l were 2.3 % and 10.5 % respectively. The sensitivity of the assay 
was 0.3 µg/l. 
Plasma concentrations of PRL were determined with a previously validated 
heterologous RIA (Okkens et al., 1985). The intra- and interassay coefficients of variation 
were 3.5 % and 11.5 %, respectively. The sensitivity of the assay was 0.8 µg/l. 
 
Statistical analysis 
1. Cross-over studies 
Mixed models with dog as random effect were fitted to study the association between 
treatment (ghrelin, GHRP-6, GHRH, and NaCl 0.9 %) and the plasma hormone 
concentrations (GH, ACTH, cortisol, TSH, LH, and PRL) in the young and the old dogs. 
Treatment, day of treatment (day 1-4), and time (repeated measures of adenohypophyseal 
hormones and cortisol starting with the basal concentration) were included as fixed effects. 
The four treatments were compared pair wise adjusting for multiple comparisons (Tukey’s 
correction). In addition, difference between the plasma hormone concentration (GH, ACTH, 
cortisol, TSH, LH, and PRL) just before (0 min) injection of the GHSs or NaCl 0.9 % and the 
maximal plasma hormone concentration after injection was calculated (referred to as the 
maximal increment) and used to capture the effect of treatment. Therefore, a mixed model 
was fitted to the maximal increments as response variables with dog as random effect and day 
of treatment and treatment as fixed effects. The four treatments were compared pair wise 
(Tukey’s correction). 
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2) Comparison between young and old dogs 
The basal plasma hormone concentrations (mean of -15 and 0 min, collected in the 
cross-over studies) of the young and the old dogs were compared using an independent 
samples t-test to study differences between age groups before treatment. Additionally, if the 
analyses based on the cross-over studies indicated a significant treatment effect in one or both 
age groups, a repeated measures analysis was performed in order to compare the respective 
hormone response between old and young dogs. Therefore, models were fitted including dog 
as random effect, and age (young versus old dogs), time (-15, 0, 5, 10, 20, 30, and 45 min), 
and the interaction between age and time as categorical fixed effects. A first-order 
autoregressive covariance structure was used to model the correlation in the repeated 
measures of the response variables.  
Statistical significance was defined at P ≤ 0.05. Values are expressed as mean 
concentrations of all hormone measurements ± SEM. Analyses were performed with SAS 
version 8.02 (SAS Institute Inc) and S-Plus version 6.1 for Windows (Insightful Corp). 
 
Ethics of the study 
This study was approved by the Ethical Committees of the Faculty of Veterinary 
Medicine, Utrecht University, the Netherlands, and the Faculty of Veterinary Medicine, 
Ghent University, Belgium. 
 
Results 
No side effects were observed during or after administration of the GH-releasing 
agents.  
The mean plasma GH concentration in the young dogs when treated with ghrelin was 
15.0 ± 5.1 µg/l, which was significantly higher than the concentration in the dogs when 
treated with GHRP-6 (2.7 ± 1.2 µg/l) or NaCl 0.9 % (1.8 ± 1.1 µg/l). The mean plasma GH 
concentration in the young dogs when treated with ghrelin did not differ significantly from 
this concentration in dogs when treated with GHRH (7.5 ± 3.8 µg/l). The mean GH 
concentration in the young dogs when treated with GHRH did not differ significantly from 
that in dogs when treated with GHRP-6 (Figure 1a). Analysis of the maximal increment 
indicated that the mean plasma GH response was significantly higher after treatment with 
ghrelin when compared with this response after GHRP-6 (P = 0.01) or NaCl 0.9 % (P = 
Chapter 5 
 
 
118 
0.007) injection, and tended to be higher than the response induced by administration of 
GHRH (P = 0.06) (Figure 2a).  
The mean plasma ACTH concentration in the young dogs when treated with ghrelin, 
GHRP-6, GHRH, and NaCl 0.9 % was 68 ± 22 ng/l, 61 ± 17 ng/l, 33 ± 7 ng/l, and 38 ± 9 ng/l, 
respectively. Although plasma ACTH concentrations were higher when the dogs were 
injected with ghrelin or GHRP-6, the concentrations were not significantly different from 
these measured when GHRH or NaCl 0.9 % were administered (Figure 1b). A treatment 
effect could not be demonstrated based on comparison of the maximal increments (Figure 2b). 
The mean plasma cortisol concentration in the young dogs when treated with ghrelin, 
GHRP-6, and GHRH was 102 ± 23 nmol/l, 109 ± 22 nmol/l, and 87 ± 21 nmol/l, respectively. 
These levels were not significantly different from that obtained when NaCl 0.9 % was 
administered (84 ± 21 nmol/l) (Figure 1c). No treatment effect was present based on 
comparison of the maximal increments (Figure 2c). 
In the young dogs, the mean plasma TSH, LH, and PRL concentrations did not differ 
significantly when treated with the GH-releasing agents or NaCl 0.9 % (Figures 1d-f, 
respectively), and no treatment effects were present based on comparison of the maximal 
increments (Figures 2d-f, respectively). 
The mean plasma GH concentration in the old dogs when treated with ghrelin, GHRP-
6, and GHRH was 1.8 ± 0.5 µg/l, 2.7 ± 1.0 µg/l, and 5.5 ± 1.0 µg/l, respectively, which was 
significantly higher than the concentration in the dogs when treated with NaCl 0.9 % (0.9 ± 
0.2 µg/l). The mean plasma GH concentration in dogs when treated with GHRH was 
significantly higher than in dogs when treated with ghrelin or GHRP-6 (Figure 3a). Moreover, 
analysis of the maximal increment indicated that the plasma GH response was significantly 
higher after treatment with GHRH than the response after administration of ghrelin or NaCl 
0.9 % (Figure 4a).  
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Figure 1. (a-f) Mean plasma concentrations of GH, ACTH, cortisol, TSH, LH, and PRL before and after 
intravenous administration of ghrelin (♦), GHRP-6 (▲), GHRH (■), or NaCl 0.9 % (○) in eight healthy young 
dogs. The arrows indicate the intravenous administration of the treatment. 
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Figure 2. (a-f) The mean (+SEM) difference in plasma concentrations of GH, ACTH, cortisol, TSH, LH and 
PRL between 0 min and the maximal increment after administration of the GHSs and NaCl 0.9 % in eight 
healthy young dogs.  
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The mean plasma ACTH concentration in the old dogs when treated with ghrelin (25 ± 
5 ng/l), GHRP-6 (30 ± 6 ng/l), and GHRH (21 ± 4 ng/l) was not significantly different from 
that in the dogs when treated with NaCl 0.9 % (25 ± 5 ng/l) (Figure 3b). Also, the mean 
plasma cortisol concentration in the old dogs when treated with ghrelin (64 ± 19 nmol/l), 
GHRP-6 (80 ± 24 nmol/l), or GHRH (55 ± 8 nmol/l) did not differ significantly from that in 
the dogs when treated with NaCl 0.9 % (73 ± 13 nmol/l) (Figure 3c). Additionally, no 
treatment effects were present based on comparison of the maximal increments (Figures 4b 
and 4c, respectively). 
In the old dogs, the mean plasma TSH, LH, and PRL concentrations did not differ 
significantly when treated with the GH-releasing agents or NaCl 0.9 % (Figures 3d-f, 
respectively), and no treatment effects were present based on comparison of the maximal 
increments (Figures 4d-f, respectively).  
The mean basal plasma GH concentration in the young dogs (1.4 ± 0.5 µg/l) did not 
differ significantly from that in the old dogs (1.6 ± 0.3 µg/l). The mean basal plasma 
concentrations of ACTH and cortisol were significantly lower in the old dogs (26 ± 3 ng/l and 
55 ± 4 nmol/l, respectively) than in the young dogs (36 ± 4 ng/l and 76 ± 7 nmol/l, 
respectively). The mean basal plasma concentrations of TSH, LH, and PRL were significantly 
higher in the old dogs (0.32 ± 0.05 µg/l, 4.4 ± 0.7 µg/l, 4.2 ± 0.4 µg/l, respectively) than in the 
young dogs (0.13 ± 0.01 µg/l, 1.9 ± 0.2 µg/l and 2.1 ± 0.2 µg/l, respectively).  
The mean plasma GH response after treatment with ghrelin, GHRP-6, and GHRH, 
respectively, was compared between young and old dogs. The mean plasma GH response 
after administration of ghrelin was significantly lower in the old dogs compared with the 
young dogs. In addition, this plasma GH response evolved significantly different over time 
between both groups (Figure 1a versus Figure 3a). The mean plasma GH response after 
treatment with GHRP-6 or GHRH was lower in the old dogs when compared with the young 
dogs, but this was not statistically significant. Additionally, this plasma GH response did not 
evolve significantly different over time when both groups were compared (Figure 1a versus 
Figure 3a). 
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Figure 3. (a-f) Mean plasma concentrations of GH, ACTH, cortisol, TSH, LH, and PRL before and after 
intravenous administration of ghrelin (♦), GHRP-6 (▲), GHRH (■), or NaCl 0.9 % (○) in eight healthy old dogs. 
The arrows indicate the intravenous administration of the treatment.  
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Figure 4. (a-f) The mean (+SEM) difference in plasma concentrations of GH, ACTH, cortisol, TSH, LH and 
PRL between 0 min and the maximal increment after administration of the GHSs and NaCl 0.9 % in eight 
healthy old dogs. 
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Discussion 
The results of the present study demonstrate that the natural ligand of the GHS-R, 
ghrelin, causes a significant rise in plasma GH levels in healthy young and old dogs. In the 
young dogs, ghrelin is a potent releaser of GH when compared with the other stimulants used 
in our study. However, in the old dogs, GHRH elicited higher plasma GH levels than ghrelin, 
GHRP-6, or NaCl 0.9 % administration. With regard to the GH-releasing potency of GHSs, 
these findings further substantiate the existence of remarkable species-related differences. In 
rats, the GH-releasing potency of ghrelin is similar to that of GHRH (Kojima et al., 1999), 
whereas in humans ghrelin is a more potent stimulus of GH secretion than GHRH or the 
synthetic GHS hexarelin (Takaya et al., 2000; Arvat et al., 2001).  
Our findings also indicate the existence of age-related differences in the GH-releasing 
potency of GHSs. The ghrelin-induced GH response was much lower at old age than at young 
age. In addition, the GHRP-6- and GHRH-induced release of GH was lower in the old versus 
the young dogs, although this difference was not statistically significant. These observations 
are compatible with findings in humans, showing that not only the GH-releasing effect of 
ghrelin (Broglio et al., 2003) but also that of GHRH and peptidyl or nonpeptidyl synthetic 
GHSs undergoes an age-related decrease (Bowers et al., 1992; Aloi et al., 1994; Chapman et 
al., 1996; Muccioli et al., 2002; Broglio et al., 2003). In old rats, the GH response to synthetic 
GHSs is impaired as well (Ceda et al., 1986; Walker et al., 1990). Also in old dogs, the GH 
responsiveness to the synthetic GHS hexarelin has been reported to be low (Cella et al., 
1995).  
The GH-releasing activity of ghrelin and synthetic GHSs depends on the functional 
integrity of the hypothalamus-pituitary unit (Muccioli et al., 2002). In humans, it has been 
demonstrated that the age-related reduction of both spontaneous and stimulated GH secretion 
reflects age-related changes in the neural control of somatotrope function (Giustina and 
Veldhuis; 1998; Ghigo et al., 1999). These changes include a concomitant reduction in the 
secretion of GHRH and enhancement in somatostatin release (Kelijman, 1991; Giustina and 
Veldhuis; 1998; Ghigo et al., 1999; Muller et al., 1999). It seems that an impairment of 
pituitary function does not play a major role (Muller et al., 1999). Indeed, repeated GHRH 
injections in elderly subjects, combined administration of GHRH and clonidine in old dogs, or 
GHRH + GHRP-6 injection in aged rats (Walker et al., 1991) significantly increases 
circulating GH levels (Cella et al., 1993; Nicolas et al., 1994). Additionally, the age-related 
decrease of the GH response to ghrelin and synthetic GHSs agrees with the well-known in 
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vitro hyporesponsiveness of the aged somatotroph cells to the majority of provocative stimuli, 
including GHRH, despite the availability of a remarkable GH-releasable pool (Giustina and 
Veldhuis, 1998; Ghigo et al., 1999; Muccioli et al., 2002) 
These observations support the idea that the somatopause is driven primarily by the 
hypothalamus and that the pituitary somatotrophs retain their capacity to synthesize and 
secrete adequate levels of GH (Franchimont et al., 1989; Walker et al., 1990; Corpas et al., 
1992; Cella et al., 1993; Muller et al., 1999; Muccioli et al., 2002).  
A decline of GHS-Rs in the ageing brain (Arvat et al., 1998; Muccioli et al., 2002) 
could further explain the reduced GH response to ghrelin/GHSs in elderly humans. Based on 
the relative great age-related decline in the GH response to ghrelin compared with that to 
GHRH in dogs, it may be hypothesized that also in dogs GHS-R expression decreases 
considerably with age.  
In the present study, the old dogs were significantly heavier than the young dogs. 
Obesity, a condition commonly observed in adulthood, is associated with an impaired GH 
response to GH-releasing stimuli (Daughaday and Rotwein, 1989; Bowers, 1993; Arvat et al., 
1998). This may have played a contributing role in the age-associated decline of the GH 
response. A longitudinal study, in which the GHS-induced hormone responses in dogs in 
function of age are investigated over several years while maintaining a constant body weight 
in all dogs, could lead to more reliable conclusions.  
Also with regard to the effects of GHSs on the release of adenohypophyseal hormones 
other than GH, there are interesting species-related differences. In this study, the action of 
ghrelin and GHRP-6 appeared to be GH-specific in dogs, i.e., the stimulants did not induce a 
significant rise in plasma concentrations of ACTH, cortisol, TSH, LH, and PRL in either the 
young dogs or the old dogs. The absence of a TSH and LH response to GHSs is compatible 
with the results of previous studies of the hormone-releasing effects of ghrelin in humans and 
rats (Arvat et al., 1997; Kojima et al., 1999). In contrast, the stimulatory effect of ghrelin and 
synthetic GHSs on PRL secretion varies with the species studied.  
In humans, ghrelin and synthetic GHSs induce a significant release of PRL which is 
independent of both gender and age and probably results from direct stimulation of 
somatomammotroph cells (Renner et al., 1994; Arvat et al., 1997; Takaya et al., 2000; 
Muccioli et al., 2002). In dogs (Hickey et al., 1994) and rats (Kojima et al., 1999), synthetic 
GHSs do not stimulate PRL release. This species-related difference may be explained by 
different numbers of somatomammotrophs in various species (Raun et al., 1998), with 
humans having a high proportion of these cells (Frawley and Boockfor, 1991).  
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Furthermore, administration of the GHSs did not elicit a significant activation of the 
pituitary-adrenocortical axis in the dogs. In contrast, intravenous administration of ghrelin or 
synthetic GHSs, such as hexarelin, considerably increases circulating levels of ACTH and 
cortisol in healthy humans (Massoud et al., 1996; Arvat et al., 1997; Takaya et al., 2000). 
Kojima et al. (1999) reported that intravenously administered ghrelin specifically stimulates 
GH release in anaesthetized rats and in isolated rat pituitary cells, but does not affect the 
release of other adenohypophyseal hormones. However, Thomas et al. (1997) have shown 
that GHRP-6 mediates the release of ACTH and cortisol in conscious rats. The mechanism by 
which ghrelin and synthetic GHSs stimulate the pituitary-adrenocortical axis is still unknown, 
but seems to be mediated via the hypothalamus as it is lost after cutting the pituitary stalk 
(Loche et al., 1995). They may interact with hypothalamic peptides (e.g. corticotrophin-
releasing hormone, arginine vasopressin, and neuropeptide Y) controlling ACTH release 
(Dickson and Luckman, 1997; Thomas et al., 1997; Korbonits et al., 1999; Broglio et al., 
2003), most probably primarily via arginine vasopressin (Korbonits et al., 1999).  
In swine, some recently developed selective GHSs, such as ipamorelin, induce 
massive GH secretion without any elevation in ACTH, cortisol, or PRL release (Raun et al., 
1998), whereas GHRP-6 and GHRP-2 administration in this species cause a strong activation 
of the pituitary-adrenocortical axis. This suggests the existence of subtypes of GHS-Rs with 
differential effects on GH, ACTH, and PRL release. Furthermore, intravenous bolus 
administration of ghrelin or synthetic GHSs results in high blood levels and reflects a 
pharmacological rather than a physiological action of the peptides. It is possible that, at 
physiological concentrations, these GHSs do not increase ACTH, cortisol, or PRL 
concentrations (Svensson et al., 1998).  
Most basal plasma hormone concentrations did differ significantly when the young 
and old dogs were compared. Although it is generally accepted that basal GH secretion 
decreases in humans and animals with increasing age (Finkelstein et al., 1972; Sonntag et al., 
1980; Zadik et al., 1985; Borst et al., 1994; De Gennaro Colonna et al., 1994; Wilshire et al., 
1995), the basal plasma GH concentration in our study was not significantly different in the 
young and the old dogs. For identifying age-related differences in GH secretion, 
determination of the pulsatile secretion pattern of GH is much more sensitive. Indeed, the 
pulsatile secretion pattern of GH is significantly lower in old humans, rats, and dogs than in 
young individuals (Zadik et al., 1985; Cella et al., 1989; Borst et al., 1994). The higher basal 
plasma concentrations of ACTH and cortisol in the young dogs may indicate that the stress of 
handling caused a stronger activation of the pituitary-adrenocortical axis in these young dogs 
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than in the old dogs. In some species, ageing is associated with a decrease in stress-induced 
activation of adrenocortical function (Van Eekelen et al., 1995).  
In conclusion, the results of this study demonstrate the existence of age-related 
differences with regard to the GH-releasing activity of GHSs. Ghrelin is, compared to GHRH 
and GHRP-6, the most potent stimulator of GH release in young dogs. In old dogs, GHRH 
administration is associated with the highest elevations in plasma GH levels when compared 
to administration of GHRP-6 or ghrelin. The GH-releasing capacity of ghrelin decreases with 
age whereas this decline is considerably lower for GHRP-6 or GHRH. Furthermore, ghrelin 
and GHRP-6 are specific releasers of GH and do not stimulate the pituitary-adrenocortical 
axis or the release of TSH, LH, or PRL in dogs.  
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Abstract 
This study investigated whether ghrelin, a potent releaser of growth hormone (GH) 
secretion, is a valuable tool in the diagnosis of canine pituitary dwarfism. The effect of 
intravenous administration of ghrelin on the release of GH and other adenohypophyseal 
hormones was investigated in German shepherd dogs with congenital combined pituitary 
hormone deficiency and in healthy Beagles.  
Analysis of the maximal increment (i.e. difference between pre- and maximal post-
ghrelin plasma hormone concentration) indicated that the GH response was significantly 
lower in the dwarf dogs compared with the healthy dogs. In none of the pituitary dwarfs, the 
ghrelin-induced plasma GH concentration exceeded 5 µg/l at any time. However, this was 
also true for three healthy dogs. In all dogs, ghrelin administration did not affect the plasma 
concentrations of adrenocorticotrophic hormone (ACTH), cortisol, thyroid-stimulating 
hormone (TSH), luteinizing hormone (LH), and prolactin (PRL) . 
Thus, while a ghrelin-induced plasma GH concentration above 5 µg/l excludes GH 
deficiency, false-negative results may occur.  
 
 
 
 
 
 
 
 
 
 
 
Chapter 6 
 
 
136 
Ghrelin-stimulation test in the diagnosis of canine pituitary dwarfism 
 
 
137 
Introduction 
 The secretion of growth hormone (GH) is primarily under control of the central 
nervous system and is mainly regulated by the opposing effects of the hypothalamic 
hormones GH-releasing hormone (GHRH) and somatostatin (Plotsky and Vale, 1985). The 
existence of another, unknown factor involved in the control of somatotroph function has 
been hypothesized for several years. This was based on the observation that synthetic peptidyl 
and non-peptidyl compounds, named GH secretagogues (GHSs) or GH-releasing peptides 
(GHRPs), showed a strong GH-releasing effect (Bowers et al., 1977; Casanueva and Dieguez 
1999) and acted on a specific GHS-receptor (GHS-R), i.e. the GHS-R type 1a (Howard et al., 
1996; McKee et al., 1997). The endogenous ligand of the GHS-R type 1a has recently been 
purified from rat and human stomach (Kojima et al., 1999) and has also been identified in the 
fundus of the canine stomach (Tomasetto et al., 2001). This 28-amino-acid peptide, ghrelin, 
has a unique structure with an n-octanoyl ester at its third Serine residue which is crucial for 
its biological activity, at least in terms of GH release (Kojima et al., 1999; Bednarek et al., 
2000, Date et al., 2000; Hayashida et al., 2001). 
Ghrelin is a potent stimulator of GH release in several species such as humans (Arvat 
et al., 2000; Peino et al., 2000; Takaya et al., 2000), rats (Kojima et al., 1999) and dogs 
(Bhatti et al., 2002; Bhatti et al., 2006 in press). In rats, the GH-releasing potency of ghrelin is 
similar to that of GHRH (Kojima et al., 1999), whereas in humans, ghrelin releases more GH 
than GHRH and the synthetic GHS hexarelin (Ghigo et al., 2001). In young dogs, ghrelin is a 
more potent stimulator of GH secretion than GHRH or GHRP-6 (Bhatti et al., 2006 in press). 
However, the action of ghrelin and the synthetic GHSs is not exclusively confined to GH 
release. For example, in humans these substances also stimulate the secretion of prolactin 
(PRL), adrenocorticotrophic hormone (ACTH), and cortisol (Massoud et al., 1996; Takaya et 
al., 2000; Arvat et al., 2001; Ghigo et al., 2001). In rats, GHRP-6 activates the hypothalamic-
pituitary-adrenal axis (Thomas et al., 1997). In contrast, ghrelin and GHRP-6 specifically 
release GH in young dogs (Bhatti et al., 2006 in press). 
Pituitary dwarfism or congenital GH deficiency in dogs is encountered most often in 
German shepherd dogs. In this breed, pituitary dwarfism is due to a simple, autosomal 
recessive inherited abnormality (Andresen and Willeberg, 1976). In contrast to 
disproportionate dwarfism caused by for example congenital hypothyroidism, the condition of 
congenital GH deficiency is characterized by profound proportionate dwarfism with retention 
of puppy coat or secondary hairs and lack of primary or guard hairs, and symmetrical 
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alopecia. Intrapituitary cysts are often detected at a young age and gradually enlarge with time 
(Kooistra et al., 1998). Functionally, German shepherd dwarf dogs have a combined pituitary 
hormone deficiency. An absolute deficiency of GH, PRL and thyroid-stimulating hormone 
(TSH) is associated with an impaired release of gonadotrophins, whereas ACTH secretion is 
preserved (Hamann et al., 1999; Kooistra et al., 2000). The abnormality in these dwarfs is 
most likely caused by a mutation in a developmental transcription factor that precludes 
effective expansion of a pituitary stem cell after the differentiation of the corticotroph cells 
(Kooistra et al., 2000). To date, sequence analysis of genomic DNA from German shepherd 
dwarfs has not revealed causative mutations in candidate genes (Lantinga-van Leeuwen et al., 
2000a; Lantinga-van Leeuwen et al., 2000b; van Oost et al., 2002). 
As ghrelin is a more potent stimulator of GH release than GHRH in young dogs, it 
may be useful for diagnostic purposes. We therefore investigated the effects of intravenous 
administration of ghrelin on the plasma concentration of GH in German shepherd dogs with 
pituitary dwarfism. Additionally, the plasma concentrations of ACTH, cortisol, TSH, PRL, 
and luteinizing hormone (LH) before and after ghrelin administration were measured in these 
dogs. 
 
Materials and methods 
Dogs 
Six German shepherd dwarfs from different litters (four males and two females) 
referred to the Department of Clinical Sciences of Companion Animals, Utrecht University, 
because of an abnormal hair coat and proportionate growth retardation were used in this 
study. The mean age at presentation was 12 months (range 9 to 21 months) and the mean 
body weight was 9.6 kg (range 7.5 to 14.0 kg).  
The results of the pituitary dwarfs were compared with data available from a 
previously conducted study in eight Beagle dogs (four males and four females) with a mean 
age of 13 months (range 10 to 17 months) and a mean body weight of 11.8 kg (range 10.0 to 
13.5 kg) (Bhatti et al., 2006 in press). The dogs had free access to tap water and were fed a 
commercial dog food. They had no history of illness and had not received any medications.  
The mean age of the healthy dogs did not differ significantly (P = 0.5, independent 
samples t-test) from that in the pituitary dwarfs. The mean body weight of the healthy dogs 
was slightly higher (P = 0.04, independent samples t-test) than in the dwarfs. 
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All experiments were carried out in conscious animals after an overnight fast. In the 
female healthy dogs, blood samples were obtained in anoestrus.  
 
Study design and blood sample collection 
In all dogs, human ghrelin (MW 3370.9) (Peninsula Laboratories Inc. Belmont, CA, 
USA), was administered intravenously in a dose of 2 µg/kg body weight through an 
intravenous catheter. The peptide was dissolved according to the Peninsula laboratory 
requirements and was stored at -20° C. Ghrelin, in a concentration of 10 µg/ml, was thawed 
before administration. For each dog a fresh vial was applied. The mean volume to be injected 
was 1.9 ml for the pituitary dwarfs and 2.4 ml for the healthy dogs. 
Blood samples for the determination of plasma concentrations of GH, ACTH, cortisol, 
TSH, LH and PRL were collected by jugular venipuncture at 15 min before and 0, 5, 10, 20, 
30, and 45 min after ghrelin injection. Blood samples for the determination of plasma 
concentrations of insulin-like growth factor-1 (IGF-I) were collected by jugular venipuncture 
at -15 min and 0 min. The samples were immediately transferred to ice-chilled EDTA-coated 
tubes (GH, IGF-I, ACTH, cortisol, LH and PRL) or heparin-coated tubes (TSH) and 
centrifuged at 4o C for 10 min. Plasma was stored at -25o C until assayed.  
 
Hormone determination 
Plasma GH concentrations were determined with a homologous radioimmunoassay 
(RIA) (Eigenmann and Eigenmann, 1981). The intra- and interassay coefficients of variation 
were 3.8 % and 7.2 % respectively, and the sensitivity of the assay was 0.3 µg/l. The degree 
of cross-reaction with canine PRL was 2 %.  
Plasma ACTH concentrations were determined with an immunoradiometric assay 
(Nichols Institute, Wijchen, The Netherlands). The interassay coefficient of variation was 7.8 
% and the sensitivity was 0.2 pmol/l.  
Plasma cortisol concentrations were determined with a commercially available RIA 
(Diagnostic Products Corporation (DPC), Los Angeles, CA, USA), validated for dogs. The 
intra-assay and inter-assay coefficients of variation ranged from 3.0 % to 5.1 % and from 4.0 
% to 6.4 %, respectively. The sensitivity of the assay was 5.5 nmol/l.  
Plasma TSH concentrations were determined with a homologous solid-phase, two-site 
chemiluminiscent enzyme immunometric assay (Immulite® canine TSH, DPC, Los Angeles, 
CA, USA) according to the instructions of the manufacturer. The intra-assay coefficients of 
variation were 5.0 %, 4.0 %, and 3.8 % at TSH levels of 0.20, 0.50, and 2.60 µg/l, 
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respectively. The interassay coefficients of variation were 6.3 % and 8.2 % at TSH levels of 
0.16 and 2.80 µg/l, respectively. The sensitivity of the assay was 0.03 µg/l. Cross-reactivity 
with FSH and LH was negligible.  
Plasma LH concentrations were determined with a heterologous RIA as described 
previously by Nett et al., (1975). A rabbit antiserum raised against ovine LH (CSU-204), 
radioiodinated NIAMDD-bLH-4, and canine pituitary standard LER 1985-1 were used in this 
assay. The intra- and interassay coefficients of variation for concentrations higher than 0.5 
µg/l were 2.3 % and 10.5 %, respectively. The sensitivity of the assay was 0.3 µg/l. 
Plasma concentrations of PRL were determined with a previously validated 
heterologous RIA (Okkens et al., 1985). The intra- and inter-assay coefficients of variation 
were 3.5 % and 11.5 %, respectively. The sensitivity of the assay was 0.8 µg/l. 
Plasma IGF-I concentrations were determined with a heterologous RIA validated for 
the dog (Nap et al., 1993). The intra-assay and interassay coefficients of variation were 4.7 % 
and 15.6 %, respectively, and the sensitivity of the assay was 3 µg/l. 
 
Statistical analysis 
Basal plasma concentrations (mean of -15 and 0 min) of GH, IGF-I, ACTH, cortisol, 
TSH, LH and PRL in the dogs with pituitary dwarfism and the healthy dogs were compared 
using an independent samples t-test to study differences between both dog groups before 
treatment.  
Additionally, the difference between the plasma hormone concentration just before (0 
min) injection of ghrelin and the maximal plasma hormone concentration after injection was 
calculated for each dog (referred to as the maximal increment) and used to capture the effect 
of treatment. Therefore, an independent samples t-test was used to study the differences in 
maximal increments between both dog groups.  
Statistical significance was defined at P ≤ 0.05. Values are expressed as mean 
concentration ± SEM. Statistical analysis was performed with SPSS version 12.0 for windows 
(SPSS Inc., Chicago, Illinois, USA). 
 
Ethics of the study 
This study was approved by the Ethics Committee of the Faculty of Veterinary 
Medicine, Utrecht University. 
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Results 
No side effects were observed during or after intravenous administration of ghrelin, 
neither in the German shepherd dwarfs nor in the healthy dogs.  
The mean basal plasma GH concentration was not significantly different in the dogs 
with pituitary dwarfism (0.7 ± 0.1 µg/l) and in the healthy dogs (0.5 ± 0.1 µg/l) and neither 
was the mean basal plasma IGF-I concentration (55 ± 14 µg/l versus 88 ± 13 µg/l, 
respectively) (Table 1). The mean basal plasma concentrations of ACTH and cortisol in the 
dogs with pituitary dwarfism (67 ± 17 ng/l and 94 ± 20 nmol/l, respectively) did not differ 
significantly from those in the healthy dogs (38 ± 6 ng/l and 71 ± 15 nmol/l, respectively). 
However, the mean basal plasma concentration of TSH and PRL in the dogs with pituitary 
dwarfism (0.06 ± 0.01 µg/l and 1.3 ± 0.2 µg/l, respectively) were significantly lower 
compared with those in the healthy dogs (0.12 ± 0.02 µg/l and 2.2 ± 0.2 µg/l, respectively). 
The mean basal plasma concentration of LH in the pituitary dwarfs (3.7 ± 0.6 µg/l) was 
significantly higher than in the healthy dogs (1.8 ± 0.3 µg/l). 
Analysis of the maximal increment indicated that the mean plasma GH response after 
ghrelin injection was significantly lower in the dwarf dogs (1.4 ± 0.4 µg/l) compared with that 
in the healthy dogs (45.3 ± 14.8 µg/l) (Figure 1a). In none of the pituitary dwarfs, the ghrelin-
induced plasma GH concentration exceeded 5 µg/l at any time (Table 1). However, this was 
also true for 3 healthy dogs. Administration of ghrelin did not affect the plasma 
concentrations of ACTH, cortisol, TSH, LH and PRL in either the dogs with pituitary 
dwarfism or in the healthy dogs (Figures 1b-f, respectively) . 
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Figures 1. (a-f) Mean (± SEM) plasma concentrations of GH, ACTH, cortisol, TSH, LH, and PRL respectively, 
before and after intravenous administration of 2 µg/kg ghrelin (arrow) in six German shepherd dogs with 
pituitary dwarfism (○) and in eight healthy Beagle dogs (●). 
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Table 1. Mean basal (-15 and 0 min) plasma IGF-I (Basal IGF-I) and GH (Basal GH) concentration and 
maximal plasma GH concentration after intravenous administration of ghrelin (GH max) in eight healthy Beagle 
dogs and in six German shepherd dogs with pituitary dwarfism.  
  Basal IGF-I 
(µg/l) 
Basal GH  
(µg/l) 
GH max  
(µg/l) 
Healthy dogs Dog 1 125 0.8 1.7 
 Dog 2 124 0.2 76 
 Dog 3 72 0.2 124 
 Dog 4 123 0.2 0.2 
 Dog 5 51 0.6 4.8 
 Dog 6 43 1.0 47 
 Dog 7 63 0.9 57 
 Dog 8 58 0.5 69 
Pituitary dwarfs Dog 1 52 0.4 4.1 
 Dog 2 3 0.4 0.7 
 Dog 3 106 0.6 1.9 
 Dog 4 78 1.1 1.9 
 Dog 5 45 1.2 2.2 
 Dog 6 47 0.5 1.2 
 
Discussion 
Assessment of random basal plasma GH concentrations is inadequate for 
documentation of hyposomatotropism, because circulating GH concentrations in healthy dogs 
and pituitary dwarfs may overlap (Kooistra et al., 2000). Indeed, the results of this study 
illustrate the absence of a significant difference in basal plasma GH concentration between 
healthy dogs and German shepherd dogs with pituitary dwarfism. Although the plasma IGF-I 
concentration represents the secretion of GH, this concentration cannot be used to irrefutably 
diagnose hyposomatotropism. In GH-deficient human adults, circulating IGF-I levels are 
within the reference range in about 60% of cases (Gill et al., 1998). In accordance with 
previous canine studies (Eigenmann et al., 1984; Rijnberk et al., 1993; Kooistra et al., 1998; 
Kooistra et al., 2000), the mean basal plasma IGF-I concentration in the pituitary dwarfs was 
lower than that in the healthy dogs, but due to a considerable overlap this difference did not 
reach statistical significance.  
Thus, because of comparable plasma concentrations of GH and IGF-I between 
pituitary dwarfs and healthy individuals, the diagnosis of GH deficiency has to be based upon 
the results of a stimulation test. In dogs, most α-adrenergic drugs (such as clonidine and 
xylazine) or GHRH are commonly used to test the GH secretory capability of the pituitary 
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somatotrophs. In pituitary dwarfs, there is no significant increase in plasma GH concentration 
after administration of one of the aforementioned GHSs (Eigenmann et al., 1984). Adverse 
reactions, such as sedation, bradycardia, hypotension, and collapse, may preclude the use of 
xylazine and clonidine, especially at high doses (Eigenmann and Eigenmann, 1981; Lothrop 
1988). Since ghrelin is a more potent GH-releaser than GHRH in young dogs, (Bhatti et al., 
2006 in press), we tested whether ghrelin can be used to diagnose canine pituitary dwarfism. 
In none of the dwarf dogs ghrelin administration resulted in a rise of the plasma GH 
concentration above 5 µg/l. This finding corresponds with observations in humans with 
isolated childhood-onset GH deficiency, in whom the GH response to ghrelin is also markedly 
reduced (Aimaretti et al., 2002). However, in some of the healthy dogs the plasma GH 
concentration remained low after ghrelin administration as well. Thus while a ghrelin-induced 
plasma GH concentration higher than 5 µg/l seems to exclude GH deficiency, false-negative 
results may be encountered. The reason for the blunted ghrelin-induced GH response in 
healthy dogs remains unclear. In other species such as man, mice and rats, a similar atypical 
hormone response to ghrelin has not been mentioned in literature. Stress may decrease the 
responsiveness of the pituitary somatotrophs to GH stimulation tests in humans (Lazarus, 
1984) and may have played a role in our study.  
In line with earlier findings in German shepherd dwarf dogs (Hamann et al., 1999; 
Kooistra et al., 2000), the basal plasma TSH and PRL concentrations in these dogs were 
significantly lower than those in healthy dogs. In addition, ACTH and consequently cortisol 
secretion seemed to be preserved in the dwarf dogs. In contrast with the study of Kooistra et 
al., (2000), we found that the basal plasma LH concentration was significantly higher in the 
dogs with pituitary dwarfism. This unexpected finding warrants further investigation of basal 
LH secretion in German shepherd dwarfs with combined pituitary hormone deficiency. 
Treatment of this form of combined pituitary hormone deficiency in German shepherd 
dwarfs consists of restoring the two most important hormone deficits, i.e., TSH and GH 
deficiency. The secondary hypothyroid state can easily be treated by oral supplementation of 
synthetic l-thyroxine. Growth hormone substitution therapy in these dwarfs is less 
straightforward. Canine GH is not yet available for therapeutic use. Moreover, antibody 
formation precludes the use of biosynthetic human GH (van Herpen et al., 1994). The amino 
acid sequence of canine GH is identical to that of porcine GH (Ascacio-Martinez and Barrera-
Saldana, 1994), but the results of treatment of pituitary dwarf dogs with porcine GH are not 
satisfactory (Eigenmann and Eigenmann, 1981). In addition, treatment with heterologous GH 
is expensive. At present, the only available treatment option consists of administration of 
Ghrelin-stimulation test in the diagnosis of canine pituitary dwarfism 
 
 
145 
medroxyprogesterone acetate (Kooistra et al., 1998) or proligestone (Knottenbelt and 
Herrtage, 2002). The GH production induced by progestins originates from foci of 
hyperplastic ductular epithelium in the mammary gland (Selman et al., 1994; Mol et al., 1995; 
van Garderen et al., 1997). In dogs, this mammary-derived GH reaches the systemic 
circulation (Selman et al., 1994). Unfortunately, treatment with progestins may result in 
undesirable side-effects, such as diabetes mellitus, cystic endometrial hyperplasia, recurrent 
pyoderma, and associated pruritis (Kooistra et al., 1998; Knottenbelt and Herrtage, 2002; 
Romagnoli and Concannon, 2003).  
Based on the strong and reproducible GH-releasing effect of GHSs, these molecules, 
particularly if orally active, could theoretically have therapeutic usefulness in 
hyposomatotropism. The GHS-R type 1a is present in the pituitary and hypothalamus of 
several mammalian species and is distinct from the GHRH receptor (Howard et al., 1996; 
McKee et al., 1997; Pong et al., 1996). As GHRH is not able to stimulate the release of GH 
from the pituitary somatotrophs in German shepherd dogs with pituitary dwarfism (Kooistra 
et al., 2000), theoretically the ghrelin-activated pathway offers another treatment option. 
However, in line with the absence of pituitary somatotrophs, no GH response occurred and 
consequently ghrelin is not a candidate for the treatment of this disorder. Again theoretically, 
the possibility that long-term treatment with ghrelin would restore circulating GH levels in 
dogs with hyposomatotropism can not be ruled out. Though, long-term administration of MK-
0677, a synthetic non-peptidyl GHS, was not very effective in increasing growth velocity in 
children with isolated GH deficiency, however they did benefit from recombinant human GH 
replacement therapy (Yu et al., 1998).  
In humans and rats, the endocrine activity of both ghrelin and synthetic GHSs is not 
specific for GH. In healthy humans, intravenous administration of GHRP-6 or ghrelin also 
increases circulating concentrations of PRL, ACTH, and cortisol (Massoud et al., 1996; 
Casanueva and Dieguez, 1999; Takaya et al., 2000; Arvat et al., 2001; Ghigo et al., 2001). In 
rats, GHRP-6 activates the hypothalamic-pituitary-adrenal axis (Thomas et al., 1997). In 
contrast, in the present study ghrelin did not cause significant elevations in plasma 
concentrations of ACTH, cortisol, TSH, LH and PRL, neither in the healthy dogs nor in the 
German shepherd dwarfs.  
The data of the ghrelin-stimulation test in German shepherd dwarfs were compared 
with those in healthy Beagle dogs. This may raise the question whether the differences in the 
results might be attributable to differences in breed. However, in a study of Meij et al., 
(1997), no breed-related variation in the response of GH to stimulation with GHRH was 
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noticed in dogs with pituitary-dependent hyperadrenocorticism. Therefore the lack of 
response of the pituitary somatotrophs to stimulation with ghrelin can be considered abnormal 
in the German shepherd dwarfs. Comparison with healthy, normal-sized German shepherd 
dogs of a comparable age as the dwarf dogs might have been more appropriate, but these dogs 
were not available for endocrine testing. In addition, these dogs would have weighed 
considerably more than the German shepherd dwarfs and this discrepancy could also have 
influenced the plasma GH levels. For these reasons, healthy Beagle dogs of a comparable age 
and body weight were used as a control group.  
It can be concluded that administration of the natural ligand of the GHS-R type 1a, 
i.e., ghrelin, is not able to induce a considerable rise in plasma GH concentration in German 
shepherd dogs with pituitary dwarfism. While a ghrelin-induced plasma GH concentration 
higher than 5 µg/l seems to exclude GH deficiency, false-negative results may be 
encountered.  
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Abstract 
The growth hormone (GH)-releasing peptide ghrelin, primarily secreted by the stomach, 
causes weight gain by increasing food intake and reducing fat utilization and seems to play a 
role in meal initiation in several mammalian species. In this study, blood samples were 
collected from 8.30 a.m. to 5 p.m. in nine healthy Beagle dogs when food was administered as 
usual at 10 a.m., after a 1-day fast, after a 3-day fast, and after re-feeding at 10 a.m. the next 
day. Circulating concentrations of acylated ghrelin, GH, insulin-like growth factor-I (IGF-I), 
glucose, and insulin were determined. 
The overall mean plasma ghrelin concentrations were significantly lower when food 
was administered than after fasting. Shortly after feeding, the time-specific mean plasma 
ghrelin concentrations decreased, but this decline did not reach statistical significance. The 
overall mean plasma GH and IGF-I concentrations did not differ significantly between the 4 
different periods. The time-specific mean plasma GH concentration differed significantly over 
time with a maximum concentration at 0 min. This concentration did not change differently 
over time in the 4 different periods. Circulating overall mean glucose and insulin 
concentrations were significantly higher after re-feeding the day after the 3-day fast compared 
with the 3 other periods. The time-specific mean plasma glucose and serum insulin 
concentrations differed significantly over time. In addition, the course of these concentrations 
over time differed significantly in the 4 sampling periods.  
In conclusion, in dogs fasting and food intake are associated with higher and lower 
circulating ghrelin concentrations, respectively, suggesting that also in this species ghrelin 
participates in the control of feeding behavior and energy homeostasis. The changes in plasma 
ghrelin concentrations are not associated with similar changes in plasma GH concentrations, 
whereas insulin and glucose concentrations appear to change reciprocally with the ghrelin 
concentrations. 
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Introduction 
In 1999, Kojima and co-workers reported the isolation of ghrelin from the rat stomach 
(Kojima et al., 1999). The presence of ghrelin in the stomach has been confirmed in humans, 
cows, pigs, dogs, and horses (Date et al., 2000; Hayashida et al., 2001; Tomasetto et al., 
2001). Ghrelin acts as the ligand for the growth hormone secretagogue receptor type 1a 
(GHS-R 1a) and is able to stimulate growth hormone (GH) secretion from pituitary cells in 
many species such as rats, humans, goats, dogs, and fish (Kojima et al., 1999, Date et al., 
2000; Hayashida et al., 2001, Bhatti et al., 2002; Kaiya et al., 2003; Bhatti et al., 2006 in 
press). The mature ghrelin molecule contains 28 amino acids and its third Serine residue is 
acylated by n-octanoic acid which is essential for binding to the GHS-R 1a, for the GH-
releasing capacity of ghrelin, and most likely for its other endocrine actions (Kojima et al., 
1999; Bednarek et al., 2000; Muccioli et al., 2001). 
Through activation of pathways distinct from those leading to GH secretion, ghrelin 
also acts as a potent orexigenic peptide (Kamegai et al., 2000; Tschop et al., 2000; Wren et 
al., 2000; Wren et al., 2001). In rodents, ghrelin causes weight gain by increasing food intake 
and reducing fat utilization (Kamegai et al., 2000; Wren et al., 2000; Nakazato et al., 2001). 
Ghrelin is the only known circulating orexigen, and has a potency similar to that of 
neuropeptide Y (NPY). This appetite-stimulating effect appears to be mediated, at least in 
part, through activation of NPY/agouti gene-related peptide (AGRP) neurons in the 
hypothalamic arcuate nucleus, 94 % of which express the GHS-R (Willesen et al., 1999). 
NPY and AGRP are thought to be mediators of the ghrelin-induced increased food intake 
because antagonism of either NPY or AGRP signalling in the brain attenuates the orexigenic 
potency of injected ghrelin (Dickson et al., 1997; Kamegai et al., 2000; Asakawa et al., 2001; 
Shintani et al., 2001). 
Ghrelin may also play a role in meal initiation in humans, since the concentration of 
this peptide increases immediately prior to a meal and decreases after eating (Cummings et 
al., 2001). Also in sheep and cows it has been demonstrated that preprandial ghrelin surges 
occur as many times per day as meals are provided (Sugino et al., 2002a,b; Miura et al., 
2004). These results indicate that ghrelin secretion may be a trigger for endogenous appetite 
signals. 
Consistent with this, circulating ghrelin concentrations are increased in anorexia and 
cachexia and reduced in obesity (Shiiya et al., 2002; Cummings and Shannon, 2003; Tolle et 
al., 2003). These changes are opposite to those induced by leptin, an adipocyte-derived 
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hormone that reduces appetite and increases energy expenditure in animal models. Thus both 
ghrelin and leptin reflect the metabolic balance and may drive neuroendocrine and metabolic 
responses to changes in nutritional status (Inui et al., 2001; Yoshihara et al., 2002; Cummings 
and Foster, 2003).  
Ghrelin production in the stomach is not only stimulated by fasting but is also related 
to glucose and insulin metabolism. In humans, oral and intravenous glucose administration 
decreases plasma ghrelin concentrations, whereas lipids or high-fat diets suppress the 
postprandial ghrelin concentrations less effectively (Mohlig et al, 2002; Monteleone et al., 
2003; Weigle et al., 2003). Moreover, Blom et al. (2005) have shown in humans that the 
ghrelin response to a high-carbohydrate meal is related to insulin secretion. 
So far there are only a few reports (Jeusette et al., 2005a,b; Yokoyama et al., 2005) on 
the role of ghrelin in dogs, a carnivorous animal with an evolutionary background of being 
able to cope with long periods of starvation. However, nowadays the domestic dog does not 
need to endure starvation but rather food surplus, that often leads to obesity.  
In this study we investigated the physiological endocrine effects of food intake and 
fasting in healthy Beagle dogs. Therefore, the circulating concentrations of ghrelin, GH, 
insulin-like growth factor-I (IGF-I), glucose, and insulin were measured when food was 
administered at the usual time, after a 1-day fast, after a 3-day fast, and after re-feeding the 
next day. 
 
Materials and methods 
Dogs 
Nine normal-weight ovariohysterectomized Beagle dogs, 5 years of age, were used. 
They received a commercial dog food (Hill’s Science Plan - Adult - Canine Maintenance®) at 
10 a.m. each day and were given water ad libitum. The mean body weight of the dogs was 12 
kg (range 9.5-14.0 kg). The dogs were accustomed to the laboratory environment and 
procedures such as collection of blood samples. 
 
Study design and blood sample collection 
The dogs were randomly assigned to three groups. For the second and third group the 
study started one and two days, respectively, after that of the first group. All dogs were put on 
a food-fast regimen for five consecutive days: on day 1, food was given as usual at 10 a.m.; 
on days 2, 3, and 4, food was withheld; and on day 5, the dogs were re-fed at 10 a.m. 
Effects of food intake and fasting on the plasma ghrelin concentration in healthy dogs 
 
 
157 
Blood samples were collected by jugular venipuncture on days 1 (= period 1), 2 (= 
period 2), 4 (= period 3), and 5 (= period 4) at 8.30 a.m., 10 a.m., 10.30 a.m., 11 a.m., 11.30 
a.m., 12.30 p.m., 1.30 p.m., 3 p.m., and 5 p.m. In these blood samples the concentrations of 
acylated ghrelin, GH, glucose, and insulin were determined. Plasma IGF-I concentrations 
were determined only in the blood samples collected at 8.30 a.m. and 10 a.m. 
For the determination of plasma ghrelin concentrations, the collection procedures and 
storage were carried out in accordance with the protocol supplied by the manufacturer 
(Ghrelin (active) radioimmunoassay (RIA) kit, Linco Research, St Louis, MO, USA). Blood 
samples were immediately transferred to ice-chilled EDTA-coated tubes and centrifuged at 4° 
C for 10 min. Per one ml plasma, 50 µl of 1 N HCl and 10 µl phenylmethylsulfonyl fluoride 
was added. Plasma was immediately stored at -25° C until analysis.  
For the determination of plasma GH and IGF-I concentrations, the blood samples were 
immediately transferred to ice-chilled EDTA-coated tubes and centrifuged at 4o C for 10 min. 
Plasma was stored at -25o C until assayed.  
Blood samples for the measurement of plasma glucose concentrations were collected 
in sodium-fluoride tubes, and those for the measurement of serum insulin concentrations were 
collected in tubes with cloth activator. 
 
Hormone determination 
Plasma ghrelin concentrations were measured with a (human) ghrelin RIA kit (Linco 
Research, St Louis, MO, USA). This assay specifically measures biologically active ghrelin 
(Janssen et al., 2001). The RIA technique detects human ghrelin with equal accuracy in the 
dog (Yokoyama et al., 2005). Values of ghrelin measured with the human ghrelin RIA kit 
after serial dilutions of various dog samples showed good linearity, indicating that in this 
assay canine ghrelin behaves immunochemically similar to that of the human ghrelin 
standards. The sensitivity of the assay was 10 ng/l.  
Plasma GH concentrations were measured using a commercially available RIA for 
porcine and canine GH (PGH-46HK; Linco Research, St. Charles MS). The intra-assay 
coefficient of variation value was 7.6 % at a plasma concentration of 4.4 µg/l. The sensitivity 
of the assay was 1 µg/l. 
Total plasma IGF-I concentrations were measured after acid-ethanol extraction to 
remove interfering IGF binding proteins. Plasma IGF was extracted using a mixture of 87.5 % 
(v/v) ethanol and 12.5 % 2 M formic acid. Tubes containing 100 µl plasma and 400 µl of the 
ethanol-formic acid mixture were mixed thoroughly and incubated for 30 min at room 
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temperature. After centrifugation for 30 min at 5500 g at 4° C, a 50 µl aliquot of the 
supernatant was diluted 1:50 with assay buffer containing 63 mM Na2HPO4 (pH 7.4), 13 mM 
Na2EDTA, and 0.25 % (w/v) BSA. The extraction efficiency amounted to 92.5 ± 5.7 %. 
Plasma IGF-I concentrations were measured with a heterologous RIA validated for the dog 
(Favier et al., 2001). The intra-assay coefficient of variation was 8.6 % at a plasma 
concentration of 100 µg/l. The sensitivity of the assay was 10 µg/l. IGF-I antiserum 
AFP4892898 and human IGF-I for iodination were obtained from the National Hormone and 
Peptide Programme (Harbor-UCLA Medical Center, Torrance CA).  
Serum immunoreactive insulin concentrations were measured by immunoradiometric 
assay (IRMA). The two-site IRMA method (INS-Irma®: BioSource Europe S.A., Nivelles, 
Belgium) had an intra-assay and interassay coefficient of variation of 4.5 % and 4.7 %, 
respectively. According to information supplied by the manufacturer, there is 0 % cross-
reactivity with human pro-insulin. Serial dilutions of canine serum were parallel to the 
standard curve of human insulin. The sensitivity of the assay was 7 pmol/l. 
 
Statistical analysis 
Changes in circulating concentrations of ghrelin, GH, glucose and insulin were 
analyzed based on a mixed model with dog as random effect (repeated measures ANOVA 
with compound symmetry structure) and period (1 to 4), blood sampling times (8.30 a.m., 10 
a.m., 10.30 a.m., 11 a.m., 11.30 a.m., 12.30 p.m., 1.30 p.m., 3 p.m., and 5 p.m.), and their 
interaction as categorical fixed effects. In the analysis both mean concentrations over the 
different sampling points (denoted by overall mean concentration) and concentrations at 
different sampling points (denoted by time-specific mean concentration) were compared, with 
mean referring to the mean over the different dogs. The four periods were compared pair wise 
using Tukey’s multiple comparisons technique at a global significance level of 5 %. Plasma 
IGF-I concentrations between the four periods were compared with one-way ANOVA. All 
values are expressed as mean ± SEM.  
Analyses were performed with SAS version 9.1 for Windows (Insightful Corp., 
Seattle, US). 
 
Ethics of the study 
This study was approved by the Ethics Committee of the Faculty of Veterinary 
Medicine, Ghent University. 
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Results 
The overall mean plasma ghrelin concentration when food was given at day 1 (152 ± 
34 ng/l) was significantly (P = 0.005) lower than after a 1-day fast (181 ± 42 ng/l). The 
overall mean plasma ghrelin concentration after re-feeding the day after the 3-day fast (143 ± 
32 ng/l) was significantly lower than after a 1-day fast (181 ± 42 ng/l, P = 0.001) and after a 
3-day fast (183 ± 53 ng/l, P = 0.009) (Figure 1a and Figure 1b).  
The time-specific mean plasma ghrelin concentrations decreased shortly after feeding, 
but this decline did not reach statistical significance. Additionally, the time-specific mean 
plasma ghrelin response did not change differently over time when the 4 periods were 
compared (Figure 1a). There was a considerable interindividual variation in the pre-food and 
post-food changes of the time-specific plasma ghrelin concentration (Figure 1c). 
 
 
 
 
 
 
 
 
 
Figure 1c. Plasma ghrelin profiles in two Beagle dogs before (-90 and 0 min) and after (30, 60, 90, 150, 210, 
300, 420 min) ingestion of a meal at 10 a.m (arrow). Note the heterogeneity in the rise before and the decline 
after food intake. 
The overall mean plasma GH concentrations in the dogs when food was given at day 
1, after a 1-day fast, after a 3-day fast, and after re-feeding the next day (1.7 ± 0.3 µg/l, 1.5 ± 
0.2 µg/l, 1.4 ± 0.3 µg/l, and 1.5 ± 0.3, respectively) did not differ significantly (Figure 2). The 
time-specific mean plasma GH concentration differed significantly over time (P<0.0001) with 
a maximum concentration at 0 min. The time-specific mean plasma GH concentration did not 
change differently over time in the 4 different periods (Figure 2). No significant differences 
were found in the overall mean plasma IGF-I concentrations when the dogs were given food 
at day 1 (63 ± 9 µg/l), after a 1-day fast (60 ± 8 µg/l), after a 3-day fast (53 ± 7 µg/l), and after 
re-feeding the next day (47 ± 6 µg/l). 
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Figure 1b.                                                                                                          Figure 1c. 
 
Figure 1a. Mean (± SEM) plasma ghrelin concentrations in 9 Beagle dogs before (-90 and 0 min) and after (30, 60, 90, 150, 210, 300, 420 min) ingestion of a meal at 10 a.m. 
(1), after a consecutive 1-day fast (2), after a 3-day fast (3), and before and after ingestion of a meal at 10 a.m. the day after the 3-day fasting period (4). 
 
 
 
 
Figure 1b. Mean (+ SEM) plasma ghrelin concentration when a meal was given at 10 a.m. 
(1), after a 1-day fast (2), after a 3-day fast (3), and when a meal was given again at 10 a.m. 
the day after the 3-day fasting period (4). Significant differences between periods are 
indicated with an asterisk. 
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The overall mean plasma glucose concentrations when food was given at day 1 (4.5 ± 
0.1 mmol/l), after a 1-day fast (4.6 ± 0.1 mmol/l), and after a 3-day fast (4.5 ± 0.1 mmol/l) 
were significantly lower (P < 0.0001) compared with this concentration after re-feeding the 
day after the 3-day fast (5.0 ± 0.2 mmol/l) (Figure 3). 
The overall mean serum insulin concentrations when food was given at day 1 (28 ± 5 
IU/l) and after re-feeding the day after the 3-day fast (27 ± 4 IU/l) were significantly higher (P 
< 0.0001) than after a 1-day fast (14 ± 2 IU/l) and after a 3-day fast (12 ± 2 IU/l) (Figure 4). 
The time-specific mean plasma glucose and serum insulin concentrations differed 
significantly (P<0.0001) over time (Figures 3 and 4, respectively). In addition, the course of 
these concentrations over time differed significantly (P<0.0001) in the 4 sampling periods 
(Figures 3 and 4, respectively).  
 
Discussion 
The results of the present study demonstrate a significant difference in overall mean 
plasma ghrelin concentrations between food intake and fasting, characterized by lower plasma 
ghrelin concentrations when a meal was administered and higher plasma ghrelin 
concentrations during fasting. These findings are consistent with those for other species. For 
example, in rodents, circulating ghrelin concentrations increase with fasting and are 
suppressed within min by re-feeding or enteral infusions of nutrients but not water (Tschop et 
al., 2000; Asakawa et al., 2001). These observations suggest that the gastric peptide ghrelin 
may play an important role in controlling feeding behaviour and energy homeostasis. 
The higher plasma ghrelin concentrations during fasting may be consistent with a 
physiological role for this hormone in increasing appetite and the initiation of food intake. 
Similar to the situation in rodents, circulating ghrelin concentrations in humans are rapidly 
suppressed by food intake, and 24-h plasma ghrelin profiles reveal marked preprandial 
increases and postprandial decreases associated with every meal (Cummings et al., 2001). 
Although meal-time hunger is a common, daily experience in humans and animals, the 
molecular determinants of this sensation remain incompletely understood. Several 
observations, mostly from animal studies, indicate that ghrelin contributes to the sensation of 
hunger and participates in meal initiation. 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Mean (± SEM) plasma GH concentrations in 9 Beagle dogs before (-90 and 0 min) and after (30, 60, 90, 150, 210, 300, 420 min) ingestion of a meal at 10 a.m. (1), 
after a consecutive 1-day fast (2), after a 3-day fast (3), and before and after ingestion of a meal at 10 a.m. the day after the 3-day fasting period (4). 
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Figure 4. 
 
 
 
 
 
 
 
 
 
 
Figure 3. Mean (± SEM) plasma concentrations of glucose in 9 Beagle dogs before (-90 and 0 min) and after (30, 60, 90, 150, 210, 300, 420 min) ingestion of a meal at 10 
a.m. (1), after a consecutive 1-day fast (2), after a 3-day fast (3), and before and after ingestion of a meal at 10 a.m. the day after the 3-day fasting period (4). 
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Figure 4. Mean (± SEM) serum concentrations of insulin in 9 Beagle dogs before (-90 and 0 min) and after (30, 60, 90, 150, 210, 300, 420 min) ingestion of a meal at 10 a.m. 
(1), after a consecutive 1-day fast (2), after a 3-day fast (3), and before and after ingestion of a meal at 10 a.m. the day after the 3-day fasting period (4). 
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Firstly, the majority of circulating ghrelin is produced by the stomach and duodenum, organs 
well positioned to detect recently ingested food (Kojima et al., 1999; Gnanapavan et al., 2002; 
Date et al., 2000). Secondly, despite being produced peripherally, ghrelin acts centrally to 
stimulate food intake (Tschop et al., 2000; Nakazato et al., 2001; Wren et al., 2000). Thirdly, 
the orexigenic actions of ghrelin are rapid and short-lived, increasing both food intake 
(Asakawa et al., 2001) and gastric acid secretion (Masuda et al., 2000) within 20 min after 
intraperitoneal injection, a time course that is consistent with a role in meal initiation. 
Fourthly, exogenous ghrelin triggers eating when administered at times of minimal 
spontaneous food intake (Nakazato et al., 2001; Wren et al., 2000). Finally, the most clearly 
documented targets of ghrelin action in the brain are the hypothalamic neurons that co-secrete 
the well-known orexigens, NPY and AGRP (Cummings and Shannon, 2003). These 
neuropeptides are implicated in the central regulation of meal initiation as their expression 
increases at times of maximal spontaneous food intake in rodents, whereas that of other 
neuropeptides involved in energy balance remain relatively constant throughout the day (Lu et 
al., 2002). 
With regard to the plasma ghrelin concentration in the present study, neither a 
significant time effect, nor a significant interaction between time and the four different 
periods was observed. Nevertheless, at day 1 the highest time-specific plasma ghrelin 
concentrations were observed immediately before feeding. It is possible that this insignificant 
preprandial rise occurred as an anticipatory response to feeding because the dogs had been fed 
at the same time of the day for several years. That a psychological factor might have played a 
role in the present study is further supported by the observation that, after a few days of 
fasting, the highest time-specific plasma ghrelin level was observed not before food 
administration but immediately after the “unexpected” administration of food on day 5. In line 
with this assumption, Sugino et al. (2002a) demonstrated that psychological factors, i.e. an 
expectation of food administration, may stimulate ghrelin secretion just before feeding in 
sheep. This transient increase in ghrelin secretion just before feeding may be part of a 
conditioned emotional response. It is well known that secretion of saliva and gastric acid 
preceding food intake is induced by a conditioned emotional response through the stimulation 
of the vagal nerve (Harding and Leek, 1973). In this respect, ghrelin secretion may be induced 
by the vagal neural system in the same manner as the secretion of saliva and gastric acid. 
Like in humans and rodents, also in our dogs the time-specific mean plasma ghrelin 
concentrations decreased shortly after food intake, but this decline did not reach statistical 
significance. However, in another study it was demonstrated that also in dogs circulating 
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plasma ghrelin concentrations decrease significantly after eating (Yokoyama et al., 2005). The 
results of the present study do show that feeding results in a significantly lower overall mean 
plasma ghrelin concentration compared to fasting in dogs. The mechanism by which nutrients 
suppress ghrelin concentrations are beginning to be elucidated. Absorbed nutrients are 
thought to be the most likely mediators of the postprandial decrease in plasma ghrelin 
concentrations in rodents (Tschop et al., 2000). Ingested nutrients suppress ghrelin release in 
rats and humans with an efficacy of carbohydrates > proteins > lipids (Overduin et al., 2005). 
Surprisingly, food-related ghrelin suppression does not require luminal nutrient exposure in 
the stomach or duodenum, the principal sites of ghrelin production (Williams et al., 2003a; 
Overduin et al., 2005). Instead, signals mediating this response originate further downstream 
in the intestines and from post-absorptive events. In addition to nutrients, also changes in 
plasma insulin concentrations, intestinal osmolarity, and enteric neural signalling probably 
play a role, whereas gastric distension, vagal nerve activity, and glucagon-like peptide-1 are 
not required (Williams et al., 2003b; Gelling et al., 2004).  
There was considerable interindividual variation in time-specific mean plasma ghrelin 
concentrations in our dogs, as has been reported previously in humans (Cummings et al., 
2001; Janssen et al., 2001). Interestingly, a strong correlation in plasma ghrelin concentrations 
has been found within one individual when samples are collected with an interval of 1 year 
(Janssen et al., 2001). This suggests that the variation in plasma ghrelin concentrations is 
mainly determined by the variation between individuals and less by intra-individual factors. 
Also, a large heterogeneity was found in the pre-food surge and post-food decline between 
dogs, indicating that not only basal ghrelin concentrations but also the ghrelin responses have 
a strong individual variation. 
Time-specific mean plasma GH concentrations increased just before the time when 
feeding normally occurred. Also in cows a single GH surge during feeding has been 
demonstrated (Gaynor et al., 1995). The two principal hypothalamic regulators of GH 
secretion, GHRH and somatostatin, do not seem to be responsible for the rise in circulating 
GH concentrations around feeding (McMahon et al., 2000). Because ghrelin is also a potent 
GH-releasing peptide, it can be hypothesized that a preprandial rise in circulating ghrelin 
concentrations may be responsible for the preprandially increased GH secretion. Indeed, some 
studies in humans (Cummings et al., 2001), goats, and sheep (Sugino et al., 2002a,b) have 
demonstrated that a preprandial rise in plasma ghrelin concentration is associated with a GH 
surge. The results of the present study, however, do not provide evidence for such a 
relationship in dogs, because the significant preprandial GH surge was not associated with a 
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significant preprandial ghrelin surge. Moreover, in contrast to the overall mean plasma ghrelin 
profiles the overall mean plasma GH profiles did not differ significantly in the fed compared 
to the fasted state. In addition, the overall mean plasma IGF-I concentrations did not differ 
between the several food-fast regimens. Similar to the situation in our dogs, a link between 
plasma ghrelin concentrations and plasma GH concentrations could not be demonstrated in 
cows (Miura et al., 2004).  
The overall mean plasma profiles of ghrelin on the one hand and the overall mean 
profiles of insulin and glucose on the other hand changed reciprocally after feeding and 
fasting in our dogs. While the overall mean plasma ghrelin concentrations were significantly 
lower after feeding than after fasting, the opposite was true for the overall mean serum insulin 
concentrations. These findings are in agreement with a study in humans, in which plasma 
ghrelin concentrations changed oppositely to circulating insulin concentrations (Cummings et 
al., 2001). The observation that both ghrelin and insulin are involved in the physiological 
response to food intake as well as in body weight regulation and that they display reciprocal 
24-h profiles (Cummings et al., 2001), raises the question whether insulin negatively regulates 
ghrelin or vice versa. The former hypothesis has been investigated by many groups (Saad et 
al., 2002; Flanagan et al., 2003; Kamegai et al., 2004). Taken together, these studies 
demonstrated that while insulin can suppress ghrelin release when administered in 
supraphysiologic doses or at high-normal concentrations for prolonged periods of time, 
physiological concentrations of insulin do not appear to regulate ghrelin release (Caixas et al., 
2002; Schaller, et al., 2003; Soriano-Guillen et al., 2004). It has also been suggested that 
ghrelin may act as a counter-regulatory hormone blocking insulin secretion and insulin action 
to maintain blood glucose concentrations (Broglio et al., 2001; Cummings et al., 2005). 
Indeed, several studies have shown that ghrelin can inhibit glucose-mediated insulin 
secretion, both in vitro and in vivo (Egido, et al., 2002; Reimer, et al., 2003; Colombo, et al., 
2003). Similarly, exogenous ghrelin administration decreases circulating insulin 
concentrations in mice (Reimer, et al., 2003) and humans (Broglio et al., 2003). Recently, a 
novel ghrelin-producing pancreatic islet cell type has been identified, the ε-cell (Wierup et al., 
2004). These cells are derived from the same progenitors as are the four classical islet cell 
types (producing insulin, glucagon, somatostatin, and pancreatic polypeptide), and can replace 
the other islet cells when the latter are eliminated by for example genetic deletion of vital 
transcription factors. Because ghrelin is highly expressed in the fetal pancreas (6-7 times more 
than in the stomach) (Chanoine and Wong, 2004), it may participate in pancreatic islet 
development. Preliminary evidence also suggests that ghrelin has paracrine effects on insulin 
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secretion in adults. If ghrelin derived from the pancreatic islets, rather than from the 
gastrointestinal tract, is the more critical regulator of insulin release, this raises the interesting 
possibility of an intra-islet ghrelin/insulin glucoregulatory axis. 
In conclusion, in dogs, fasting and food intake are associated with higher and lower 
circulating ghrelin concentrations, respectively, suggesting that also in this species ghrelin 
participates in the control of feeding behaviour and energy homeostasis. The changes in 
plasma ghrelin concentrations are not associated with similar changes in plasma GH 
concentrations, whereas circulating insulin and glucose concentrations appear to change 
reciprocally with the ghrelin concentration. 
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Abstract 
Endogenous progesterone and synthetic progestins may induce hypersecretion of 
growth hormone (GH) of mammary origin, hyperplastic ductular changes in the mammary 
gland, and the development of cystic endometrial hyperplasia (CEH) in dogs. It was 
investigated whether progestin-induced mammary GH plays a role in the pathogenesis of 
CEH in the bitch. During one year, bitches with surgically excised mammary glands and 
healthy control bitches received 10 mg medroxyprogesterone acetate (MPA)/kg body weight  
at 4-week intervals. The 6-h plasma profile of GH was studied before and 3, 6, 9, and 12 
months after the onset of MPA administration. Before and after MPA treatment, uterine and 
mammary tissues were collected for histological examination, for the immunohistochemical 
presence of GH, and for the expression of the genes encoding for GH, insulin-like growth 
factor-I (IGF-I), the GH receptor (GHR), and the progesterone receptor (PR). 
In the control group, MPA administration resulted in higher basal plasma GH 
concentrations, lower area under the curves (AUCs) above the baseline for GH, lower GH 
pulse frequencies, and higher AUCs above the zero-level for GH compared with the 
mastectomized dogs. After MPA administration, the mammary tissue in the control dogs had 
differentiated into lobulo-alveolar structures and CEH was present in all uteri of both dog 
groups. In the MPA-exposed mammary tissue of the control dogs, GH could only be 
demonstrated immunohistochemically in proliferating epithelium. After treatment with MPA 
the dogs of both groups had immunohistochemically demonstrable GH in the cytoplasm of 
hyperplastic glandular uterine epithelial cells. RT-PCR analysis of the mammary gland tissue 
after MPA administration demonstrated a significant higher GH gene expression, and lower 
GHR and PR gene expression than before MPA administration. In the uterus, the expression 
of the gene encoding for GH was significantly increased in the mastectomized dogs, whereas 
in the control dogs the expression of the gene encoding for IGF-I had significantly increased 
with MPA administration. MPA treatment significantly down regulated PR gene expression in 
the uterus in both dog groups.  
These results indicate that progestin-induced GH of mammary origin is not an 
essential component in the development of CEH in the bitch. Nevertheless, the presence of 
immunoreactive GH in the cytoplasm of hyperplastic glandular uterine epithelial cells of dogs 
with CEH suggests that GH may play a role in the pathogenesis of CEH. 
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Introduction 
Cystic endometrial hyperplasia (CEH) is a common disorder of the canine uterus and 
may result in infertility (McEntee, 1990; Arthur et al., 1996; Niskanen and Thrusfield, 1998). 
The condition begins with endometrial glandular hyperplasia and progresses to cystic 
transformation of the glands. When CEH is accompanied by inflammation and usually by 
bacterial infection, the disorder is called CEH-endometritis or, if the cervix is closed, 
pyometra (Dow, 1958; Hardy and Osborne, 1974; Sevelius et al., 1990; Schaefers-Okkens, 
1996; Noakes et al., 2001). This systemic disease may result in death due to toxaemia, kidney 
problems and peritonitis (Arthur et al., 1989). The pathogenesis of CEH remains incompletely 
understood, but progestins play an important role in the development of CEH in bitches 
(Teunissen, 1952). Consequently, CEH is frequently seen in bitches treated repeatedly with 
progestins for oestrus prevention (Capel-Edwards et al., 1973; Sokolowski and Zimbelman, 
1973; Goyings et al., 1977). Cystic endometrial hyperplasia may also develop spontaneously 
during the luteal phase of the oestrous cycle of middle-aged and elderly bitches, i.e. bitches 
that repeatedly have been under the influence of high concentrations of endogenous 
progesterone (Dow, 1958).  
In dogs, endogenous progesterone or synthetic progestins such as 
medroxyprogesterone acetate (MPA) may induce growth hormone (GH) hypersecretion, 
leading to acromegalic features and insulin resistance (Eigenmann and Rijnberk, 1981; 
Eigenmann et al., 1983; Selman et al., 1994a). This GH excess originates in the mammary 
gland. Progestins induce the production of GH in foci of hyperplastic ductular epithelium 
(Selman et al., 1994b, van Garderen et al., 1997). The gene encoding GH in the mammary 
gland is identical to that in the pituitary gland (Mol et al., 1995a). Moreover, the progestin-
induced mammary-derived protein is identical to pituitary GH and biologically active 
(Selman et al., 1994b). The progestin-induced elevations of plasma GH concentrations do not 
have a pulsatile secretion pattern (Watson et al., 1987), characteristic of pituitary GH 
secretion in healthy dogs (Kooistra et al., 2000). Additionally, the progestin-induced GH 
overproduction can neither be stimulated with GH-releasing hormone (GHRH), nor can it be 
inhibited by somatostatin, indicating autonomous secretion (Watson et al., 1987; Selman et 
al., 1991). 
Locally produced GH probably plays a paracrine role in the progestin-induced 
proliferation and differentiation of mammary epithelium (Feldman et al., 1993; Mol et al., 
1995a). Because of the similarity of the progestin-induced epithelial changes in both the 
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mammary gland and the uterus, it can be hypothesized that GH is also involved in the 
development of progestin-induced CEH. Although immunoreactive GH (iGH) has been found 
in uterine epithelial cells of progestin-treated dogs, the absence of mRNA encoding GH in 
uterine tissue suggests that it does not originate in the uterus (Kooistra et al., 1997). This 
finding refutes the hypothesis that local production of GH is involved in the pathogenesis of 
progestin-induced CEH. However, there is still the possibility that mammary-derived GH 
plays a role in the pathogenesis of CEH. To address this hypothesis, the effects of monthly 
injections with MPA on the development of CEH were investigated in bitches with surgically 
excised mammary glands and in a control group of bitches with intact mammary glands.  
 
Materials and methods 
Dogs 
Thirteen Beagle bitches, 3 to 9 years of age, were housed with outdoor access, fed a 
commercial dog food once a day, and given water ad libitum. The dogs were randomly 
assigned to two groups (mastectomized and control dogs). The mean age and body weight of 
the eight mastectomized dogs (5 years and 8 months and 10.5 kg, respectively) did not differ 
significantly from those of the five control dogs (5 years and 2 months and 9.5 kg, 
respectively). The dogs were accustomed to the laboratory environment and procedures such 
as collection of blood samples. Inspection of the vulva (swelling, discharge) was performed 
and serum progesterone concentration was measured on a regular basis to determine the stage 
of the oestrous cycle. 
 
Surgical procedure 
Prior to surgery food was withheld for 18h. After pre-anaesthetic medication with 
acepromazine (Placivet 2 %®, Codifar, Wommelgem, Belgium) and methadone 
(Mephenon®, Federa S.A., Brussels, Belgium) (iv), anaesthesia was induced with propofol 
(Diprivan 1 %®, Astra Zeneca, Brussels, Belgium) (iv) and maintained with isoflurane 
(Isoba®Vet, Schering-Plough Animal Health, Middlesex, England) in oxygen. Epidural 
anaesthesia (between lumbar vertebra L7 and sacrum) was performed in dogs that underwent 
mastectomy and consisted of lidocain hydrochloride (Xylocaïne 2 %®, NV Astra Zeneca, 
Brussels, Belgium), bupivacain hydrochloride (Marcaïne 0.5 %®, NV Astra Zeneca, Brussels, 
Belgium), and morphine hydrochloride (Stellorphine®, Stella, Liège, Belgium). Antibiotics 
(amoxicillin/clavulanic acid (Synulox®, Pfizer Animal Health, Borgo San Michele, Italy)) 
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were administered pre- and postoperatively. Post surgical analgesia consisted of carprofen 
(Rimadyl®, Pfizer Animal Health, Dundee, Scotland, UK) and buprenorphine (Temgesic®, 
Schering-Plough, Brussels, Belgium).  
All surgical procedures were performed during anoestrus. The tip of the right uterine 
horn, the corresponding ovary and the entire mammary gland were excised in eight dogs 
(mastectomized group). Surgical removal of all mammary gland tissue was performed in 2 
sessions with an interval of 4-6 weeks. In the five control dogs only the tip of the right uterine 
horn and the corresponding ovary were excised.  
At the end of the series of MPA injections, the remainder of the uterus and the left 
ovary were removed (both dog groups), and a sample of the mammary gland was collected 
(control dogs). In all dogs intra-uterine fluid was collected for bacteriological examination. 
After surgical removal, a part of the tissue samples was fixed in a phosphate-buffered 
formalin solution, processed, and embedded in paraffin; another part was frozen in liquid 
nitrogen and stored at -80° C until analysis.  
 
Treatment 
Treatment was started in both groups after the first surgical procedures, i.e., during 
anoestrus, and consisted of subcutaneous MPA injections (Depo-Promone®, Pharmacia 
Animal Health, Puurs, Belgium) in a dose of 10 mg/kg body weight at intervals of 4 weeks, 
for a total of 13 administrations.  
 
Blood sample collection 
In all dogs, two blood samples, with an interval of 15 min, for determination of the 
plasma insulin-like growth factor-I (IGF-I) concentrations were collected by jugular 
venipuncture before surgery and the first MPA administration, and 1, 4, 7, and 10 months 
after the onset of treatment. 
In all dogs, blood samples for the determination of the plasma profiles of GH were 
collected at 15-min intervals between 0800h and 1400h before surgery and the first MPA 
administration, and 3, 6, 9, and 12 months after the onset of treatment. 
The blood samples were collected after an overnight fast, immediately transferred to 
ice-chilled EDTA-coated tubes and centrifuged at 4o C for 10 min. Plasma was stored at -25o 
C until assayed.  
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Hormone determination 
Plasma progesterone concentrations were determined with a previously validated 
radioimmunoassay (RIA) (Henry et al., 1987). The intra-assay and interassay coefficients of 
variation were 7.05 % and 8.75 %, respectively. The sensitivity of the assay was 0.005 ng. 
Plasma GH concentrations were measured using a commercially available RIA for 
porcine and canine GH (PGH-46HK; Linco Research, St. Charles MS, USA). The intra-assay 
coefficient of variation was 7.6 % at a plasma concentration of 4.4 µg/l. The sensitivity of the 
assay was 1 µg/l. 
Total plasma IGF-I concentrations were measured after acid-ethanol extraction to 
remove interfering IGF-binding proteins. Plasma IGF was extracted using a mixture of 87.5 
% (v/v) ethanol and 12.5 % 2 M formic acid. Tubes containing 100 µl plasma and 400 µl of 
the ethanol-formic acid mixture were mixed thoroughly and incubated for 30 min at room 
temperature. After centrifugation for 30 min at 5500 g at 4° C, a 50 µl aliquot of the 
supernatant was diluted 1:50 with assay buffer containing 63 mM Na2HPO4 (pH 7.4), 13 mM 
Na2EDTA, and 0.25 % (w/v) BSA. The extraction efficiency amounted to 92.5 ± 5.7 %. 
Plasma IGF-I concentrations were measured in a heterologous RIA validated for the dog 
(Favier et al., 2001). The intra-assay coefficient of variation was 8.6 % at a plasma 
concentration of 100 µg/l. The sensitivity of the assay was 10 µg/l. IGF-I antiserum 
AFP4892898 and human IGF-I for iodination were obtained from the National Hormone and 
Peptide Programme (Harbor-UCLA Medical Center, Torrance CA).  
 
Histology and immunohistochemistry  
The formalin fixed, paraffin embedded uterine and mammary tissues were cut at 5 µm 
for histological and immunohistological staining. For standard histological examination the 
slides were stained with haematoxylin and eosin (HE). Periodic Acid Shiff (PAS) stainings 
were made of all uteri with CEH (i.e. after treatment with MPA) and were used to assess the 
secretory activity of the endometrial glands. 
For immunohistochemistry, a polyclonal rabbit anti-porcine GH antibody (generous 
gift of S.J. Dieleman, Department of Herd Health and Reproduction, Faculty of Veterinary 
Medicine, Utrecht University) was used in an indirect immunoperoxidase staining procedure 
(PAP method) as follows. The paraffin wax of the sections was removed with xylene and the 
sections were cleared in 100 % alcohol. Endogenous peroxidase was blocked by incubation in 
1 % H2O2 in methanol for 20 min at room temperature. The sections were rehydrated by 
passage through 96 % and 70 % alcohol to distilled water. They were then rinsed in 
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phosphate-buffered saline (PBS) (3 x 5 min) and preincubated with normal goat serum in PBS 
(1:20) for 20 min at room temperature. Incubation with the polyclonal rabbit anti-porcine GH 
antibody in a 1:5000 dilution in PBS took place overnight at 4° C and then for 30 min at room 
temperature. After incubation, the sections were rinsed for 3 x 5 min in PBS and incubated 
with goat anti-rabbit serum (Dakopatts Inc., Glostrup) diluted 1:20 for 60 min. Thereafter, the 
sections were washed in PBS for 3 x 5 min and incubated with rabbit peroxidase-
antiperoxidase complex (Dakopatts Inc., dilution 1:100). Immunoreactive GH was visualized 
using 0.3 % (v/v) H2O2 and 0.5 % (w/v) 3,3,-diaminobenzidine tetrahydrochloride (Sigma, 
Brussels, Belgium) diluted in 0.05 mol Tris/l in HCl buffer, during a 10 min incubation step. 
After rinsing in distilled water for 2 min the sections were counterstained with Mayer’s 
haematoxylin for 1 min. A canine pituitary gland served as a positive control. Approximately 
70 % of the cells in the adenohypophysis stained positive for GH. The negative controls were 
sections of uterine and mammary tissue processed in the same way, except that normal rabbit 
antiserum was used instead of rabbit anti-porcine GH antibody. 
 
Isolation of total RNA and cDNA synthesis 
Surgically removed mammary and uterine specimens were snap frozen in liquid 
nitrogen and stored at -80° C until used for RNA isolation. Total RNA was extracted from 0.2 
to 1 g tissue using TRIzol reagent (Invitrogen, Groningen, The Netherlands). Purification was 
performed with the Rneasy Midi Kit (Qiagen, Leusden, The Netherlands) according to the 
manufacturer’s protocol. Purified total RNA was subjected to DNase treatment using the 
DNA free kit (Qiagen, Leusden, The Netherlands). cDNA synthesis was carried out from 1.5 
µg total RNA in 60 µl reaction mix using the iScripttm cDNA synthesis kit (Biorad, 
Veenendaal, The Netherlands) according to the manufacturer’s protocol. 
 
Real time polymerase chain reaction (RT-PCR) 
Primers (Table 1) were designed using primer select software of DNA star and 
primer3 (Rozen and Skaletsky, 2000) according to the parameters outlined in the Biorad 
icycler manual. Specificity of each primer pair was confirmed by sequencing its product. 
HPRT and GAPDH genes were used as the non-regulated reference genes for normalization 
of target gene expressions.  
RT-PCR was performed using the Biorad MyiQ detection system (Biorad Laboratories 
Ltd.) with SYBR green fluorophore. Reactions were performed in a total volume of 25 µl 
Chapter 8 
 
 
184 
containing 12.5 µl 2x SYBR green super mix (Biorad Laboratories Ltd.), 1 µl of each primer 
at 400 nM concentration, 0.8 µl of cDNA, and 9.7 µl RNase and DNase free water. 
RT-PCR reactions for each primer set were optimized by performing reactions under a 
gradient of annealing temperature using five serial 10x dilutions of pooled cDNA from all 
tissue samples. The protocol used was as follows: denaturation (95° C for 5 min), 
amplification cycle repeated 40 times (95° C for 30 sec, a PCR specific annealing temperature 
(Table 1) for 30 sec, 72° C for 30 sec). A melt cure analysis was performed following every 
run to ensure a single amplified product for every reaction. 
All reactions were performed in triplicate for every sample. The reference standard 
dilution series was repeated on every plate. Triplicate negative controls were run with every 
experimental plate to assess the specificity and to identify any potential contamination. 
 
Table 1. Primers were designed using primer select software of DNA star and primer3 (Rozen and Skaletsky, 
2000) according to the parameters outlined in the Biorad icycler manual. 
Target gene Forward primer Reverse primer Optimum annealing  
temperature (°C) 
HPRT agcttgctggtgaaaaggac ttatagtcaagggcatatcc 56 
GH ctgctgctcatccagtcgt caggtccttgagcttctcgt 60 
GHR gcgcatcccagagtctaca accatgacgaaccccatct 58 
IGF-I tgtcctcctcgcatctctt gtctccgcacacgaactg 60 
PR caatggaagggcagcataac cagcactttctaaggcgaca 58 
GAPDH tgtccccacccccaatgtatc ctccgatgcctgcttcactacctt 58 
 
Statistical analysis 
The 6-h plasma profiles of GH were analyzed by means of the Pulsar programme 
developed by Merriam and Wachter (1982). The programme identifies secretory peaks by 
height and duration from a smoothed baseline, using the assay standard deviation (SD) as a 
scale factor. The cut-off parameters G1-G5 of the Pulsar programme were set at 3.98, 2.40, 
1.68, 1.24, and 0.93 times the assay SD as criteria for accepting peaks 1, 2, 3, 4, and 5 points 
wide, respectively. The smoothing time, a window used to calculate a running mean value 
omitting peaks, was set at 5h. The splitting cut-off parameter was set at 0.5 and the weight 
assigned to peaks was 0.05. The A-, B-, and C- values of the Pulsar programme, used to 
calculate the variance of the assay, were set at A=0, B=7.2, and C=5. The values extracted 
from the Pulsar analysis included the mean of the smoothed baseline, the pulse frequency, and 
the area under the curve (AUC). The AUC was calculated above the zero-level (AUC0) as 
well as above the baseline (AUCbase). 
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The AUC0 for GH, the basal plasma GH concentration and the plasma IGF-I 
concentration were analyzed by a mixed model with dog as random effect and time, group 
(mastectomized and control dog group) and their interaction as categorical fixed effects. 
Using this model, the mastectomized and control dog group were compared. Additionally the 
evolution over time of these parameters was evaluated in each group separately.   
Because the GH pulse frequency and the AUCbase for GH were not distributed 
normally, the two dog groups were compared at each time point (before surgery and MPA 
injection and 3, 6, 9, and 12 months after the onset of MPA treatment) based on the Mann-
Whitney test. Furthermore, the differences within a dog group between 0 months (= before 
surgery and MPA treatment) and 3, 6, 9, and 12 months after the onset of MPA administration 
were also analyzed by the Mann-Whitney test.  
All statistical tests were performed at a global 5 % significance level, applying the 
Bonferroni correction for multiple comparisons. All values are expressed as mean ± SEM 
except for the AUCbase for GH and the GH pulse frequency which are expressed as median 
values. Analyses were performed with SAS version 9.1 for Windows (Insightful Corp., 
Seattle, US). 
The difference in expression of the target genes by RT-PCR between dogs before and 
after treatment with MPA were assessed using the pair wise fixed reallocation randomization 
test incorporated in the software programme REST-XL (Pfaffl et al., 2002) at the 5 % 
significance level. Dogs which were subjected to mastectomy before treatment with MPA and 
dogs with intact mammary gland tissue were treated as separate groups for data analysis.  
 
Ethics of the study 
This study was approved by the Ethics Committee of the Faculty of Veterinary 
Medicine, Ghent University. 
 
Results 
In both dog groups, the 6-h plasma profile of GH before surgery and MPA treatment 
was characterized by a fluctuating baseline with occasional distinct elevations, indicating 
pulsatile secretion of GH. During treatment with MPA, in the control dogs the basal secretion 
of GH increased and the pulsatile secretion of GH decreased, whereas in the mastecomized 
dogs the pulsatile secretion persisted, without changes in the basal GH concentration (Figure 
1).
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Figure 1. The secretory profiles of GH (µg/l) (=Y-axis) in a five-year-old mastectomized bitch (●) and in a five-
year-old control bitch (○). Blood samples were collected at 15-min intervals for 6 h (from 0800h to 1400h = X-
axis), before surgery and treatment with MPA (0 months) and 3, 6, 9, and 12 months after the onset of MPA 
treatment. Significant pulses, calculated by the Pulsar programme, are indicated by an asterisk. 
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The mean basal plasma GH concentration evolved significantly (P = 0.0002) different 
over time between both dog groups. In the control group the mean basal plasma GH 
concentration was significantly higher after 9 months (3.4 ± 0.5 µg/l, P < 0.0001) and 12 
months (2.8 ± 0.6 µg/l, P = 0.001) of MPA administration than in the mastectomized group 
(1.4 ± 0.2 µg/l and 1.6 ± 0.2 µg/l, respectively). Within the mastectomized group the mean 
basal plasma GH concentration before surgery and treatment with MPA (1.6 ± 0.1 µg/l) did 
not differ significantly from that after 3 (1.9 ± 0.2 µg/l), 6 (1.1 ± 0.1 µg/l), 9 (1.4 ± 0.2 µg/l), 
and 12 (1.6 ± 0.2 µg/l) months of MPA treatment. Within the control group the mean basal 
plasma GH concentration before surgery and treatment with MPA (1.7 ± 0.1 µg/l) was 
significantly lower than that after 9 months (P < 0.0001) and 12 months (P = 0.0002) of MPA 
treatment (Figure 2a). 
The mean AUC0 for GH evolved significantly (P = 0.0002) different over time 
between both dog groups. In the control group the mean AUC0 for GH after 9 months of MPA 
treatment (20.4 ± 2.9 µg/lx6h) was significantly higher (P = 0.0002) than that in the 
mastectomized group (9.5 ± 1.5 µg/lx6h). Within the mastectomized group the mean AUC0 
for GH before surgery and treatment with MPA (11.4 ± 0.4 µg/lx6h) did not differ 
significantly from that after 3 (14.2 ± 1.5 µg/lx6h), 6 (9.8 ± 1.9 µg/lx6h), 9 (9.5 ± 1.5 
µg/lx6h), and 12 (11.9 ± 1.3 µg/lx6h) months of MPA treatment. Within the control group the 
mean AUC0 for GH before surgery and treatment with MPA (11.3 ± 1.0 µg/lx6h) was 
significantly lower compared to that after 9 months (20.4 ± 2.9 µg/lx6h, P < 0.0001) and 12 
months (17.0 ± 3.6 µg/lx6h, P = 0.005) of MPA treatment (Figure 2b). 
 
 
 
 
 
 
 
 
Figure 2. (a) The mean (± SEM) basal plasma GH concentration, (b) the mean (± SEM) area under the curve 
above the zero-level (AUC0) for GH in eight mastectomized Beagle bitches (●) and in five control Beagle 
bitches (○). Blood samples were collected at 15-min intervals for 6 h before surgery and treatment with MPA (0 
months) and 3, 6, 9, and 12 months after the onset of MPA treatment (= X-axis). ‘a’ indicates significant 
difference between both dog groups and ‘b’ indicates significant difference within the group compared with the 
value before surgery and MPA treatment. 
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The median AUCbase for GH in the mastectomized group was significantly higher after 
3 months (2.3 µg/lx6h; range = 0 to 9.5 µg/lx6h, P = 0.01) and 9 months (0.2 µg/lx6h; range =  
0 to 5.5 µg/lx6h, P = 0.003) of MPA administration than in the control group (at both time 
points median AUCbase = 0 and range = 0 to 0). In both groups, the median AUCbase for GH 
before surgery and MPA treatment did not differ significantly with that after 3, 6, 9, and 12 
months of MPA treatment. 
The median GH pulse frequency in the mastectomized group was significantly higher 
after 6 months (2 peaks per 6h; range = 0 to 5 peaks per 6h, P = 0.01) and 9 months (1 peak 
per 6h; range = 0 to 5 peaks per 6h, P = 0.01) of MPA treatment than that in the control group 
(at both time points median GH pulse frequency = 0 peaks and range = 0 to 0 peaks per 6h). 
In both groups the median GH pulse frequency before surgery and MPA treatment did not 
differ significantly with that after 3, 6, 9, and 12 months of MPA treatment. 
The mean plasma IGF-I concentration evolved significantly (P < 0.0001) different 
over time between both dog groups. In the control group, the mean plasma IGF-I 
concentration was significantly higher after 4 (116 ± 18 µg/l, P = 0.006), 7 (143 ± 29 µg/l, P = 
0.001) and 10 months (180 ± 30 µg/l, P < 0.0001) of MPA treatment than in the 
mastectomized group (54 ± 9 µg/l, 68 ± 12 µg/l, and 57 ± 8 µg/l, respectively). Within the 
mastectomized group the mean plasma IGF-I concentration before surgery and treatment with 
MPA (35 ± 7 µg/l) did not differ significantly from that after 1 (35 ± 7 µg/l), 4, 7, and 10 
months of MPA administration. Within the control dog group the mean plasma IGF-I 
concentration before surgery and treatment with MPA (28 ± 6 µg/l) was significantly lower 
than that after 4, 7, and 10 months of MPA treatment (P < 0.0001 at all time points) (Figure 
3).  
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Figure 3. The mean (± SEM) plasma IGF-I concentration in eight mastectomized Beagle bitches (●) and in five 
control Beagle bitches (○) before surgery and treatment with MPA (0 months) and 1, 4, 7, and 10 months after 
the onset of MPA treatment. ‘a’ indicates significant difference between both dog groups and ‘b’ indicates 
significant difference within the group compared with the value before surgery and MPA treatment. 
 
 
Histological examination of the mammary gland tissue before MPA treatment (Figure 
4a) revealed inactive mammary tissue characterized by the presence of involuted ductular 
structures outlined by flattened epithelial cells, absent or small alveolar lumina, and a high 
stroma/parenchyma ratio. After MPA treatment (Figure 4b), the mammary tissue had 
differentiated into lobulo-alveolar structures in which milk protein synthesis occurred. The 
epithelial cells were cuboidal and surrounded by myoepithelial cells, and the 
stroma/parenchyma ratio was low. In one dog there was proliferating mammary epithelium, 
with focal hyperplastic changes of ductular epithelial cells, i.e. ductal budding structures. In 
the mammary tissues before treatment with MPA, immunohistochemical examination did not 
reveal iGH. Also after MPA treatment no iGH was found in the mammary tissues, except for 
the dog with focal hyperplastic changes of ductular epithelial cells (Figure 5a). In this dog, 
iGH was observed in hyperplastic ductular epithelial cells (Figure 5b).  
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Figure 4. (a) Histology of mammary gland tissue before MPA treatment revealed inactive mammary tissue 
characterized by the presence of involuted ductular structures with only remnants of lobules (arrows) and an 
overrepresentation of stromal cells (S). (b) Histology after one year of MPA treatment revealed differentiated 
lobulo-alveolar glandular mammary tissue with milk protein synthesis (arrows). The amount of stroma is 
strongly reduced (S). HE staining - Bar = 200 µm 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. (a) Immunohistochemical examination of mammary gland tissue in a four-year-old Beagle dog after 
one year of MPA treatment. Immunoreactive GH is absent in lobulo-alveolar structures (L) and is focally present 
in hyperplastic ductular epithelial cells (“ductal buds”) (arrow). Bar = 100 µm. (b) Enlargement of a part of 
figure 5a (dotted arrow). Immunohistochemical localization of GH in the cytoplasm of hyperplastic epithelial 
cells of mammary gland tissue after one year of treatment with MPA (arrows). Bar = 25 µm. 
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Histological examination of the uterine tissue before treatment with MPA confirmed 
that all dogs were in the anoestrous phase of the ovarian cycle and that none of the uteri 
showed histological signs of CEH (Figure 6a). The inactive endometrium contained small 
endometrial glands outlined by cuboidal cells. The myometrium consisted of smooth muscle 
cells with dense nuclei and a small amount of cytoplasm. After MPA administration, CEH 
was macro- and microscopically present in all dogs of both dog groups. Histological changes 
were severe and included multiple, large, mucus-filled cystic, PAS-positive endometrial 
glands, hyperplasia of the epithelium of the endometrial glands, labyrinth-like proliferations 
of the surface epithelium and endometrial stroma (Figure 6b). In all dogs, there was a variable 
degree of necrosis in the endometrium characterized by dense, small nuclei indicating 
pyknosis, and a small to moderate infiltration with inflammatory cells (neutrophils and foci of 
lymphocytes and plasma cells). Bacteriological examination of the intra-uterine fluid was 
negative in all dogs. Immunohistochemical examination of the uterine tissues before MPA 
treatment did not demonstrate the presence of iGH in any dog. Immunohistochemical 
examination of the uterine tissues after MPA treatment revealed iGH in all dogs of both dog 
groups. In general, iGH was located in the cytoplasm of hyperplastic glandular epithelial cells 
(Figures 7a and b).  
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Figure 6. (a) Histology of the uterus before MPA administration with the characteristics of anoestrus, including 
the endometrium containing small endometrial glands (arrow). (b) Severe CEH after MPA administration 
characterized by multiple, large mucus-filled endometrial cysts and labyrinth-like proliferations of the surface 
epithelium. HE staining - Bar =  200  µm 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. (a) Immunohistochemical examination of the uterus after one year of MPA administration shows the 
presence of GH in hyperplastic glandular epithelial cells (arrows). Bar = 100 µm. (b) Enlargement of a part of 
figure 7a (dotted arrow). Immunoreactive GH in the uterus is present in the vacuolated cytoplasm of the 
hyperplastic epithelium (arrows). Bar = 25 µm. 
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RT-PCR analysis of the mammary gland tissue of the control dogs after MPA 
treatment demonstrated a significantly (P = 0.002) higher mean GH gene expression than 
before treatment. The mean mammary GH receptor (GHR) and progesterone receptor (PR) 
gene expression was significantly (P = 0.01 and P = 0.03, respectively) lower after MPA 
administration than before treatment. No significant difference was observed in the mean 
mammary IGF-I mRNA content after MPA treatment compared to that before treatment 
(Figure 8). In the mastectomized dogs, the mean GH gene expression in the uterus was 
significantly (P = 0.002) higher after treatment with MPA than before treatment, whereas in 
the control dogs, the mean IGF-I gene expression was significantly (P = 0.001) higher after 
MPA administration. A trend (P = 0.052) for a lower mean GHR gene expression after 
treatment with MPA was found in the uterus of the control dogs compared with that before 
MPA administration. In both dog groups the mean mRNA content encoding the PR after 
treatment with MPA was significantly (P = 0.001 for both groups) down regulated compared 
to the PR mRNA content before treatment (Figure 9).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Difference in mean gene expression of growth hormone (GH), the GH receptor (GHR), the 
progesterone receptor (PR), and insulin like growth factor-I (IGF-I) between before and after treatment with 
MPA in the mammary gland of Beagle dogs demonstrated by RT-PCR. Significant differences in gene 
expression before and after MPA treatment are indicated with an asterisk.  
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Figure 9. Difference in mean gene expression of growth hormone (GH), the GH receptor (GHR), the 
progesterone receptor (PR), and insulin like growth factor-I (IGF-I) between before and after treatment with 
MPA in the uterus of five control Beagle dogs (□) and eight mastectomized dogs (■) demonstrated by RT-PCR. 
Significant differences in gene expression before and after MPA treatment are indicated with an asterisk.  
 
Discussion 
In the control dogs MPA treatment resulted in a higher basal GH secretion and less 
GH secreted in pulses compared to the mastectomized dogs. This is consistent with (partial) 
suppression of pituitary GH secretion by progestin-induced GH secretion from the mammary 
gland. In the mastectomized dogs MPA treatment did not result in a change of the basal GH 
concentration, the AUC0 for GH, the AUCbase for GH, and the GH pulse frequency, also 
demonstrating the mammary origin of progestin-induced GH excess. Dogs are not unique 
among other mammalian species in that the gene encoding GH is expressed in the mammary 
gland. RT-PCR has revealed that this gene is also expressed in the mammary gland of women 
and cats (Mol et al., 1995a and 1995b). However, until now the dog is the only species in 
which it has been demonstrated unequivocally that progestin-induced mammary-derived GH 
reaches the systemic circulation, and is biologically active (Selman et al., 1994b).  
  After several months of MPA treatment, there was a low GH pulse frequency and a 
corresponding low AUCbase for GH in the control dogs compared to the mastectomized dogs. 
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A similarly decreased GH pulsatility has also been reported in women during the second half 
of pregnancy (Eriksson et al., 1989). In these women the loss of GH pulsatility is due to the 
release of a placental GH variant (Eriksson et al., 1989). Thus, in both species the loss of GH 
pulsatility can be ascribed to the negative feedback effects of non-episodically secreted extra-
pituitary GH. It has been demonstrated in humans that GH exerts its negative feedback by a 
stimulation of hypothalamic somatostatin secretion (Berelowitz et al., 1981). Additionally, in 
the control dogs the progestin-induced elevated GH concentrations had induced raised IGF-I 
concentrations, which will have contributed to the inhibition of pulsatile pituitary GH 
secretion (Hartman et al., 1993). 
With regard to the physiological role of the progestin-induced mammary GH 
production, local autocrine and paracrine effects in the mammary gland as well as systemic 
endocrine effects have to be considered. It is thought that the progestin-induced GH 
production in the mammary gland leads to local production of IGFs, whereby the growth-
promoting effect is modulated by locally synthesized IGF-binding proteins (Mol et al., 1996). 
Thus a proliferative environment for the glandular epithelium is created, i.e., the 
autocrine/paracrine background for the physiological proliferation and differentiation of 
mammary gland tissue. This is in agreement with the results of studies in rats, indicating that 
GH and GH-induced IGF-I are necessary for mammary development (Feldman et al., 1993; 
Walden et al., 1998). Also in the ewe mammogenesis is partly dependent upon GH (Kann, 
1997). However, until now it has not been demonstrated in this species that this GH originates 
from the mammary gland.  
In the dog, the histological features of the mammary gland vary strongly with the stage 
of the ovarian cycle (van Garderen et al., 1999). In the anoestrous phase, the glandular tissue 
is inactive, and microscopically only involuted ductular structures and remnants of lobules are 
encountered. These were also the characteristics of the mammary gland tissue of our dogs 
before treatment with MPA. In the luteal phase, after ovulation, there is nodular epithelial 
proliferation resulting in ductal buds that parallels high endogenous progesterone 
concentrations in dogs. A similar proliferation of these epithelial cells can be induced by 
exogenous progestins. In the bitch, ovulation is followed by a relatively long luteal phase, 
irrespective of pregnancy (Concannon et al., 1975). During this longstanding progesterone-
dominated phase of approximately two months, epithelial cells in budding structures 
proliferate and finally differentiate into lobulo-alveolar structures, fully equipped for milk 
synthesis. In the present study, mammary gland tissue was examined histologically after a 
long period of progestin administration. This may be the reason that epithelial buds were 
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found in only one dog and that most of the glandular tissue had differentiated into lobulo-
alveolar structures in which milk synthesis occurred.  
In canine mammary tissue iGH and GH gene expression is found predominantly in the 
ductal epithelial buds in the early and midluteal phase of the ovarian cycle (van Garderen et 
al., 1997). In contrast, the GH gene expression is diminished in differentiated lobulo-alveolar 
glandular tissue and in the anoestrous phase of the canine ovarian cycle (van Garderen et al., 
1997). Similar immunohistochemical features were found in the present study. 
Immunoreactive GH was not detected in the mammary gland tissue of the anoestrous dogs 
before treatment with MPA. Additionally, iGH was absent in the mammary gland tissue of the 
control bitches treated for twelve months with MPA, except for one dog. In this dog, iGH 
appeared to be present only in hyperplastic ductular epithelium that consisted of more than 2 
cell layers, i.e. epithelial cells in budding structures. 
RT-PCR analysis, which is more sensitive than immunohistochemical examination 
demonstrated that MPA administration increased GH gene expression in mammary gland 
tissue of the control dogs. Also in another study, increased GH mRNA levels were found in 
mammary gland tissue of dogs after prolonged treatment with progestins (Mol et al., 1995a). 
Whereas in primates, GH can bind to the GHR and the prolactin receptor, in nonprimate 
mammals, such as the dog, GH can only bind to its specific receptor, the GHR (Rutteman et 
al., 1986). van Garderen et al. (1999) demonstrated that immunohistochemical expression of 
the GHR is down regulated in completely differentiated alveolar epithelial cells at the end of 
the luteal phase. Similarly, RT-PCR analysis of the mammary tissue in our control dogs after 
prolonged MPA treatment confirmed that GHR gene expression was significantly lower 
compared to this expression before MPA administration.  
A possible systemic endocrine effect of mammary GH is the effect on uterine 
epithelium. After MPA treatment the uterine tissues of both the intact and the mastectomized 
dogs had iGH. This indicates that progestin-induced mammary-derived GH does not play a 
key role in the development of CEH in the bitch. Nevertheless, the widespread presence of 
iGH in uterine epithelial cells of dogs with CEH suggests an association between GH and this 
uterine pathology. Next to GH, a previous study (De Cock et al., 2000) also demonstrated the 
presence of iIGF-I in the uterus of dogs with CEH. These growth factors have an intrinsic 
growth promoting effect on most cell types in the body (Schoenle et al., 1982; Simmen, 1991; 
Jones and Clemmons, 1995; McCusker, 1998). The growth promoting effect of IGF-I on the 
uterus is further illustrated by the fact that IGF-I knock out mice have severe hypoplastic uteri 
(Baker et al., 1996). In addition, IGF-I is involved in the postnatal growth of the uterus in the 
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rat (Gu et al., 1999) and the pig (Simmen et al., 1992). IGF-I treatment of ovariectomized rats 
induces uterine endometrial hyperplasia (Sahlin et al., 1994). 
RT-PCR revealed that, after MPA treatment, the GH mRNA content of uterine tissue 
was only increased in the mastectomized dogs and not in the control dogs. Comparable with 
the progestin-induced GH gene expression in canine mammary tissue during development of 
ductal epithelial buds (van Garderen et al., 1997), MPA treatment also resulted in more GH 
gene expression in the uterine epithelial tissue. Apparently, in the control dogs the elevated 
circulating concentrations of GH of mammary origin and the subsequently increased plasma 
IGF-I concentrations suppressed uterine GH gene expression, similar to what has been 
reported for the pituitary (Hartman et al., 1993). MPA treatment also resulted in increased 
expression of the IGF-I gene in the uterine tissue, but this was significant only in the control 
dogs. This may be explained by the stimulating effect of the elevated circulating 
concentrations of GH, originating from the mammary gland, on uterine IGF-I gene expression 
in these dogs. As the presence of mRNA encoding for the GHR has already been 
demonstrated in the human uterus (Mercado et al., 1994; Sharara and Nieman, 1995), 
circulating GH may indeed influence intracellular effects in uterine cells.  
In this study MPA did not promote the expression of GHRs in uterine epithelium. This 
makes it unlikely that increased numbers of GHRs can explain the presence of iGH in uterine 
cells, as proposed earlier (Kooistra et al., 1997).  
Uterine steroid hormone receptor status is a crucial element in pathological conditions 
such as CEH and pyometra (De Cock et al., 1997; Noakes et al., 2001). Progesterone 
exposure is considered the initiating step in the development of CEH (Teunissen, 1952; 
Capel-Edwards et al., 1973; Sokolowski and Zimbelman, 1973; Goyings et al., 1977; Evans 
and Sutton, 1989; Allen, 1992; Von Berky and Townsend, 1993). In the present study one 
year of MPA treatment decreased the expression of the gene encoding for PR. In line with this 
observation, immunohistochemical studies (De Bosschere et al., 2002) found a severe 
reduction in the canine uterine PR after 12 weeks of MPA administration. The uterine 
concentration and distribution of progesterone receptors are influenced by hormonal changes 
during the oestrous cycle and by administration of MPA in the bitch (Dhaliwal, 1997). An 
increase in plasma progesterone concentration results in a decline of PR content in the uterus 
(Fernandes et al., 1989; Clarke and Sutherland, 1990; Vesanen et al., 1991; Graham and 
Clarke, 1997; Vermeirsch et al., 2000) and explains the decrease of PR mRNA with MPA 
treatment in the present study. 
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In conclusion, MPA administration caused hypersecretion of GH and IGF-I in the 
control dogs, but failed to do so in the mastectomized dogs. All dogs of both groups 
developed CEH, indicating that mammary GH is not a requirement for the development of 
progestin-induced CEH. Nevertheless, the presence of iGH in the cytoplasm of hyperplastic 
glandular uterine epithelial cells of dogs with CEH suggests that GH may play a role in the 
pathogenesis of CEH.   
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Abstract 
The aim of this study was to investigate the effects of treatment with 
medroxyprogesterone acetate (MPA) on canine adenohypophyseal function. Five Beagle 
bitches were treated with MPA (10 mg/kg, every 4 weeks) and their adenohypophyseal 
function was assessed in a combined adenohypophyseal function test. Four hypophysiotrophic 
hormones (corticotrophin-releasing hormone, growth hormone (GH)-releasing hormone, 
gonadotrophin-releasing hormone (GnRH), and thyroid-releasing hormone (TRH)) were 
administered before and 2, 5, 8, and 11 months after the start of MPA treatment, and blood 
samples for determination of the plasma concentrations of adrenocorticotrophic hormone 
(ACTH), cortisol, GH, insulin-like growth factor-I (IGF-I), luteinizing hormone (LH), 
follicle-stimulating hormone (FSH), prolactin (PRL), α-melanocyte-stimulating hormone (α-
MSH), and thyroid-stimulating hormone (TSH) were collected at -15, 0, 5, 10, 20, 30, and 45 
min after supra-pituitary stimulation.  
Medroxyprogesterone acetate successfully prevented the occurrence of oestrus, 
ovulation, and a subsequent luteal phase. Treatment with MPA did not affect basal and 
GnRH-induced plasma LH concentrations. The basal plasma FSH concentration was 
significantly higher at 2 months after the start of MPA treatment than before or at 5, 8, and 11 
months after the start of treatment. The maximal FSH increment and the area under the curve 
(AUC) for FSH after supra-pituitary stimulation were significantly higher before treatment 
than at 5, 8, and 11 months of MPA treatment. Differences in mean basal plasma GH 
concentrations before and during treatment were not significant, but MPA treatment resulted 
in significantly elevated basal plasma IGF-I concentrations at 8 and 11 months. Treatment 
with MPA did not affect basal and stimulated plasma ACTH concentrations, with the 
exception of a decreased AUC for ACTH at 11 months. In contrast, the maximal cortisol 
increment and the AUC for cortisol after supra-pituitary stimulation were significantly lower 
during MPA treatment than prior to treatment. Treatment with MPA did not affect basal 
plasma concentrations of prolactin, TSH, and α-MSH, with the exception of slightly increased 
basal plasma TSH concentrations at 8 months of treatment. Treatment with MPA did not 
affect TRH-induced plasma concentrations of prolactin and TSH. 
In conclusion, the effects of chronic MPA treatment on adenohypophyseal function 
included increased FSH secretion, unaffected LH secretion, activation of the mammary GH-
induced IGF-I secretion, slightly activated TSH secretion, suppression of the hypothalamic-
pituitary-adrenocortical axis, and unaffected secretion of PRL and α-MSH. 
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Introduction 
Progestins, such as medroxyprogesterone acetate (MPA), are commonly used to 
prevent oestrus in the bitch (Schaefers-Okkens, 1996; Romagnoli and Concannon, 2003). 
Whether the oestrus-preventing properties of progestins in the bitch are due to effects on the 
hypothalamus, on the pituitary gland, or at the ovarian level is not clear. McCann et al. (1987) 
and Colon et al. (1993) reported that basal plasma levels of luteinizing hormone (LH) and 
follicle-stimulating hormone (FSH) do not change during progestin treatment. Information 
about the effect of gonadotrophin-releasing hormone (GnRH) on the secretion of LH during 
progestin treatment is conflicting. GnRH-induced increases in plasma LH concentrations in 
progestin-treated dogs did not differ from those in control dogs in one study (Colon et al., 
1993), while in another study the GnRH-induced LH levels were reduced (McCann et al., 
1987). In dogs there is no information on the effect of progestins on GnRH-stimulated FSH 
concentrations.  
In women, progestins are known to prevent ovulation by inhibiting the mid-cycle 
surges of FSH and LH, whereas the tonic release of these gonadotrophins continues at luteal 
phase levels (Mishell, 1996; Jain et al., 2004). Long-term use of depot MPA in women does 
not affect the pituitary responsiveness of LH and FSH to GnRH administration, suggesting 
that the pituitary is not the primary site for ovulation inhibition in women (Ismael et al., 
1987).  
Prolonged treatment with progestins in bitches is associated with alterations in the 
release of pituitary hormones other than gonadotrophins. Progestin administration leads to a 
decrease in the pituitary responsiveness of growth hormone (GH) to growth hormone 
releasing hormone (GHRH) (Watson et al., 1987; Selman et al., 1991, 1994a). This change is 
due to GH release from foci of hyperplastic ductular mammary epithelium (Selman et al., 
1994b; van Garderen et al., 1997), leading to elevated plasma GH levels that do not have a 
pulsatile plasma profile (Watson et al., 1987). The hypothalamic-pituitary-adrenocortical 
(HPA) axis is suppressed by progestins (McCann et al., 1987; Rutteman et al., 1987; Selman 
et al., 1997), due to the intrinsic glucocorticoid properties of progestins (Guthrie and John, 
1980; Selman et al., 1996; Selman et al., 1997). While basal plasma concentrations of 
adrenocorticotrophic hormone (ACTH) are only moderately affected (Selman et al., 1997), 
the basal plasma concentrations of cortisol are markedly decreased (Concannon et al, 1980; 
McCann et al., 1987; Rutteman et al., 1989; Selman et al., 1997). In addition, the response of 
ACTH and cortisol to stimulation with corticotrophin-releasing hormone (CRH) may be 
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reduced (McCann et al., 1987; Selman et al., 1997). Also, in women the administration of 
MPA causes suppression of the HPA axis (Jones et al., 1974). 
With regard to other anterior pituitary hormones, such as prolactin (PRL) and thyroid-
stimulating hormone (TSH), there is little information about the effect of progestin treatment 
on their release. In the bitch, progestin treatment does not seem to affect mean PRL 
(Concannon et al., 1980) and TSH concentrations (Frank et al., 1979). Information with 
regard to pituitary responsiveness of PRL to supra-pituitary stimulation is limited to one 
study, in which MPA administration did not change PRL response to thyroid-releasing 
hormone (TRH) in ovariohysterectomized, oestradiol-primed bitches (Rutteman et al., 1987). 
On the other hand, there is evidence that treatment with MPA increases the pituitary PRL 
responsiveness to TRH in women (Mishell et al., 1977). Finally, there are no reports on the 
effect of progestins on the pituitary release of α-melanocyte-stimulating hormone (α-MSH). 
The aim of the present study was to obtain an integral picture of the effect of 
progestins on the function of the adenohypophysis in the bitch. For this purpose, the effects of 
supra-pituitary stimulation on the release of seven adenohypophyseal hormones were studied 
before and several times during MPA treatment in Beagle bitches by means of a combined 
anterior pituitary function test (Meij et al., 1996a), 
 
Materials and methods 
Dogs 
Studies were carried out in five healthy intact Beagle bitches, aged 3 to 9 years and 
weighing 9.0 to 10.3 kg, that never had been treated with progestins. They were housed with 
outdoor access, fed a commercial diet once daily, and given water ad libitum. They were 
accustomed to the laboratory environment and procedures such as collection of blood 
samples. Throughout the study the general condition of the dogs was monitored by physical 
examination and routine clinical chemistry.  
 
Study design and blood sample collection  
In the dogs used in this study, the tip of the right uterine horn and the corresponding 
ovary had been excised to serve as control tissues in another study. This surgical procedure 
had been performed 245 ± 42 days (mean ± standard deviation (SD)) before the start of the 
treatment with MPA. After the surgery, all of the dogs had had one complete oestrous cycle. 
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Treatment with the synthetic progestin depot preparation MPA (Depo-Promone®, 
Pharmacia Animal Health, Puurs, Belgium) was begun during anoestrus in a dose of 10 mg/kg 
body weight subcutaneously at intervals of 4 weeks, for a total of 13 injections. Three days 
before the start of the treatment with MPA, the mean plasma progesterone concentration was 
0.9 ± 0.3 nmol/l (mean ± SD).  
Before and at 2, 5, 8, and 11 months after the start of the treatment with MPA, a 
combined anterior pituitary function test was performed using four releasing hormones (4RH 
test) according to methods described previously (Meij et al., 1996a; Meij et al., 1996b). 
Briefly, an intravenous catheter was placed in the cephalic vein of each dog to facilitate rapid 
sequential injection. Immediately after the collection of the zero blood sample from the 
jugular vein, four releasing hormones were injected intravenously within 30 sec, in the 
following order and doses per kg body weight: 1 µg oCRH (Peninsula Laboratories Inc., 
Belmont, CA, USA), 1 µg hGHRH (hGHRF; Peninsula Laboratories Inc., Belmont, CA, 
USA), 10 µg GnRH (Fertagyl®; Intervet, Boxmeer, The Netherlands), and 10 µg TRH 
(Hoffman-La Roche, Basel, Switzerland). During progestin treatment, the 4RH tests were 
always performed immediately before the next 4-weekly administration of MPA. The clock 
for blood sampling was started immediately after the administration of the last releasing 
hormone. Blood samples were collected at -15, 0, 5, 10, 20, 30, and 45 min from the jugular 
vein and transferred to ice-chilled EDTA-coated and heparinized (for TSH) tubes. Samples 
were centrifuged at 4º C for 10 min. Plasma was stored at -25º C until assayed for ACTH, 
cortisol, GH, FSH, LH, PRL, and TSH. Plasma concentrations of α-MSH and insulin-like 
growth factor-I (IGF-I) were determined in the -15 and 0 min samples only.  
 
Hormone determination  
Plasma progesterone concentrations were measured in a previously validated 
radioimmunoassay (RIA) (Henry et al., 1987). The sensitivity of the assay was 0.0005 ng. 
The intra-assay and interassay coefficients of variation were 7.05 % and 8.75 %, respectively. 
Plasma ACTH concentrations were measured by use of a two-site immunoradiometric 
assay (IRMA) (Nichols Institute, Wijchen, The Netherlands). The antiserum is highly specific 
for ACTH1-39. The intra-assay and interassay coefficients of variation were 3.2 % and 7.8 %, 
respectively, and the sensitivity of the assay was 0.22 pmol/l. The antiserum cross-reacts with 
neither α-MSH nor ACTH precursors (Hodgkinson et al., 1984; Findling et al., 1990). 
Plasma cortisol concentrations were measured by a RIA validated for the dog (Coat-A-
Count® Cortisol, Diagnostic Product Corporation, Los Angeles, CA, USA). Intra-assay and 
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interassay coefficients of variation ranged from 3.0 to 5.1 % and from 4.0 to 6.4 %, 
respectively. The sensitivity of the assay was 1 nmol/l. 
Plasma FSH concentrations were measured by a homologous canine IRMA (AHC004, 
Biocode SA, Liège, Belgium). The intra-assay and interassay coefficients of variation for 
values above 1.6 µg/l were 3.2 % and 15 %, respectively. The sensitivity of the assay was 1.5 
µg/l. 
Plasma GH concentrations were measured by a commercially available RIA for 
porcine and canine GH (PGH-46HK; Linco Research, St. Charles MS). The intra-assay 
coefficient of variation was 7.6 % at a plasma concentration of 4.4 µg/l. The sensitivity of the 
assay was 1 µg/l 
Total plasma IGF-I concentrations were measured in a heterologous RIA, validated for 
the dog, after acid-ethanol extraction to remove interfering IGF binding proteins (IGFBPs). 
Plasma IGF was extracted using a mixture of 87.5 % (v/v) ethanol and 12.5 % 2 M formic 
acid. Tubes containing 100 µl plasma and 400 µl of the ethanol-formic acid mixture were 
mixed thoroughly and incubated for 30 min at room temperature. After centrifugation for 30 
min at 5500 g at 4° C, a 50 µl aliquot of the supernatant was diluted 1:50 with assay buffer 
containing 63 mM Na2HPO4 (pH 7·4), 13 mM Na2EDTA, and 0·25 % (w/v) BSA. The 
extraction efficiency was 92.5 ± 5.7 %. Plasma IGF-I concentrations were measured in a 
heterologous RIA validated for the dog (Favier et al., 2001). The intra-assay coefficient of 
variation was 8.6 % at a plasma concentration of 100 µg/l. The sensitivity of the assay was 10 
µg/l. IGF-I antiserum AFP4892898 and human IGF-I for iodination were obtained from the 
National Hormone and Peptide Programme (Harbor-UCLA Medical Center, Torrance CA).  
Plasma LH concentrations were measured in a heterologous RIA described previously 
by Nett et al. (1975), with a few modifications. A rabbit antiserum raised against ovine LH 
(CSU-204, kindly supplied by G D Niswender, Colorado State University, CO, USA), radio-
iodinated bovine LH-7981 as prepared for our bovine LH assay (Dieleman and Bevers, 1987), 
and canine pituitary standard LER 1685-1 (a gift of Dr L E Reichert, Albany Medical 
College, NY, USA) were used in this assay. The intra-assay and interassay coefficients of 
variation for values above 0.5 µg/l were 2.3 % and 10.5 % respectively. The sensitivity of the 
assay was 0.3 µg/l.  
Plasma concentrations of α-MSH were measured by RIA without extraction according 
to methods described previously (Mol et al., 1987). The intra-assay and interassay coefficients 
of variation were less than 8 % and 23 %, respectively. The sensitivity of the assay was 5 
pmol/l.  
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Plasma PRL concentrations were measured by a previously validated heterologous 
RIA (Okkens et al., 1985). The intra-assay and interassay coefficients of variation were 3.5 % 
and 11.5 %, respectively. The sensitivity of the assay was 0.8 µg/l. 
Plasma TSH concentrations were measured in a homologous solid-phase, two-site 
chemoluminescent enzyme immunometric assay (Immulite canine TSH, Diagnostic Products 
Corporation, Los Angeles, CA, USA) according to the manufacturer’s instructions. The intra-
assay coefficients of variation were 5.0 %, 4.0 % and 3.8 % at TSH levels of 0.20, 0.50, and 
2.6 µg/l, respectively. The interassay coefficients of variation were 6.3 % and 8.2 % at TSH 
levels of 0.16 and 2.8 µg/l, respectively. The sensitivity of the assay was 0.03 µg/l. 
 
Statistical analysis  
Differences in body weight before and after the study were assessed in a paired 
Student’s t-test. Plasma α-MSH concentrations below the limit of quantitation were assigned a 
value of 5 pmol/l. The following response variables were considered: basal hormone value, 
maximal increment from basal level, and area under the curve above the basal hormone level 
(AUC). The basal concentration was defined as the mean of the hormone concentrations at -
15 and 0 min. The AUC for hormone concentration following stimulation was calculated by 
the trapezoidal method. Basal hormone concentration, maximal increment, and AUC before 
and after MPA treatment were compared for the different hormone concentrations using a 
mixed model with dog as random effect and period (0, 2, 5, 8, and 11 months after MPA 
treatment) as categorical fixed effects factor. The periods were compared in pairs, applying 
Tukey’s multiple comparisons technique at a global significance level of 5% to obtain 
adjusted P values. 
Additionally, a mixed model was used with dog as random effect and period, time 
(min after stimulation) and the period by time interaction as categorical fixed effects to 
investigate whether the time evolution after stimulation differed from period to period.      
Analyses were performed with SAS version 9.1 for Windows (Insightful Corp., 
Seattle, US). 
 
Ethics of the study 
The study protocol was approved by the Ethical Committee of the Faculty of 
Veterinary Medicine, Ghent University, Belgium.  
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Results 
No signs of oestrus were detected during the 12 months of MPA treatment. In 
addition, plasma progesterone concentrations were low at 5 months (0.6 ± 0.6 nmol/l; mean ± 
SD) and 12 months (0.6 ± 0.3 nmol/l) after the start of the treatment. The mean body weight 
of the dogs on the day of the last MPA injection (12.4 ± 1.6 kg, mean ± SD) was significantly 
higher (P = 0.02) than that on the day of the first injection of MPA (9.5 ± 0.7 kg).  
Basal plasma LH concentrations did not change significantly. In each sampling period, 
supra-pituitary stimulation resulted in a significant rise (P < 0.001) in plasma LH 
concentration. The maximal increment and the AUC for LH did not vary significantly with 
time (Table 1, Figure 1).  
 Basal plasma FSH concentrations were significantly higher at 2 months after the start 
of treatment with MPA than before treatment (P = 0.004) or at 5 (P = 0.004), 8 (P = 0.002), or 
11 months (P < 0.001) after the start of the treatment. In each sampling period, supra-pituitary 
stimulation resulted in a significant rise (P < 0.001) in the plasma FSH concentration. The 
maximal increment was significantly higher before treatment than after 5 (P = 0.01) or 11 
months (P = 0.01) of treatment with MPA, while the difference was not significant (P = 0.07) 
at 8 months. The AUC for FSH was significantly higher before MPA treatment than after 5 (P 
< 0.001), 8 (P = 0.03), or 11 (P = 0.02) months of treatment with MPA (Table 1, Figure 1).  
 
Table 1. Characteristics of LH and FSH secretion in 5 Beagle dogs in a combined anterior pituitary function test 
according to Meij et al. (1996a) before and 2, 5, 8, and 11 months after starting treatment with MPA. The values 
are expressed as mean ± SEM or median and range. Tmax indicates the time at which maximal supra-pituitary 
stimulation was observed. 
 
   Months after treatment with MPA 
 Before MPA  2 5 8 11 
LH basal (µg/l) 3.0 ± 1.2  4.6 ± 1.9 2.9 ± 0.6 3.9 ± 2.1 2.5 ± 1.1 
LH increment (µg/l) 57.4 ± 9.3  58.3 ± 8.9 62.3 ± 10.6 82.9 ± 21.3 82.0 ± 19.3 
LH Tmax (min) 10 (5-20)  10 (10-20) 10 (10-20) 10 (10-20) 10 (10-20) 
LH AUC (µg/lx45min) 1633 ± 262  1801 ± 363 1797 ± 302 2019 ± 558 2024 ± 386 
FSH basal (µg/l) 7.4 ± 0.9  14.2 ± 2.1 a 7.5 ± 1.2 6.9 ± 1.2 5.6 ± 0.9 
FSH increment (µg/l) 27.2 ± 4.3  22.2 ± 3.8 17.6 ± 3.2 b 20.2 ± 4.1 17.5 ± 3.6 b 
FSH Tmax (min) 20 (10-20)  20 (20-30) 20 (20-45) 20 (10-20) 20 (10-20) 
FSH AUC (µg/lx45min) 932 ± 137  756 ± 121 599 ± 116 b 645 ± 135 b 608 ± 118 b 
 
a: significantly different from before treatment and at 5, 8, and 11 months after starting treatment with MPA; b: 
significantly different from before MPA treatment. 
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Figure 1. Plasma LH and FSH responses (mean ± SEM) in 5 dogs in a combined anterior pituitary function test 
according to Meij et al. (1996a) before and 2, 5, 8, and 11 months after starting treatment with MPA. Blood 
samples were collected at -15, 0, 5, 10, 20, 30, and 45 min following the injection of the releasing hormones at 0 
min (arrow).  
 
 
Differences in basal plasma GH concentrations before and during treatment with MPA 
were not significant. At 8 months after the start of treatment with MPA supra-pituitary 
stimulation resulted in a significant rise (P < 0.001) in plasma GH concentration, while no 
significant effect was noted during the other periods. Differences in the maximal increment 
and the AUC for GH before and during the treatment with MPA were not significant (Table 2, 
Figure 2). Basal plasma IGF-I concentrations were significantly higher at 8 months (P = 0.02) 
and 11 months (P < 0.001) of treatment with MPA than before treatment. In addition, basal 
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plasma IGF-I concentratios were significantly higher at 11 months of treatment than at 2 
months (P = 0.02) (Table 2). 
 
 
Table 2. Characteristics of GH and IGF-I secretion in 5 Beagle dogs in a combined anterior pituitary function 
test according to Meij et al. (1996a) before and 2, 5, 8, and 11 months after starting treatment with MPA. The 
values are expressed as mean ± SEM or median and range. Tmax indicates the time at which maximal supra-
pituitary stimulation was observed. 
 
   Months after treatment with MPA 
 Before MPA  2 5 8 11 
GH basal (µg/l) 2.7 ± 0.9  2.3 ± 0.3 2.5 ± 0.3 2.7 ± 0.4 3.0 ± 0.5 
GH increment (µg/l) 1.8 ± 1.5  0.6 ± 0.3 0.9 ± 0.4 1.1 ± 0.2 0.6 ± 0.4 
GH Tmax (min) 5 (-15-45)  20 (10-30) 10 (-15-20) 20 (5-45) 10 (0-20) 
GH AUC (µg/lx45min) 5.1 ± 44.4  13.1 ± 9.5 23.3 ± 17.6 34.5 ± 7.4 12.4 ± 13.7 
IGF-I basal (µg/l) 45 ± 6  108 ± 25 135 ± 35 159 ± 30 a 224 ± 53 a,b 
 
a: significantly different from before MPA treatment; b: significantly different from 2 months after starting 
treatment with MPA. 
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Figure 2. Plasma GH responses (mean ± SEM) in 5 dogs in a combined anterior pituitary function test according 
to Meij et al. (1996a) before and 2, 5, 8, and 11 months after starting treatment with MPA. Blood samples were 
collected at -15, 0, 5, 10, 20, 30, and 45 min following the injection of the releasing hormones at 0 min (arrow).  
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Differences in basal plasma ACTH concentrations before and during treatment with 
MPA were not significant. In each sampling period, supra-pituitary stimulation resulted in a 
significant rise (P < 0.001) in plasma ACTH concentration. Differences in the maximal 
increment before and during the treatment with MPA were not significant. The AUC for 
ACTH after 11 months of MPA treatment was significantly lower (P = 0.05) than at 2 and 8 
months after the start of the MPA treatment (Table 3, Figure 3). Differences in basal plasma 
cortisol concentrations before and during treatment with MPA were not significant. In each 
sampling period, supra-pituitary stimulation resulted in a significant rise (P < 0.001) in 
plasma cortisol concentration. The maximal increments decreased significantly during 
treatment (P = 0.003, P = 0.01, P = 0.002, and P = 0.002, respectively). The AUC for cortisol 
in the four periods of treatment with MPA was significantly lower than that before MPA 
treatment (P = 0.002, P = 0.003, P = 0.002, and P = 0.002, respectively) (Table 3, Figure 3).  
 
 
 
Table 3. Characteristics of ACTH and cortisol secretion in 5 Beagle dogs in a combined anterior pituitary 
function test according to Meij et al. (1996a) before and 2, 5, 8, and 11 months after starting treatment with 
MPA. The values are expressed as mean ± SEM or median and range. Tmax indicates the time at which maximal 
supra-pituitary stimulation was observed. 
 
   Months after treatment with MPA 
 Before MPA  2 5 8 11 
ACTH basal (pmol/l) 4.0 ± 0.9  6.0 ± 0.7 4.0 ± 0.6 5.0 ± 0.4 5.0 ± 0.4 
ACTH increment (pmol/l) 68 ± 14  59 ± 7 47 ± 5 64 ± 8 42 ± 7 
ACTH Tmax (min) 5 (5-10)  10 (5-30) 10 (5-30) 10 (5-10) 10 (5-45) 
ACTH AUC (pmol/lx45min) 1840 ± 286  2005 ± 212 1498 ± 94 2027 ± 180 1276 ± 231 a 
cortisol basal (nmol/l) 48 ± 5  60 ± 11 58 ± 18 53 ± 10 58 ± 14 
cortisol increment (nmol/l) 380 ± 39  238 ± 12 b 258 ± 19 b 231 ± 24 b 226 ± 16 b 
cortisol Tmax (min) 30 (30-45)  30 (30-45) 45 (30-45) 30 (20-45) 30 (20-30) 
cortisol AUC (nmol/lx45min) 12199 ± 1121  7825 ± 331 b 8042 ± 572 b 7785 ± 707 b 7585 ± 433 b 
 
a: significantly different from 2 and 8 months after starting treatment with MPA; b: significantly different from 
before MPA treatment. 
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Figure 3. Plasma ACTH and cortisol responses (mean ± SEM) in 5 dogs in a combined anterior pituitary 
function test according to Meij et al. (1996a) before and 2, 5, 8, and 11 months after starting treatment with 
MPA. Blood samples were collected at -15, 0, 5, 10, 20, 30, and 45 min following the injection of the releasing 
hormones at 0 min (arrow).  
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Differences in basal plasma PRL concentrations before and during treatment with 
MPA were not significant. In each sampling period, supra-pituitary stimulation resulted in a 
significant rise (P < 0.001) in plasma PRL concentration. Differences in the maximal 
increment and the AUC for PRL before and during treatment with MPA were not significant 
(Table 4, Figure 4).  
Basal plasma TSH concentrations at 8 months of MPA treatment were significantly 
higher than before treatment (P = 0.03) and at 5 months of treatment (P = 0.05). In each 
sampling period, supra-pituitary stimulation resulted in a significant rise (P < 0.001) in 
plasma TSH concentration. Differences in the maximal increment and the AUC for TSH 
before and during MPA treatment were not significant (Table 4, Figure 4). 
Basal plasma α-MSH concentrations were 20.7 ± 4.9 pmol/l before treatment and 20.3 
± 5.3, 21.3 ± 5.3, 25.6 ± 8.4, and 32.1 ± 4.4 pmol/l at the four sampling times during MPA 
treatment. Differences in the mean plasma α-MSH concentrations were not significant. 
 
 
Table 4. Characteristics of TSH and PRL secretion in 5 Beagle dogs in a combined anterior pituitary function 
test according to Meij et al. (1996a) before and 2, 5, 8, and 11 months after starting treatment with MPA. The 
values are expressed as mean ± SEM or median and range. Tmax indicates the time at which maximal supra-
pituitary stimulation was observed. 
 
   Months after treatment with MPA 
 Before MPA  2 5 8 11 
TSH basal (µg/l) 0.09 ± 0.03  0.21 ± 0.06 0.14 ± 0.04 0.22 ± 0.08 a 0.17 ± 0.07 
TSH increment (µg/l) 0.76 ± 0.25  1.01 ± 0.21 0.88 ± 0.17 1.13 ± 0.27 0.91 ± 0.25 
TSH Tmax (min) 10 (5-20)  20 (10-30) 30 (10-30) 10 (10-20) 10 (10-30) 
TSH AUC (µg/lx45min) 23.4 ± 6.1  34.1 ± 8.0 30.0 ± 5.6 36.2 ± 7.6 28.7 ± 6.1 
PRL basal (µg/l) 8.5 ± 2.5  9.1 ± 3.2 11.4 ± 6.7 4.7 ± 0.8 8.0 ± 2.5 
PRL increment (µg/l) 53.2 ± 18.0  42.4 ± 14.3 28.5 ± 7.2 66.2 ± 20.1 33.2 ± 6.6 
PRL Tmax (min) 10 (5-20)  10 (5-10) 10 (5-20) 10 (5-10) 10 (5-20) 
PRL AUC (µg/lx45min) 1086 ± 231  1038 ± 272 698 ± 211 1418 ± 260 806 ± 148 
 
a: significantly different from before MPA treatment and at 5 months of MPA treatment. 
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Fig 4. Plasma TSH and PRL responses (mean ± SEM) in 5 dogs in a combined anterior pituitary function test 
according to Meij et al. (1996a) before and 2, 5, 8, and 11 months after starting treatment with MPA. Blood 
samples were collected at -15, 0, 5, 10, 20, 30, and 45 min following the injection of the releasing hormones at 0 
min (arrow).  
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that basal plasma gonadotrophin levels and the response of these hormones to an 
intramuscular injection of a GnRH analogue were unaffected by unilateral ovariectomy. 
Furthermore, the difference in plasma FSH concentration between intact and unilateral 
oophorectomized women was not significant (Cooper and Thorp, 1999). Thus the dogs used 
in this study can be regarded as having an intact hypothalamus-pituitary-ovarian axis. 
The results of this study demonstrate that treatment with MPA affects the 
hypothalamic-pituitary-ovarian axis. Oestrus, ovulation, and a subsequent luteal phase did not 
occur in any of the bitches during treatment with MPA, as judged by the lack of external signs 
of oestrus and low plasma levels of progesterone. The prevention of oestrus by MPA in the 
present study cannot be ascribed to a significant reduction in circulating levels of either FSH 
or LH. On the contrary, during the first months of MPA treatment there was an increase in 
basal plasma FSH without a concomitant change in basal plasma LH. The progestin-induced 
change in FSH concentration was not observed by Colon et al. (1993) and its recognition may 
be explained by the repeated sampling employed in the present study. 
The results of this study thus indicate that the progestin-induced changes in 
gonadotrophin release are confined to FSH secretion. One mechanism for the differential 
control of LH and FSH secretion is gonadal feedback. Both oestradiol and inhibin can 
specifically suppress FSH synthesis and secretion (Mann et al, 1992; Shupnik, 1996). 
Reduced secretion of these ovarian hormones can explain the elevated circulating FSH 
concentration during the first months of MPA treatment. On the other hand, the gonadal 
peptide activin specifically stimulates FSH secretion. Consequently, a temporary progestin-
induced change in the secretion of activin might also explain the initial divergent basal levels 
of LH and FSH. Other important factors in gonadotrophin control are the frequency and 
amplitude of GnRH pulses, which have been shown to differentially alter LH and FSH gene 
expression and secretion (Haisenleder et al., 1991; Shupnik, 1996; Vizcarra et al., 1997).  
The elevated basal plasma FSH level during the first months of MPA treatment may 
thus be due to a direct inhibitory effect of MPA at the ovarian level, resulting in suppression 
of the ovarian secretion of oestradiol or inhibin, or stimulation of activin release. In this 
context, increased plasma gonadotrophin levels and low ovarian oestradiol production have 
been reported in women treated with progestins (Poindexter et al., 1993; Heikinheimo et al., 
1996). Observations in monkeys indicate that the inhibitory effects of progesterone on 
follicular development persist even in the presence of elevated plasma FSH levels, providing 
additional evidence that progestins may have a direct effect at the ovarian level (Goodman et 
al., 1982). In women, there are also indications for a hypothalamic site of progestin action 
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(Couzinet and Schaison, 1993). An initial progestin-induced change in the pattern of 
hypothalamic secretion of GnRH may therefore be an alternative explanation for the rise in 
the basal plasma FSH level during the first months of MPA treatment observed in this study.  
With continuing MPA treatment, basal plasma FSH returned to pretreatment levels 
and the pituitary FSH response to supra-pituitary stimulation decreased. These observations 
may be explained by down-regulation of the pituitary GnRH receptors due to continuous 
GnRH stimulation (Belchetz et al., 1978). The high GnRH secretion associated with MPA 
treatment postulated in the previous paragraph may therefore have resulted in desensitization 
of the response of the gonadotrophs to GnRH. The decline to pretreatment FSH levels and the 
decrease in responsiveness of pituitary FSH secretion to GnRH are probably part of the 
oestrus-preventing effects of MPA, because increased FSH secretion is a critical event in the 
initiation of ovarian folliculogenesis (Kooistra et al., 1999a,b). In other words, MPA 
treatment for oestrus prevention may prohibit the normal rise in plasma FSH concentration 
during late anoestrus. 
The present results confirm previous findings that progestins alter the GH-IGF-I axis 
in the bitch (Eigenmann and Rijnberk, 1981). Basal plasma GH concentration tended to 
increase gradually during the course of the MPA treatment, but the change was not 
significant. In another study (Concannon et al., 1980), plasma GH concentration did not rise 
in 27 out of 36 MPA-treated bitches. However, the significant increase in circulating IGF-I 
concentration during MPA treatment in the present study is consistent with excessive 
exposure to GH (Selman et al., 1994a). Plasma IGF-I concentration may thus be a more 
sensitive indicator than plasma GH concentration for the effect of the progestin treatment on 
the GH-IGF-I axis.  
In contrast to previous observations (Meij et al., 1996a), the GH response to supra-
pituitary stimulation prior to MPA treatment was not significant. This may be due to ageing 
(Bhatti et al., 2002), since the dogs in our study were considerably older than those in the 
study of Meij et al. (1996a). In addition, a relatively high plasma GH level before supra-
pituitary stimulation in one of the dogs, probably explained by sampling during a GH pulse, 
had a substantial influence on basal plasma GH concentration. In agreement with previous 
observations (Selman et al., 1991), there was no pituitary GH response to supra-pituitary 
stimulation during MPA treatment in three of the four tests. This may be ascribed to the 
negative feedback effect of the nonepisodically secreted mammary GH. It has been 
demonstrated in humans that GH exerts its negative feedback effect by stimulating 
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hypothalamic somatostatin secretion (Berelowitz et al., 1981). Additionally, the GH-induced 
elevated circulating IGF-I levels also inhibit pituitary GH secretion (Hartman et al., 1993). 
In addition to interacting with the progesterone receptor, MPA also has a relatively 
high affinity for the glucocorticoid receptor (Selman et al., 1996). Suppression of the HPA 
axis was thus expected during MPA treatment, as was reported in both humans (Willemse et 
al., 1990) and dogs (Selman et al., 1994c; Selman et al., 1996). Indeed, we found the cortisol 
response to stimulation to be decreased with MPA treatment , although ACTH secretion was 
not demonstrably changed, possible because MPA affects the HPA axis for only 2-3 weeks 
(Selman et al, 1994c). Although this leads to adrenocortical atrophy (Selman et al, 1997),  by 
3 weeks (Selman et al., 1994c) or 4 weeks (present study) after administration of MPA, the 
initially suppressed ACTH (and cortisol) concentrations can have returned to normal.  
Treatment with MPA causes significant increases in body weight. The intrinsic 
glucocorticoid properties of MPA (Selman et al., 1996), leading to increased appetite, may 
have contributed to this increase in body weight. However, it is difficult to attribute this effect 
to the glucocorticoid action of MPA alone, since treatment with MPA also affected the GH-
IGF-I axis. 
As the luteal phase in the bitch progresses, circulating progesterone concentration 
decreases and PRL secretion increases (Kooistra and Okkens, 2002). This association has also 
been demonstrated in pregnant and pseudopregnant bitches (Steinetz et al., 1990, Okkens et 
al. 1997). Moreover, administration of a progesterone receptor antagonist to pregnant bitches 
causes plasma PRL levels to rise sharply (Galac et al., 2000). Nevertheless, in agreement with 
previous studies (Concannon et al., 1980; Rutteman et al., 1987), progestin treatment did not 
affect PRL secretion in the present study. This may be explained by persistently high 
progestin status. 
Mean basal plasma TSH concentration was higher at 8 months after the start of MPA 
treatment than it was before treatment and at 5 months after the start of treatment. There were 
no significant alterations in the TSH response to supra-pituitary stimulation. Although basal 
plasma TSH concentrations were elevated at 8 months after the start of the treatment, they 
were still within the reference range for TSH in our laboratory. Others found that MPA 
treatment had no effect on mean circulating TSH levels (Frank et al., 1979), but several 
authors have reported that total T4 and/or T3 values increase during the progesterone-
dominated luteal phase and pregnancy in bitches (Reimers et al., 1984; Dixon, 2004; Feldman 
and Nelson, 2004). It remains to be seen whether these changes have clinical significance, but 
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the results of the present study emphasize the importance of considering progestin use when 
studying the hypothalamic-pituitary-thyroid axis.   
In conclusion, MPA successfully prevented the occurrence of oestrus, ovulation, and a 
subsequent luteal phase. The effects of chronic MPA treatment on adenohypophyseal function 
included increased FSH secretion, unaffected LH secretion, activation of the mammary GH-
induced IGF-I secretion, slightly activated TSH secretion, suppression of the HPA axis, and 
unaffected secretion of PRL and α-MSH 
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Abstract 
Acromegaly or hypersomatotropism in dogs is almost always due to progestin-induced 
hypersecretion of growth hormone (GH) originating from the mammary gland. The aim of 
this study was to investigate whether aglépristone, a progesterone receptor antagonist, can be 
used to treat this form of canine acromegaly. In five Beagle bitches hypersomatotropism was 
induced by administration of medroxyprogesterone acetate (MPA) for over 1 year. 
Subsequently, aglépristone was administered. Blood samples were collected before MPA 
administration, and immediately before, during, and 3.5 and 5.5 weeks after the last 
administration of aglépristone for determination of the plasma concentrations of GH and 
insulin-like growth factor-I (IGF-I). In addition, blood samples for the determination of the 6-
h plasma profile of GH were collected before MPA administration, before aglépristone 
administration and 1 week after the last aglépristone treatment. 
Administration of MPA resulted in a significant increase of the mean plasma IGF-I 
concentration, whereas analysis of the pulsatile plasma profile demonstrated a trend (P = 
0.06) for a higher mean basal plasma GH concentration and a higher mean area under the 
curve above the zero-level (AUC0) for GH. Treatment with aglépristone resulted in a 
significant decrease of the mean plasma GH and IGF-I concentrations. Analysis of the 
pulsatile plasma profile showed a trend (P = 0.06) for a lower mean basal plasma GH 
concentration and a lower mean AUC0 for GH 1 week after the last aglépristone treatment 
compared with these values before aglépristone administration. Three and a half weeks and 
5.5 weeks after the last aglépristone administration the mean plasma IGF-I concentration 
increased again.  
In conclusion, aglépristone can be used successfully to treat dogs with progestin-
induced hypersomatotropism.  
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Introduction 
 Acromegaly is characterized by bony and soft tissue overgrowth due to excessive 
growth hormone (GH) secretion. The syndrome is known to occur in humans, dogs, and cats. 
However, the pathogenesis differs among these species. Acromegaly in humans and cats is 
commonly caused by a somatotroph adenoma of the pituitary gland (Rijnberk et al., 2003) 
whereas in dogs the GH excess usually originates from an extra-pituitary site (Selman et al., 
1994). In dogs, endogenous progesterone secreted during the luteal phase of the oestrous 
cycle or exogenous progestins such as medroxyprogesterone acetate (MPA) used for oestrus 
prevention may promote hypersecretion of GH from foci of hyperplastic ductular epithelium 
of the mammary gland (Eigenmann et al., 1983; Selman et al., 1994; van Garderen et al., 
1997). In contrast to the pulsatile secretion pattern of GH in healthy dogs (Takahashi et al., 
1981; French et al., 1987, Kooistra et al., 2000), the plasma GH profile in bitches with 
progestin-induced acromegaly is not pulsatile (Watson et al., 1987). In addition, progestin-
induced GH hypersecretion cannot be stimulated with GH-releasing hormone (GHRH) and α-
adrenergic agonists, nor can it be inhibited by somatostatin (Watson et al., 1987; Selman et 
al., 1991). The progestin-induced increase in plasma GH concentrations are associated with 
increased plasma concentrations of insulin-like growth factor-I (IGF-I) (Selman et al., 1994). 
The physical changes of progestin-related hypersomatotropism in dogs tend to develop 
gradually and consist of prominent skin folds, abdominal distension, and widening of the 
interdental spaces (Rijnberk, 1996). Due to the insulin-antagonistic action of GH, 
hyperglycaemia and eventually diabetes mellitus may occur (Eigenmann, 1983a). 
Ovariectomy is the treatment of choice in female dogs with spontaneous progesterone-
induced acromegaly. Plasma GH concentrations rapidly return to normal after 
ovariohysterectomy (Eigenmann and Venker-van Haagen, 1981). However, in dogs with 
acromegaly due to progestin administration the detrimental effects of the depot-progestins 
may continue for a long time after cessation of administration (Eigenmann, 1983b, Rijnberk, 
1996). 
Progesterone receptor blockers such as aglépristone (RU 46534) and mifepristone (RU 
38486) are competitive antagonists of the progesterone receptor (Cadepond et al., 1997; Van 
Look and Bygdeman, 1989). Aglépristone is the first progesterone receptor blocker licensed 
for veterinary use and has been used efficiently to terminate pregnancy (Galac et al., 2000; 
Fieni et al., 2001) and to induce parturition (Baan et al., 2005). Furthermore, it is successfully 
used for the treatment of fibroadenomatous mammary hyperplasia in cats (Wehrend et al., 
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2001; Görlinger et al., 2002; Meisl et al., 2003) and may be a useful adjunct in the medical 
treatment of endometritis and pyometra in the dog (Trash et al., 2003). 
The presence of progesterone receptors in mammary gland tissue of dogs (Lantinga-
van Leeuwen et al., 2000) allows for a targeted endocrine therapy with progesterone receptor 
blockers in dogs with progestin-induced hypersomatotropism. The aim of this study was 
therefore to investigate whether the progesterone receptor antagonist aglépristone can be used 
to treat canine acromegaly. 
 
Materials and methods 
Dogs 
Five intact Beagle bitches were housed with outdoor access, fed on a commercial dog 
food once a day, and given water ad libitum. The ages and body weights of the dogs ranged 
from 3 to 9 years (mean 5 years) and 9.0 to 10.3 kg (mean 9.5 kg), respectively. The dogs 
were accustomed to the laboratory environment and procedures such as collection of blood 
samples.  
 
Treatments 
The five Beagle bitches were treated with the synthetic progestin depot preparation 
Depo-Promone® (medroxyprogesterone acetate (MPA), Pharmacia Animal Health, Puurs, 
Belgium). MPA treatment was started during anoestrus and consisted of subcutaneous 
injections in a dosage of 10 mg/kg body weight at 4-week intervals for a total of 14 (3 dogs) 
or 15 (2 dogs) injections.  
Five days (= day 0) and six days (= day 1) after the last MPA injection (= day -5), 
aglépristone (Alizin®, Virbac Animal Health, Barneveld, The Netherlands) was administered 
subcutaneously in a dosage of 10 mg/kg body weight. One (= day 8), two (= day 15), and 
three (= day 22) weeks later a single aglépristone injection was given in the same dose. Three 
randomly chosen dogs received the first aglépristone injection after the 14th MPA injection, 
and the other two dogs after the 15th MPA injection so that these two dogs could serve as 
control dogs for the three dogs that received the aglépristone injection first.  
  
Blood sample collection 
Blood samples for determination of the plasma progesterone concentrations were 
collected 5 and 12 months after the start of the MPA treatment. 
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Blood samples for determination of the plasma concentrations of GH and IGF-I were 
collected before MPA treatment, at days -9, -8, -7, -5, -3, -2, -1, 0 (= immediately before 
aglépristone treatment and after MPA treatment for over 1 year), at days 1, 3, 5, 7, 8, 11, 13, 
15, 18, 20, 22, 25 (= during aglépristone treatment), and at days 46 and 60 (= 3.5 and 5.5 
weeks after the last aglépristone injection). On days of treatment (MPA or aglépristone), 
blood samples were collected prior to the drug administration. 
Blood samples for determination of the pulsatile plasma profiles of GH were collected 
at 15-min intervals between 0800h and 1400h before MPA administration, before aglépristone 
administration, and 1 week after the last administration of aglépristone (at day 28).  
All blood samples were collected by jugular venipuncture after an overnight fast, 
immediately transferred to ice-chilled EDTA-coated tubes and centrifuged at 4o C for 10 min. 
Plasma was stored at -25o C until assayed.  
  
Hormone determination 
Plasma progesterone concentrations were determined with a previously validated 
radioimmunoassay (RIA) (Henry et al., 1987). The intra-assay and interassay coefficients of 
variation were 8.8 % and 7.1 %, respectively. The sensitivity of the assay was 0.005 ng. 
Plasma GH concentrations were measured using a commercially available RIA for 
porcine and canine GH (PGH-46HK; Linco Research, St. Charles MS). The intra-assay 
coefficient of variation was 7.6 % at a plasma concentration of 4.4 µg/l. The sensitivity of the 
assay was 1 µg/l.  
Total plasma IGF-I concentrations were measured after acid-ethanol extraction to 
remove interfering IGF binding proteins. Plasma IGF was extracted using a mixture of 87.5 % 
(v/v) ethanol and 12.5 % 2 M formic acid. Tubes containing 100 µl plasma and 400 µl of the 
ethanol-formic acid mixture were mixed thoroughly and incubated for 30 min at room 
temperature. After centrifugation for 30 min at 5500 g at 4° C, a 50 µl aliquot of the 
supernatant was diluted 1:50 with assay buffer containing 63 mM Na2HPO4 (pH 7.4), 13 mM 
Na2EDTA, and 0.25 % (w/v) BSA. The extraction efficiency amounted to 92.5 ± 5.7 %. 
Plasma IGF-I concentrations were measured in a heterologous RIA validated for the dog 
(Favier et al., 2001). The intra-assay coefficient of variation was 8.6 % at a plasma 
concentration of 100 µg/l. The sensitivity of the assay was 10 µg/l. IGF-I antiserum 
AFP4892898 and human IGF-I for iodination were obtained from the National Hormone and 
Peptide Programme (Harbor-UCLA Medical Center, Torrance CA).  
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Statistical analysis 
To study the effect of MPA administration, the plasma GH and IGF-I concentrations 
before and after MPA treatment were compared using a mixed model with dog as random 
effect and period (2 levels: before and after MPA treatment) as categorical fixed effect. 
In order to assess the overall effect of aglépristone on the plasma GH and IGF-I 
concentrations, a mixed model was fitted with dog as random effect and period (3 levels: 
immediately before aglépristone, during aglépristone, and 3.5 and 5.5 weeks after the last 
aglépristone treatment) as categorical fixed effect. The three periods were compared pairwise 
using Tukey’s multiple comparisons technique.  
To study the evolution of the GH and IGF-I concentrations during the aglépristone 
period, a mixed model was fitted with dog as random effect and time since start of 
aglépristone treatment as continuous fixed effect at a global significance level of 5 %.  
The plasma GH and IGF-I concentrations before MPA treatment were compared with 
the concentrations 3 days after the last aglépristone injection (i.e. at day 25) using a mixed 
model with dog as random effect and period (2 levels: before MPA treatment and 3 days after 
the last aglépristone injection) as categorical fixed effect.  
To evaluate the effect of withdrawal of aglépristone treatment, the two last 
measurements during aglépristone treatment (days 22 and 25) were compared with the two 
measurements after aglépristone treatment (days 46 and 60) using a mixed model with dog as 
random effect and period (2 levels: days 22 and 25 and days 46 and 60) as categorical fixed 
effect. 
The 6-h plasma profiles of GH were analyzed by means of the Pulsar programme 
developed by Merriam and Wachter (1982). The programme identifies secretory peaks by 
height and duration from a smoothed baseline, using the assay standard deviation (SD) as a 
scale factor. The cut-off parameters G1-G5 of the Pulsar programme were set at 3.98, 2.40, 
1.68, 1.24, and 0.93 times the assay SD as criteria for accepting peaks 1, 2, 3, 4, and 5 points 
wide, respectively. The smoothing time, a window used to calculate a running mean value 
omitting peaks, was set at 5h. The splitting cut-off parameter was set at 0.5 and the weight 
assigned to peaks was 0.05. The A-, B-, and C- values of the Pulsar programme, used to 
calculate the variance of the assay, were set at A=0, B=7.2, and C=5. The values extracted 
from the Pulsar analysis included the mean of the smoothed baseline, the pulse frequency, and 
the area under the curve (AUC). The AUC was calculated above the zero-level (AUC0) as 
well as above the baseline (AUCbase). The difference in variables before MPA treatment, 
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before aglépristone administration, and 1 week after the last aglépristone injection (i.e. at day 
28), were analyzed by the signed rank test with dog as block. 
All values are expressed as mean ± SEM or median. Statistical significance was 
defined at P ≤ 0.05. Analyses were performed with SAS version 9.1 for Windows (Insightful 
Corp., Seattle, US). 
 
Ethics of the study 
This study was approved by the Ethics Committee of the Faculty of Veterinary 
Medicine, Ghent University. 
 
Results 
During MPA administration none of the dogs showed signs of oestrus and the mean 
plasma progesterone concentration was low 5 months (0.2 ± 0.2 ng/l) and 12 months (0.2 ± 
0.1 ng/l) after the start of the MPA treatment. The mean body weight of the dogs on the day 
of the last injection of MPA (12.4 ± 0.7 kg) was significantly higher (P < 0.02) than that on 
the day of the first injection of MPA (9.5 ± 0.3 kg) (paired Student’s t-test). Signs of 
acromegaly became apparent in three of the five dogs after 6 months of MPA treatment and 
consisted of prominent skin folds especially on the head, an increase in the interdental spaces, 
inspiratory stridor, and snoring.  
MPA administration for over 1 year resulted in a higher mean plasma GH 
concentration (2.3 ± 0.5 µg/l) compared to that before MPA treatment (1.9 ± 0.3 µg/l), 
although this difference did not reach statistical significance (Figure 1a). However, the mean 
plasma IGF-I concentration after 1 year of MPA administration (146 ± 25 µg/l) was 
significantly (P = 0.003) higher compared to that before MPA treatment (36 ± 6 µg/l) (Figure 
1b).   
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Figure 1. Mean (+ SEM) plasma concentrations of GH (1a) and IGF-I (1b) in 5 Beagle dogs before 
administration of medroxyprogesterone acetate (before MPA) and after 1 year treatment with MPA (after MPA). 
Significant differences between periods are indicated with an asterisk. 
 
Analysis of the pulsatile plasma GH profiles after 1 year of MPA administration 
revealed a trend (P = 0.06) for a higher mean basal plasma GH concentration and a higher 
mean AUC0 for GH compared to these values before MPA treatment (Table 1 and Figure 2).  
 
Table 1. Area under the curve above the baseline (AUCbase) for GH (µg/lx6h), AUC above the zero-level 
(AUC0) for GH (µg/lx6h), basal plasma GH concentration (µg/l), and GH pulse frequency (peaks per 6h) in 5 
Beagle dogs before MPA administration (before MPA), after 1 year of MPA administration (= before 
aglépristone administration) (before A), and 1 week after the last aglépristone administration (after A). 
 
 
 
 
 
 
AUCbase 
 
(mean ± SEM) 
AUC0 
 
(mean ± SEM) 
GH pulse 
frequency 
(median) 
Basal GH 
 
(mean ± SEM) 
Before MPA 1 ± 0.4 11.3 ± 1.1 1 1.7 ± 0.1 
Before A 0 ± 0.0 17.0 ± 3.6 0 2.8 ± 0.6 
After A 0.3 ± 0.2 8.8 ± 0.7 0 1.4 ± 0.1 
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Figure 2. The plasma profiles of GH in a 4-year-old Beagle bitch. Blood samples were collected at 15-min 
intervals between 0800h and 1400h, before MPA administration (□), after 1 year of MPA administration (= 
before aglépristone administration) (dotted line), and 1 week after the last aglépristone treatment (■). Significant 
pulses, calculated by the Pulsar programme, are indicated by an asterisk. 
 
The administration of aglépristone caused no side effects except a short-term skin 
irritation at the site of the injection in one dog. The mean plasma GH concentration 
immediately before aglépristone administration (2.3 ± 0.5 µg/l) was significantly higher than 
that during (1.7 ± 0.3 µg/l; P < 0.0001) and 3.5 and 5.5 weeks after (1.8 ± 0.3 µg/l; P = 0.018) 
the last administration of aglépristone (Figure 3a). Also the mean plasma IGF-I concentration 
immediately before aglépristone administration (146 ± 25 µg/l) was significantly higher than 
that during (108 ± 27 µg/l; P < 0.0001) administration of aglépristone (Figure 3b). In the 
weeks that aglépristone was administered, analysis of the course of the circulating hormone 
concentrations indicated a significant decrease in plasma GH (P = 0.005) and IGF-I (P < 
0.0001) concentrations (Figures 4a and b, respectively). 
The plasma GH and IGF-I concentrations before MPA treatment did not differ 
significantly from these concentrations 3 days after the last aglépristone injection (i.e. day 
25).  
Analysis of the pulsatile plasma GH profiles revealed a trend (P = 0.06) for a lower 
mean basal plasma GH concentration and a lower mean AUC0 for GH 1 week after the last 
aglépristone administration (i.e. day 28) compared with these concentrations before 
aglépristone treatment. The AUCbase for GH increased again 1 week after the last aglépristone 
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injection compared with this concentration before aglépristone administration, although this 
difference did not reveal statistical significance (Table 1 and Figure 2). 
The mean plasma GH concentration at the end of the period of aglépristone 
administration (i.e. days 22 and 25) (1.5 ± 0.1 µg/l) did not differ significantly from that at 3.5 
and 5.5 weeks (i.e. days 46 and 60) after withdrawal of aglépristone (1.8 ± 0.3 µg/l). 
However, the mean plasma IGF-I concentration at the end of the period of aglépristone 
administration (88 ± 22 µg/l) was significantly (P < 0.0001) lower compared with that 3.5 and 
5.5 weeks after withdrawal of aglépristone (124 ± 29 µg/l).  
In the two control dogs that did not receive aglépristone after the 14th MPA injection, 
the mean plasma concentrations of GH and IGF-I before the 14th administration of MPA (1.6 
± 0.1 µg/l and 105 ± 28 µg/l, respectively) were not different from those before the 15th 
administration of MPA (1.7 ± 0.1 µg/l and 116 ± 26 µg/l, respectively). 
 
 
 
 
 
 
 
 
Figure 3. Mean (+ SEM) plasma concentrations of GH (3a) and IGF-I (3b) in 5 Beagle dogs immediately before 
aglépristone (before A), during aglépristone (during A), and 3.5 and 5.5 weeks after the last aglépristone 
administration (after A). Significant differences between periods are indicated with an asterisk. 
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Figure 4. Mean (± SEM) plasma concentrations of GH (4a) and IGF-I (4b) in 5 Beagle dogs at 1 week, 2 weeks, 
3 weeks, and at day 25 during aglépristone administration. 
 
Discussion  
In three of the five Beagle dogs, signs of acromegaly became apparent after 6 months 
of MPA administration. In line with these changes, the mean plasma IGF-I concentrations 
were raised. Moreover, analysis of the pulsatile plasma profile showed a trend for a higher 
mean basal GH concentration and a higher mean AUC0 for GH in the five Beagle dogs. These 
findings are consistent with progestin-induced hypersecretion of GH (Concannon et al., 1980; 
Rijnberk et al., 1980; Eigenmann and Rijnberk, 1981; Eigenmann et al., 1983).  
Previous studies identified foci of hyperplastic ductular epithelium of the mammary 
gland as the site of origin of GH excess induced by progestins (Selman et al., 1994;  van 
Garderen et al., 1997). The expression of the gene encoding GH has been demonstrated in 
canine mammary gland tissue, and sequence analysis has revealed that this gene is identical to 
the pituitary GH gene (Mol et al., 1995; Mol et al., 1996). Immunohistochemical studies have 
demonstrated the intracellular co-localization of both the progesterone receptor and GH in 
progestin-exposed, hyperplastic canine mammary epithelial tissue, whereas immunoreactive 
GH could not be demonstrated in progesterone receptor-negative epithelial cells (Lantinga-
van Leeuwen et al., 2000). These observations are consistent with the central role of 
progestins in GH gene expression in the canine mammary gland and allow for a targeted 
endocrine therapy with progesterone receptor blockers in dogs with progestin-induced 
mammary-derived GH hypersecretion. 
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To the authors’ knowledge, treatment of acromegalic dogs with the progesterone 
receptor antagonist aglépristone (RU 46534) has not been reported before. The results of the 
present study demonstrate that progestin-induced elevations in circulating GH and IGF-I 
concentrations decrease significantly during treatment with aglépristone. At the end of the 
aglépristone treatment period the plasma GH and IGF-I concentrations did not differ 
significantly from those before MPA administration. Our findings are in agreement with those 
of Watson et al. (1987) who found that administration of the antiprogestin mifepristone (RU 
38486) resulted in a decrease of plasma GH concentrations and normalization of plasma IGF-
I concentrations in bitches with progestin-induced acromegaly.  
The mean basal plasma concentrations of GH and IGF-I in the two control dogs that 
did not receive aglépristone after the 14th MPA injection remained high and did not decrease. 
This indicates that indeed aglépristone is responsible for the lowering of the plasma GH and 
IGF-I concentrations in the dogs treated with the progesterone receptor blocker, and that this 
lowering is not due to, for example, a waning effect of MPA on GH and IGF-I secretion. 
The 6-h pulsatile plasma profile of GH represents a more sensitive way of analyzing 
the effects of different treatments on the secretion of GH than the plasma GH concentration 
itself. Analysis of the plasma GH profiles revealed that the mean basal plasma GH 
concentration and AUC0 for GH tended to decrease at the end of the treatment with the 
progesterone receptor blocker compared with these values before aglépristone administration. 
In addition, the AUCbase for GH, i.e., the amount of GH secreted in pulses, increased again 
during aglépristone treatment, although this difference did not reveal statistical significance. 
Thus, treatment with aglépristone resulted in partial restoration of the normal pulsatile GH 
secretion. Higher dosages of aglépristone may result in complete normalization of the 
secretion pattern of GH. 
Plasma IGF-I concentrations are generally regarded as more sensitive indicators of the 
GH status than plasma GH concentrations (Clemmons and Strasburger, 2004). Consequently, 
the significantly higher plasma IGF-I concentrations at days 46 and 60 compared with those at 
days 22 and 25 therefore suggest increased GH exposure, despite the fact that analysis of the 
plasma GH concentrations did not reveal a significant increase. The recurrence of IGF-I 
hypersecretion after withdrawal of aglépristone treatment is not surprising as all dogs received 
injections of a depot progestin preparation for a period of 1 year, and the progestin effect of 
this depot preparation is much longer than the duration of aglépristone treatment in the 
present study. Similarly, in a cat with fibroadenomatous mammary hyperplasia due to 
treatment with a depot progestin preparation hyperplasia recurred 8 days after discontinuation 
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of aglépristone administration (Wehrend et al., 2001). This indicates that treatment with an 
antiprogestin is required as long as the action of the synthetic progestin is present. Also in our 
3 dogs with acromegalic signs, no physical changes were visible during or after treatment 
with aglépristone. 
Due to the insulin-antagonistic action of GH, progestin-induced hypersecretion of GH 
may also result in hyperglycaemia and eventually manifest diabetes mellitus may ensue 
(Eigenmann and Rijnberk, 1981; Eigenmann, 1983a). Disappearance of these catabolic 
abnormalities depends on the functional status of the pancreatic β-cells. If an adequate 
population of functional β-cells is present at the time the progestin effect is blocked, 
hyperinsulinemia, carbohydrate intolerance, and hyperglycaemia may be reversible after 
correction of the hypersomatotropism (Eigenmann, 1983b). If the population of functional β-
cells is severely decreased, permanent diabetes mellitus can be anticipated. Because the 
effects of depot progestins may persist for several months, prevention or reversal of the 
catabolic effects of progestin-induced GH excess is especially important when, in case of 
hyperglycaemia, the depot progestin has been administered only recently. The results of the 
present study illustrate that in these cases aglépristone offers an effective treatment option.  
In conclusion, administration of aglépristone significantly decreases plasma GH and 
IGF-I concentrations in dogs with progestin-induced hypersomatotropism.  
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The pulsatile secretion of growth hormone (GH) is regulated predominantly by the 
opposing actions of the hypothalamic peptides GH-releasing hormone (GHRH) and 
somatostatin (SS), stimulating and inhibiting pituitary GH secretion, respectively 
(Tannenbaum and Ling, 1984). In addition, the pituitary secretion of GH is regulated by the 
negative feedback of both insulin-like growth factor-I (IGF-I) (Voss et al., 2000) and GH 
(Conway et al., 1985; Lanzi and Tannenbaum, 1992). The amplitude and frequency of GH 
secretory pulses are influenced by a variety of factors such as age, nutrition, body 
composition, exercise, and several hormones (Hartman, 2000).  
In 1999, ghrelin, a 28-amino-acid peptide with strong GH-releasing activity was 
discovered. It is predominantly produced by the stomach. The action of this peptide is 
mediated by the activation of the GH secretagogue (GHS) receptor type 1a (Kojima et al., 
1999). Before the discovery of ghrelin, this orphan receptor had been shown to be specific for 
a family of synthetic, peptidyl and nonpeptidyl GHSs such as GH-releasing peptide-6 
(GHRP-6), hexarelin, and MK-0677 (Momany et al., 1981; Momany et al., 1984; Bowers, 
1993). Apart from a potent GH releasing action, ghrelin has other activities including 
stimulation of appetite, control of energy balance, control of gastric motility, and influence on 
glucose metabolism. For a review on pituitary GH secretion and its regulation, and the diverse 
endocrine and nonendocrine effects of synthetic GHSs and ghrelin, the reader is referred to 
Chapter 2 of this thesis. 
Several pathological (e.g. obesity and chronic hypercortisolism) and non-pathological 
(e.g. ageing) states in humans are characterized by a reduction in pituitary GH secretion 
(Casanueva, 1992; Leal-Cerro et al., 1994). With regard to the effects of chronic 
glucocorticoid excess on the plasma GH profile, the results of the study described in Chapter 
3 demonstrate that GH is secreted in a pulsatile fashion in dogs with pituitary-dependent 
hypercortisolism. However, the pulsatile plasma GH profile in these dogs is characterized by 
less GH secreted per pulse, while the basal plasma GH concentration is similar to that of 
healthy control dogs of comparable age.  
Chronic hypercortisolism in humans is not only associated with reduced pituitary GH 
release but also with an impaired GH response to various stimuli (Casanueva, 1992; Leal-
Cerro et al., 1994). Even a combination of GHRH and GHRP-6, which is a very powerful 
GH-releasing stimulus, is unable to induce significant GH release in humans with Cushing’s 
syndrome (Leal-Cerro et al., 1994). Also in dogs with pituitary-dependent 
hyperadrenocorticism (PDH) administration of GHRP-6 results in a blunted GH response 
compared to healthy dogs of similar age (Chapter 4). The GH response after administration 
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of ghrelin to dogs with PDH was also low but not significantly different from that in healthy 
dogs.  
The impaired pulsatile GH secretion in dogs with PDH is not yet fully understood but 
may be ascribed to changes in supra-pituitary stimulation. Enhancement of hypothalamic SS 
release (Wehrenberg et al., 1990; Lima et al., 1993; Wajchenberg et al., 1996; Terzolo et al., 
2000), a decrease in hypothalamic GHRH synthesis and secretion (Miell et al., 1991; Senaris 
et al., 1996; Ohyma et al., 1997), or a combination of both (Leal-Cerro et al., 1998) may be 
involved. In addition to their effect at the hypothalamic level, glucocorticoids may also 
influence GH secretion by acting directly at the pituitary level (Leal-Cerro et al., 1994). As 
mentioned above, chronic glucocorticoid excess results in a decreased response of GH to GH-
releasing stimuli (Peterson and Altszuler, 1981; Wehrenberg et al., 1983; Hotta et al., 1988; 
Burguera et al., 1990; Voltz et al., 1995; Meij et al., 1997; Ohyama et al., 1997; Watson et al., 
2000). It has been postulated that post-GHRH receptor signalling is impaired in somatotrophs 
exposed to high doses of dexamethasone for long periods (Ohyama et al., 1997). The decrease 
in hypothalamic GHRH secretion may also result in a lack of priming of the somatotrophs 
and, subsequently, in reduced GH synthesis and secretion and decreased responsiveness to 
exogenous GHRH (Thakore and Dinan, 1994). Finally, it has been demonstrated that 
administration of glucocorticoids to young rats decreases the number of somatotrophs in the 
pituitary gland (Niimi et al., 1993).  
A cardinal physical feature of PDH in dogs is centripetal obesity with abdominal 
enlargement (Rijnberk, 1996). As not only chronic hypercortisolism but also obesity is 
associated with an impaired GH response to GH-releasing stimuli (Bowers, 1993), it can be 
hypothesized that the suppressed GH release in Cushing’s syndrome is related to obesity as 
well. However, in contrast to the situation of chronic hypercortisolism (Leal-Cerro et al., 
1994), intravenous administration of the combination of GHRH and GHRP-6 results in an 
elevated GH response in obese humans (Bowers, 1993). This indicates that the impaired GH 
response in individuals with Cushing’s syndrome cannot be explained solely by obesity.  
Both basal and stimulated GH secretion as well as circulating IGF-I concentrations 
decline with age in several mammalian species (Finkelstein et al., 1972; Rudman, 1985; Zadik 
et al., 1985; Corpas et al., 1992; Wilshire et al., 1995; Muller et al., 2002; Lee et al., 2004). 
Little is known about how age affects the GH response to GH-releasing stimuli in dogs. The 
results of the study described in Chapter 5 demonstrate the existence of age-related 
differences with regard to the GH-releasing activity of intravenously administered GHSs in 
dogs. In young and old healthy dogs, ghrelin caused a significant rise in plasma GH 
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concentrations when compared with the administration of 0.9 % NaCl. In young dogs, ghrelin 
was a more potent stimulator of GH release than GHRH and GHRP-6. In old dogs, however, 
GHRH administration caused higher elevations in plasma GH concentrations than GHRP-6 or 
ghrelin. These results also illustrate remarkable species-related differences, as studies in rats 
demonstrate that the GH-releasing potency of ghrelin is similar to that of GHRH (Kojima et 
al., 1999), whereas in humans ghrelin is a more potent stimulus of GH secretion than GHRH 
or the synthetic GHS hexarelin (Takaya et al., 2000; Arvat et al., 2001).  
The mean ghrelin-induced plasma GH response was significantly lower in the old 
dogs than in the young dogs. The mean plasma GH concentration after GHRH and GHRP-6 
administration was also lower in the old dogs compared with the young dogs, but this 
difference did not reach statistical significance. These observations are compatible with 
findings in humans, indicating that not only the GH-releasing effect of ghrelin (Broglio et al., 
2003) but also that of GHRH and peptidyl or nonpeptidyl synthetic GHSs undergoes an age-
related decrease (Bowers et al., 1992; Aloi et al., 1994; Chapman et al., 1996; Muccioli et al., 
2002; Broglio et al., 2003). In old rats, the GH response to synthetic GHSs is impaired as well 
(Ceda et al., 1986; Walker et al., 1990). Also in old dogs, the GH responsiveness to the 
synthetic GHS hexarelin has been reported to be low (Cella et al., 1995). In humans, it has 
been demonstrated that the age-related reduction of both spontaneous and stimulated GH 
secretion reflects age-related changes in the neural control of somatotroph function (Giustina 
and Veldhuis; 1998; Ghigo et al., 1999). These changes include a concomitant reduction in 
the secretion of GHRH and enhancement in SS release (Kelijman, 1991; Giustina and 
Veldhuis; 1998; Ghigo et al., 1999; Muller et al., 1999). A recent study of the hypothalamic 
release of GHRH and SS in monkeys has demonstrated that the GHRH pulse frequency and 
amplitude and baseline GHRH levels are much lower in aged animals than in young adult 
animals. In contrast, the amplitude of SS pulses and baseline SS levels are significantly higher 
in aged monkeys than in young adult monkeys (Nakamura et al., 2003). It seems that an 
impairment of pituitary function does not play a major role (Muller et al., 1999). Repeated 
GHRH injections in elderly subjects, combined administration of GHRH and clonidine in old 
dogs, or GHRH + GHRP-6 injection in aged rats (Walker et al., 1991) significantly increases 
circulating GH concentrations (Cella et al., 1993; Nicolas et al., 1994). These observations 
support the idea that the pituitary somatotrophs retain their capacity to synthesize and secrete 
adequate concentrations of GH during ageing (Corpas et al., 1992; Cella et al., 1993; Muller 
et al., 1999; Muccioli et al., 2002). This despite the fact that the number and size of GH-
producing cells in the human pituitary decrease with increasing age (Sun et al., 1984) and that 
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the decreased GH secretion in elderly rats is associated with reduced pituitary GH content 
(Sonntag et al., 1980), reduced pituitary GH mRNA (Takahashi et al, 1990), and low pituitary 
GHRH-receptor mRNA concentration (Kamegai et al., 1999). The diminished GH response to 
GHRH in aged humans, rats, and dogs indicates that pituitary somatotrophs also become less 
sensitive to GHRH in older individuals (Pavlov et al., 1986; Cella et al., 1989; Arce et al., 
1990). 
In the studies on the effects of GHSs on the release of adenohypophyseal hormones 
other than GH, interesting species-related differences were observed (Chapter 5). The action 
of ghrelin and GHRP-6 is GH-specific in old and young dogs, i.e., both stimulants did neither 
stimulate the pituitary-adrenocortical axis nor the release of thyroid-stimulating hormone 
(TSH), luteinizing hormone (LH), and prolactin (PRL). These results are in line with 
observations in anaesthetized rats reported by Kojima et al. (1999), who found that 
intravenous administration of ghrelin specifically stimulated GH release but did not affect 
other adenohypophyseal hormones. However, Thomas et al. (1997) have shown that GHRP-6 
mediates the release of ACTH and cortisol in conscious rats. Studies in healthy humans 
demonstrated that intravenous administration of ghrelin and synthetic GHSs apart from 
stimulating GH release, also increase circulating concentrations of PRL, adrenocorticotrophic 
hormone (ACTH), and cortisol (Arvat et al., 2001; Muccioli et al., 2002; Takaya et al., 2002). 
The diagnosis of GH deficiency should be based upon the results of a stimulation test 
because basal plasma concentrations of GH and IGF-I may overlap between pituitary dwarfs 
and healthy individuals (Gill et al., 1998; Kooistra et al., 2000). In young dogs, ghrelin is a 
more potent stimulator of GH release than GHRH. Therefore ghrelin might be used to 
diagnose GH deficiency. We investigated the effects of intravenous administration of ghrelin 
on the plasma concentration of GH in German shepherd dogs with congenital combined 
pituitary hormone deficiency and in healthy dogs of a similar age (Chapter 6).  
In none of the dwarf dogs ghrelin administration resulted in a rise of the plasma GH 
concentration above 5 µg/l. This finding corresponds with observations in humans with 
isolated childhood-onset GH deficiency, in whom the GH response to ghrelin is also markedly 
reduced (Aimaretti et al., 2002). However, in some of the healthy dogs the plasma GH 
concentration also remained low after ghrelin administration. Thus, while a ghrelin-induced 
plasma GH concentration higher than 5 µg/l seems to exclude GH deficiency, false-negative 
results may occur. 
Through activation of pathways distinct from those needed for GH secretion, ghrelin 
causes weight gain by increasing food intake and reducing fat utilization. In several 
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mammalian species this gastric peptide seems to play a role in meal initiation (Kamegai et al., 
2000; Tschop et al., 2000; Wren et al., 2000; Wren et al., 2001). Chapter 7 is a report on 
investigations on the effects of food intake and fasting in healthy Beagle dogs. Therefore, the 
plasma concentrations of ghrelin, GH, IGF-I, glucose, and insulin were measured when food 
was administered at the usual time, after a 1-day fast, after a 3-day fast, and after re-feeding at 
the usual time the next day. In agreement with observations in rodents (Tschop et al., 2000; 
Asakawa et al., 2001), administration of a meal lowered plasma ghrelin concentrations and 
fasting increased plasma ghrelin concentrations in our dogs. The high plasma ghrelin 
concentrations during fasting fits in with a physiological role for this hormone in increasing 
appetite and initiation of food intake. Similar to the situation in rodents, circulating ghrelin 
concentrations in humans are rapidly suppressed by food intake, and 24-hour plasma ghrelin 
profiles reveal marked preprandial increases and postprandial decreases associated with every 
meal (Cummings et al., 2001).  
In our dogs, the highest plasma ghrelin concentrations were observed immediately 
before the administration of food on the first day. Possibly this preprandial rise occurs as an 
anticipatory response to feeding as the dogs received their food for several years at the same 
time of the day. Sugino et al. (2002) demonstrated in sheep that expectation of food may 
stimulate ghrelin secretion . The transient increase in ghrelin secretion just before feeding is 
most likely elicited by a conditioned emotional response. It is well known that secretion of 
saliva and gastric acid preceding food intake is induced by a conditioned emotional response 
through the stimulation of the vagal nerve (Harding and Leek, 1973). Ghrelin secretion may 
be induced by the vagal system in the same manner as the secretion of saliva and gastric acid. 
Like in humans and rodents, also in our dogs the plasma ghrelin concentrations decreased 
shortly after food intake, but this decline did not reach statistical significance. In a very recent 
study in dogs this post-prandial decrease was found to be statistically significant. (Yokoyama 
et al., 2005). The mechanism by which nutrients suppress ghrelin concentrations are 
beginning to be elucidated; changes in plasma insulin concentrations, intestinal osmolarity, 
and enteric neural signalling probably play a role, whereas gastric distension, vagal nerve 
activity, and glucagon-like peptide-I are not required (Williams et al., 2003; Gelling et al., 
2004).  
In contrast with studies in humans and sheep (Cummings et al., 2001; Sugino et al., 
2002), the results of the present study, did not provide evidence for an association between a 
preprandial rise in plasma ghrelin concentrations and a GH surge in dogs. Similar to the 
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situation in our dogs, a link between plasma ghrelin and plasma GH concentrations has not 
been demonstrated in cows (Miura et al., 2004).  
In our dogs the plasma profiles of ghrelin on the one hand and the profiles of insulin 
and glucose on the other hand were reciprocal after food intake and fasting. These findings 
are in agreement with a study in humans, in which plasma ghrelin concentrations evolved 
oppositely to plasma insulin concentrations (Cummings et al., 2001). This raises the question 
whether insulin negatively regulates ghrelin or vice versa. The former hypothesis has been 
investigated by several groups (Saad et al., 2002; Flanagan et al., 2003; Kamegai et al., 2004). 
Taken together, these studies demonstrated that while insulin can suppress ghrelin release 
when administered in supraphysiologic doses or at high-normal concentrations for prolonged 
periods of time, physiological concentrations of insulin do not appear to regulate ghrelin 
release (Caixas et al., 2002; Schaller, et al., 2003; Soriano-Guillen et al., 2004). It has also 
been suggested that ghrelin may act as a counter-regulatory hormone blocking insulin 
secretion and insulin action to maintain blood glucose concentrations (Broglio et al., 2001; 
Cummings et al., 2005). Indeed, several studies have shown that ghrelin can inhibit glucose-
mediated insulin secretion, both in vitro and in vivo (Egido, et al., 2002; Colombo, et al., 
2003; Reimer, et al., 2003). Similarly, exogenous ghrelin administration decreases circulating 
insulin concentrations in mice (Reimer, et al., 2003) and humans (Broglio et al., 2003). 
The production and release of GH has been demonstrated in a variety of human extra-
pituitary tissues such as the central nervous system (Render et al., 1995) and the immune 
system (Clark, 1997; Van Buul-Offers and Kooijman, 1998). Expression of GH mRNA has 
also been found in bone marrow (Kooijman et al., 1997) and testis (Untergasser et al., 1997). 
In dogs, a pre-eminent example of extra-pituitary GH production is the progestin-
induced synthesis in the mammary gland (Selman et al., 1994a; Mol et al., 1995 a,b; Mol et 
al., 1996; van Garderen et al., 1997). In this species, mammary GH reaches the systemic 
circulation and may give rise to a syndrome of GH excess (Selman et al., 1994b). The 
progestin-induced elevations of plasma GH concentrations do not have a pulsatile pattern 
(Watson et al., 1987). Additionally, the progestin-induced GH overproduction can neither be 
stimulated with GHRH, nor can it be inhibited by SS (Watson et al., 1987; Selman et al., 
1991). Endogenous progesterone and synthetic progestins, such as medroxyprogesterone 
acetate (MPA), primarily induce the expression of GH in areas of hyperplastic mammary 
epithelium, suggesting that locally produced GH promotes epithelial proliferation and 
differentiation in an autocrine and/or paracrine fashion (van Garderen et al., 1997).  
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Locally produced GH may also play a role in tumourigenesis in the mammary gland. 
GH expression has been found in benign and malignant mammary tumours of dogs, and in 
fibroadenomatous hyperplasia of the mammary gland of cats that have been treated with 
progestins (Mol et al., 1995a). In cats mammary GH does not seem to reach the systemic 
circulation. In woman GH is expressed in unaffected mammary tissue and in mammary 
neoplasms (Mol et al., 1995a). The GH genes expressed in mammary tissues of dogs and 
women are identical to the genes encoding GH in the pituitary gland (Mol et al., 1995 a,b). 
For an overview on the effects of progesterone and synthetic progestins in the bitch, the 
reader is referred to Chapter 2 of this thesis. 
In agreement with previous publications (Takahashi et al., 1981; French et al., 1987; 
Kooistra et al., 2000), the results of the study reported in Chapter 8 demonstrate that GH is 
secreted in a pulsatile fashion in the bitch. Administration of MPA during one year resulted in 
higher basal plasma GH and IGF-I concentrations, higher area under the curves (AUCs) 
above the zero-level for GH, and lower AUCs above the baseline for GH (i.e., less GH 
secreted in pulses) in the healthy control dogs compared to dogs with a complete excision of 
the mammary gland. The findings in the control dogs are consistent with partial suppression 
of pituitary GH release by progestin-induced mammary-derived GH secretion and by elevated 
plasma IGF-I concentrations. Before treatment with MPA, in the anoestrous phase of the 
ovarian cycle, the mammary tissue of our dogs was inactive on histological examination. 
After one year of MPA administration, most of the glandular tissue had differentiated into 
lobulo-alveolar structures in which milk synthesis occurred, except in one dog where nodular 
epithelial proliferation resulting in ductal buds was present. These findings are in agreement 
with the the observations of van Garderen et al. (1997). 
In canine mammary tissue immunoreactive GH (iGH) and GH gene expression is 
found predominantly in ductal epithelial buds during the early and midluteal phase of the 
ovarian cycle. The GH gene expression is diminished in differentiated lobulo-alveolar 
glandular tissue, and in the inactive tissue during the anoestrous phase of the canine ovarian 
cycle (van Garderen et al., 1997). Similarly, iGH was not detected in the mammary gland 
tissue of the anoestrous dogs before treatment with MPA. Additionally, iGH was absent in the 
mammary gland tissue of all control bitches treated for one year with MPA, except for one 
dog. In this dog, iGH appeared to be present only in hyperplastic ductular epithelium that 
consisted of more than 2 cell layers, i.e. epithelial cells in budding structures.  
RT-PCR analysis demonstrated that MPA administration increased the GH gene 
expression and decreased the GH receptor (GHR) gene expression in mammary tissue of the 
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control dogs. Increased GH mRNA concentrations in mammary gland tissue of dogs after 
prolonged treatment with progestins have been reported earlier (Mol et al., 1995a). 
Immunohistochemical expression of the GHR may be down regulated in completely 
differentiated alveolar epithelial cells at the end of the luteal phase (van Garderen et al., 
1999). 
In this study it was hypothesized that progesterone-induced mammary GH production 
may have endocrine effects on other tissues such as the uterine epithelium. Cystic endometrial 
hyperplasia (CEH) is frequently seen in bitches treated repeatedly with progestins for 
prevention of oestrus (Capel-Edwards et al., 1973; Sokolowski and Zimbelman, 1973; 
Goyings et al., 1977). Cystic endometrial hyperplasia may also develop spontaneously during 
the luteal phase of the oestrous cycle of middle-aged and elderly bitches (Dow, 1958). 
Because of the similarity of the progestin-induced epithelial changes in both the mammary 
gland and the uterus, it was hypothesized that GH is also involved in the development of 
progestin-induced CEH. Although iGH has been found in uterine epithelial cells of progestin-
treated dogs, the absence of GH mRNA in uterine tissue suggests that it does not originate in 
the uterus (Kooistra et al., 1997). Both the control dogs and the mastectomized dogs 
developed CEH, macroscopically and histologically, with treatment of MPA. After MPA 
administration, iGH was present in uterine epithelial cells of both dog groups, whereas no 
uterine GH immunoreactivity was observed in these groups before MPA administration. 
These findings indicate that progestin-induced mammary GH does not play an essential role 
in the development of CEH in the bitch. Nevertheless, the presence of iGH in the cytoplasm 
of hyperplastic glandular uterine epithelial cells of dogs with CEH suggests that GH may be 
involved in the pathogenesis of CEH.  
RT-PCR analysis revealed that the GH mRNA content was only increased in uterine 
tissue of the mastectomized dogs and not in the control dogs after MPA treatment. 
Comparable with the progestin-induced GH gene expression in canine mammary tissue 
during development of ductal epithelial buds (van Garderen et al., 1997), MPA treatment also 
resulted in more GH gene expression in the uterine epithelial tissue. Probably in the control 
dogs the elevated circulating concentrations of GH of mammary origin and the consequently 
elevated plasma IGF-I concentrations suppressed uterine GH gene expression, as has been 
reported for the pituitary (Hartman et al., 1993). MPA treatment also resulted in increased 
expression of the IGF-I gene in uterine tissue, but this increase was significant only in the 
control dogs. This may be explained by the stimulating effect of the elevated circulating 
concentrations of GH, originating from the mammary gland, on uterine IGF-I gene expression 
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in these dogs. MPA treatment did not promote the expression of GHRs in uterine epithelium. 
This makes it unlikely that increased numbers of GHRs can explain the presence of iGH in 
uterine cells, as proposed earlier (Kooistra et al., 1997).  
In Chapter 9, an integral picture of the effects of progestins on the function of the 
adenohypophysis in the bitch is reported. The effects of supra-pituitary stimulation, using a 
combined anterior pituitary function test (Meij et al., 1996), on the release of seven 
adenohypophyseal hormones was studied in Beagle bitches before and several times during 
one year of MPA treatment. The prevention of oestrus by MPA in our bitches cannot be 
ascribed to a significant reduction in circulating concentrations of neither follicle-stimulating 
hormone (FSH) nor LH. On the contrary, during the first months of MPA treatment basal 
plasma FSH concentrations increased, without a concomitant change in the basal plasma LH 
concentrations. This elevated basal plasma FSH concentration may be due to a direct 
inhibitory effect of MPA at the ovarian level, resulting in suppression of the ovarian secretion 
of oestradiol and/or inhibin or stimulation of activin release (Couzinet and Schaison, 1993; 
Poindexter et al., 1993; Heikinheimo et al., 1996; Shupnik, 1996). With progression of the 
MPA treatment, basal plasma FSH concentrations declined to pre-treatment concentrations, 
while the pituitary FSH response to supra-pituitary stimulation decreased. These observations 
may be explained by down-regulation of the pituitary GnRH receptors due to continuous 
GnRH stimulation (Belchetz et al., 1978). 
The results of the study in Chapter 9 confirmed previous findings that progestins alter 
the GH-IGF-I axis in the bitch (Eigenmann et al., 1983; Selman et al., 1994b). Basal plasma 
GH concentrations tended to increase gradually during the course of the MPA treatment, 
although this rise was not statistically significant. This is in agreement with results of an 
earlier study, in which in 27 out of 36 MPA treated bitches plasma GH concentrations did not 
rise significantly (Concannon et al., 1980). However, the significant increase in circulating 
IGF-I concentrations during MPA treatment in our study indicates indirectly excessive 
exposure to GH (Selman et al., 1994b). Plasma IGF-I concentrations may thus be a more 
sensitive indicator than plasma GH concentrations for the effect of progestin treatment on the 
GH-IGF-I axis.  
Besides an interaction with the progesterone receptor, MPA also has a relatively high 
affinity for the glucocorticoid receptor (Selman et al., 1996). Consequently, suppression of the 
hypothalamic-pituitary-adrenocortical (HPA) axis was expected during MPA treatment, as 
has been reported before in both humans (Willemse et al., 1990) and dogs (Selman et al., 
1994c, Selman et al., 1996). However, the results of the study reported in Chapter 9 indicate 
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that the effects on ACTH secretion characteristics were limited. Because the supra-pituitary 
stimulation test was carried out four weeks after the injection of MPA, ACTH release most 
likely had returned to pre-treatment values within this timeframe. The suppression of the 
adrenocortical component of the HPA axis was more pronounced and comparable to previous 
observations (Selman et al., 1996). Apparently the suppression of the ACTH secretion was 
severe enough to cause atrophy of the adrenocortical zona fasciculata. 
The basal plasma TSH concentrations were elevated at 8 months after the start of the 
MPA treatment, although they were still within the reference range for TSH in our laboratory. 
Our results conflict with those of others, who found no effect of MPA treatment on mean 
circulating TSH concentrations (Frank et al., 1979). One may speculate that MPA had a direct 
effect on the thyroid gland as a result of its inherent glucocorticoid properties, leading to a 
(slight) rise of the plasma TSH concentrations (Kemppainen et al., 1983). 
No changes in PRL or α-melanocyte-stimulating hormone secretion were observed. 
The absence of an effect of MPA treatment on plasma PRL concentrations is in agreement 
with previous studies (Concannon et al., 1980; Rutteman et al., 1987) and may be explained 
by the absence of a clearcut decrease in progestational activity, that is known to be a trigger of 
PRL release (Galac et al., 2000). 
The presence of progesterone receptors in mammary gland tissue allows for a targeted 
endocrine therapy with progesterone receptor blockers in dogs with progestin-induced 
mammary-derived GH excess. The results of the study reported in Chapter 10 indicate that 
administration of the progesterone receptor blocker aglépristone (RU 46534) results in a 
significant decrease of plasma GH and IGF-I concentrations in dogs with progestin-induced 
hypersomatotropism. Our findings are in agreement with those of Watson et al. (1987) who 
found that administration of the antiprogestin mifepristone (RU 38486) decreases plasma GH 
concentrations and normalizes plasma IGF-I concentrations in bitches with progestin-induced 
acromegaly.  
Analysis of the plasma GH profiles revealed that the mean basal plasma GH 
concentration and AUC above the zero-level for GH tended to decrease at the end of the 
treatment period with the progesterone receptor blocker compared with these values before 
aglépristone administration. In addition, the AUC above the baseline for GH, i.e., the amount 
of GH secreted in pulses, increased again during aglépristone treatment, although this 
difference did not reach statistical significance. Thus, treatment with aglépristone resulted in 
partial restoration of the normal pulsatile GH secretion. Higher dosages of aglépristone may 
result in complete normalization of the secretion pattern of GH. 
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Three and a half and 5.5 weeks after the last administration of aglépristone the plasma 
IGF-I concentrations had increased again, suggesting recurring high GH exposure. The 
recurrence of IGF-I hypersecretion after withdrawal of aglépristone treatment is not surprising 
as all dogs received injections of a depot progestin preparation for a period of one year, and 
the progestin effect of this depot preparation is much longer than the duration of aglépristone 
treatment in the present study. This indicates that treatment with an antiprogestin is required 
as long as the action of the synthetic progestin is present.  
 
The following conclusions can be drawn for dogs: 
• Pituitary-dependent hyperadrenocorticism is not only associated with less GH secreted 
per pulse but also with an impaired response to synthetic GHSs. 
• In young dogs, ghrelin is a more potent stimulator of GH release than GHRH or 
GHRP-6. In old dogs, GHRH administration causes higher elevations of plasma GH 
concentrations than ghrelin or GHRP-6 administration. 
• The GH-releasing capacity of ghrelin decreases with age whereas this decline is 
considerably lower for stimulation with GHRP-6 or GHRH.  
• Ghrelin and GHRP-6 are specific releasers of GH. They do not stimulate the pituitary-
adrenocortical axis nor the release of TSH, LH, or PRL.  
• A ghrelin-stimulation test may be used in the diagnosis of canine pituitary dwarfism.  
• Fasting and food intake lead to higher and lower circulating ghrelin concentrations, 
respectively. 
• During food intake and fasting, the changes in plasma ghrelin concentrations are not 
associated with similar changes in plasma GH concentrations. 
• During food intake and fasting, circulating insulin and glucose concentrations change 
reciprocally with the ghrelin concentrations. 
• In healthy dogs, treatment with medroxyprogesterone acetate (MPA) results in a 
higher basal plasma GH secretion and less GH secreted in pulses compared to dogs 
with surgically excised mammary gland tissue. In mastectomized dogs however, MPA 
treatment does not change basal plasma GH concentrations, the AUC above the zero-
level for GH, the AUC above the baseline for GH, and the GH pulse frequency. 
• In both healthy dogs and mastectomized dogs, cystic endometrial hyperplasia (CEH) 
develops after one year treatment with MPA. Thus, progestin-induced mammary-
derived GH is not a requirement for the development of CEH. 
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• The presence of immunoreactive GH in the cytoplasm of hyperplastic glandular 
uterine epithelial cells of dogs with CEH suggests that GH may play a role in the 
pathogenesis of CEH. 
• The effect of MPA on gonadotrophin secretion is confined to FSH secretion. MPA 
treatment increases basal plasma FSH concentration during the first months of 
treatment, while the pituitary FSH response to supra-pituitary stimulation decreases 
during MPA administration.  
• The progesterone receptor blocker aglépristone allows for treatment of progestin-
induced hypersomatotropism. 
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De pulsatiele vrijstelling van groeihormoon (GH) door de voorkwab van de hypofyse 
wordt vooral gestuurd door de wisselwerking van de hypothalame hormonen GH-releasing 
hormoon (GHRH) en somatostatine (SS). Het GHRH stimuleert en SS remt de afgifte van GH 
(Tannenbaum en Ling, 1984). Daarnaast wordt de hypofysaire GH-secretie beïnvloed door de 
negatieve terugkoppeling van de insuline-achtige groeifactor-I (IGF-I) (Voss et al., 2000) en 
van circulerend GH (Conway et al., 1985; Lanzi en Tannenbaum, 1992). De amplitude en de 
frequentie van GH pulsen zijn afhankelijk van veel factoren, waaronder leeftijd, voeding, 
lichaamssamenstelling, lichamelijke activiteit, en verscheidene andere hormonen (Hartman, 
2000). 
In 1999 werd ghreline ontdekt, een peptide dat vooral in de maag wordt geproduceerd. 
Het bestaat uit 28 aminozuren en bevordert de afgifte van GH via de GH-secretagoog receptor 
type 1a (Kojima et al., 1999). Eerder was al vastgesteld dat deze receptor specifiek de 
werking medieert van een groep synthetische GH-afgifte bevorderende peptiden en niet-
peptiden, zoals GH-releasing peptide-6, hexareline, en MK-0677 (Momany et al., 1981; 
Momany et al., 1984; Bowers, 1993). Ghreline heeft naast de sterke GH-vrijstellende werking 
ook andere eigenschappen zoals bevordering van de eetlust, controle van de energiebalans, 
controle van de maagmotiliteit, en beïnvloeding van het glucosemetabolisme. Voor een 
overzicht van de regulatie van de secretie van het hypofysaire GH, en van de verscheidene 
endocriene en niet-endocriene functies van synthetische GH-secretagogen en ghreline wordt 
de lezer verwezen naar hoofdstuk 2 van dit proefschrift. 
Verscheidene pathologische (bv. vetzucht en hypercortisolisme) en niet-pathologische 
(bv. veroudering) veranderingen bij de mens gaan gepaard met een verminderde hypofysaire 
GH vrijstelling (Casanueva, 1992; Leal-Cerro et al., 1994). In hoofdstuk 3 worden de 
effecten van chronische glucocorticoïd-overmaat op het plasma GH-profiel beschreven bij de 
hond. Alhoewel ook bij honden met hypofyse-afhankelijk hyperadrenocorticisme (HAH) GH 
in pulsen werd afgegeven, was er sprake van een afname van de afgifte van GH per puls. De 
basale plasma GH-concentratie veranderde niet.  
Chronische overproductie van cortisol gaat bij de mens niet alleen gepaard met een 
afname van de hypofysaire GH-secretie maar ook met een verminderde GH-respons op 
diverse stimuli (Casanueva, 1992; Leal-Cerro et al., 1994). Zelfs de gecombineerde 
toediening van GHRH en GHRP-6, dat een sterke stimulus is voor GH-secretie, veroorzaakt 
geen significante stijging van de plasma GH-concentratie bij mensen met het syndroom van 
Cushing (Leal-Cerro et al., 1994). De resultaten van het onderzoek beschreven in hoofdstuk 4 
laten ook zien dat, vergeleken met gezonde honden van vergelijkbare leeftijd, toediening van 
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GHRP-6 leidt tot een verminderde GH-respons bij honden met HAH. De ghreline-
geïnduceerde GH-vrijstelling bij honden met HAH was ook laag maar niet significant 
verschillend van de GH-vrijstelling bij gezonde honden. 
De afgenomen pulsatiele secretie van GH bij honden met HAH zou een gevolg kunnen 
zijn van veranderingen in de aansturing van de hypofyse. Een toename van de hypothalame 
afgifte van SS (Wehrenberg et al., 1990; Lima et al., 1993; Wajchenberg et al., 1996; Terzolo 
et al., 2000), een afname van de hypothalame aanmaak en afgifte van GHRH (Miell et al., 
1991; Senaris et al., 1996; Ohyma et al., 1997), of een combinatie van beide (Leal-Cerro et 
al., 1998) zouden de verminderde pulsatiele hypofysaire GH-afgifte kunnen verklaren. Naast 
hun effect op de hypothalamus, zouden glucocorticoïden ook een rechtstreekse invloed op de 
groeihormoonproducerende cellen van de hypofyse kunnen uitoefenen (Leal-Cerro et al., 
1994). Zoals reeds eerder vermeld, leidt chronische cortisol-overmaat tot verminderde 
responsiviteit van GH op stimulantia zoals GHRH (Peterson en Altszuler, 1981; Wehrenberg 
et al., 1983; Hotta et al., 1988; Burguera et al., 1990; Voltz et al., 1995; Meij et al., 1997; 
Ohyama et al., 1997; Watson et al., 2000). Daarnaast is ook gepostuleerd dat het ‘post-
receptor’-systeem van de GHRH-receptor minder goed functioneert indien de 
groeihormoonproducerende cellen gedurende lange tijd worden blootgesteld aan hoge doses 
dexamethason (Ohyama et al., 1997). De hierboven beschreven afname van de hypothalame 
afgifte van GHRH zou kunnen leiden tot minder gevoelige groeihormoonproducerende cellen, 
en daarmee tot een afname van de aanmaak en secretie van GH, alsook een afgenomen 
responsiviteit op toegediend GHRH (Thakore en Dinan, 1994). Tenslotte, bij jonge ratten is 
aangetoond dat toediening van glucocorticoïden het aantal groeihormoonproducerende cellen 
in de hypofyse vermindert (Niimi et al., 1993). 
Typische lichamelijke kenmerken van HAH bij de hond zijn vetzucht en een 
toegenomen buikomvang (Rijnberk, 1996). Aangezien niet alleen chronisch hypercortisolisme 
maar ook vetzucht gepaard gaat met een verminderde GH-respons op GH-stimulantia 
(Bowers, 1993) kan de gedachte opkomen dat de onderdrukte GH-vrijstelling bij het 
syndroom van Cushing ook veroorzaakt wordt door vetzucht. In tegenstelling tot de situatie 
bij chronisch hypercortisolisme (Leal-Cerro et al., 1994), leidt intraveneuze toediening van 
GHRH en GHRP-6 bij zwaarlijvige personen echter wel tot een toegenomen GH-respons 
(Bowers, 1993). Dit impliceert dat de verminderde GH-respons bij het syndroom van Cushing 
niet alleen kan worden verklaard door vetzucht. 
Bij een groot aantal zoogdieren nemen de basale en gestimuleerde GH-vrijstelling, 
alsook de circulerende IGF-I-concentraties af met de leeftijd (Finkelstein et al., 1972; 
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Rudman, 1985; Zadik et al., 1985; Corpas et al., 1992; Wilshire et al., 1995; Muller et al., 
2002; Lee et al., 2004). Gegevens over leeftijdsgebonden verschillen in de gestimuleerde GH-
vrijstelling bij de hond zijn echter nauwelijks voorhanden. De resultaten van het onderzoek 
beschreven in hoofdstuk 5 laten zien dat er ook bij honden leeftijdsgebonden verschillen zijn 
met betrekking tot de GH-respons op intraveneus toegediende GH-secretagogen. Bij zowel 
jonge als oude honden veroorzaakt toediening van ghreline, in vergelijking met 0.9 % NaCl, 
een significante toename in de plasma GH-concentraties. Bij jonge honden is ghreline een 
sterkere stimulus voor GH-secretie dan GHRH en GHRP-6. Bij oude honden echter, is 
GHRH-toediening een sterkere stimulus voor GH-vrijstelling dan de toediening van ghreline 
of GHRP-6. Er zijn ook interessante diersoortgebonden verschillen. Bij de rat is de vrijstelling 
van ghreline-geïnduceerd GH vergelijkbaar met die na GHRH-toediening (Kojima et al., 
1999), terwijl bij de mens toediening van ghreline leidt tot hogere GH-concentraties dan 
toediening van GHRH of hexareline (Takaya et al., 2000; Arvat et al., 2001). 
De gemiddelde ghreline-geïnduceerde plasma GH-respons was significant lager bij 
oude honden dan bij jonge honden. Deze plasma GH-respons was ook lager bij de oude 
honden dan bij de jonge honden na GHRH en GHRP-6 toediening, maar dit verschil was niet 
significant. Deze observaties zijn vergelijkbaar met die bij de mens waar niet alleen het GH-
vrijstellend effect van ghreline (Broglio et al., 2003), maar ook dat van GHRH en van 
synthetische GH-secretagogen een leeftijdsgebonden afname vertoont (Bowers et al., 1992; 
Aloi et al., 1994; Chapman et al., 1996; Muccioli et al., 2002; Broglio et al., 2003). Ook bij 
oude ratten (Ceda et al., 1986; Walker et al., 1990) en oude honden (Cella et al., 1995) is de 
GH-respons op synthetische GH-secretagogen afgenomen. De leeftijdsgebonden afname van 
zowel basaal als gestimuleerd GH wordt bij de mens toegeschreven aan veranderingen in de 
neurale controle van de groeihormoonproducerende cellen in de hypofysevoorkwab (Giustina 
en Veldhuis; 1998; Ghigo et al., 1999). Deze veranderingen kunnen het gevolg zijn van 
wijzigingen in de hypothalame aansturing van de hypofyse, waarbij vooral gedacht moet 
worden aan het gelijktijdig optreden van verminderde GHRH-secretie en toegenomen SS-
afgifte (Kelijman, 1991; Giustina en Veldhuis; 1998; Ghigo et al., 1999; Muller et al., 1999). 
Bevindingen van een recente studie over de hypothalame afgifte van GHRH en SS bij apen 
laten zien dat de frequentie en de amplitude van de GHRH-pulsen en de basale GHRH-
concentratie bij oude apen veel lager zijn dan bij jongvolwassen apen. Daarentegen zijn de 
amplitude van de SS-pulsen en de basale SS-concentratie significant hoger bij oude apen dan 
bij jongvolwassen apen (Nakamura et al., 2003). Veranderingen op het niveau van de 
groeihormoonproducerende cellen spelen waarschijnlijk geen essentiële rol (Muller et al., 
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1999). Inderdaad, herhaalde GHRH-injecties bij oude mensen, gecombineerde toediening van 
GHRH en clonidine bij oude honden, of GHRH + GHRP-6 injectie bij oude ratten (Walker et 
al., 1991) veroorzaken een significante toename van circulerend GH (Cella et al., 1993; 
Nicolas et al., 1994). Deze bevindingen tonen aan dat de groeihormoonproducerende cellen 
van de hypofysevoorkwab in staat blijven om voldoende GH te synthetiseren en vrij te stellen 
tijdens veroudering (Corpas et al., 1992; Cella et al., 1993; Muller et al., 1999; Muccioli et al., 
2002), ondanks het feit dat het aantal en de grootte van de groeihormoonproducerende cellen 
afneemt met voortschrijdende leeftijd (Sun et al., 1984) en dat de afgenomen GH-afgifte bij 
oude ratten gepaard gaat met een afname van de hoeveelheid hypofysair GH (Sonntag et al., 
1980), een afname van mRNA coderend voor GH (Takahashi et al, 1990) en een lage 
concentratie mRNA coderend voor de GHRH-receptor in de hypofyse (Kamegai et al., 1999). 
De verminderde GH-respons op GHRH-toediening bij oude mensen, ratten en honden geeft 
aan dat de groeihormoonproducerende cellen in de hypofyse minder gevoelig zijn voor 
GHRH (Pavlov et al., 1986; Cella et al., 1989; Arce et al., 1990). 
De resultaten van het onderzoek beschreven in hoofdstuk 5 tonen aan dat ghreline en 
GHRP-6 GH-specifiek zijn bij jonge en oude honden, dit wil zeggen dat beide stimulantia 
noch de hypofyse-bijnierschors-as, noch de vrijstelling van thyroïd-stimulerend hormoon 
(TSH), luteïniserend hormoon (LH) of prolactine (PRL) beïnvloeden. Deze bevindingen zijn 
vergelijkbaar met die in studies bij ratten onder narcose waarbij intraveneuze toediening van 
ghreline enkel GH-vrijstelling stimuleerde zonder verandering in de plasmaconcentraties van 
de andere hypofysevoorkwabhormonen (Kojima et al., 1999). Toediening van GHRP-6 
induceert echter bij ratten bij bewustzijn vrijstelling van adrenocorticotroop hormoon (ACTH) 
en cortisol (Thomas et al.,1997). Bij de mens is aangetoond dat intraveneuze toediening van 
ghreline en synthetische GH-secretagogen, niet alleen de GH-afgifte bevordert, maar ook leidt 
tot verhoogde circulerende concentraties van PRL, ACTH, en cortisol (Arvat et al., 2001; 
Muccioli et al., 2002; Takaya et al., 2002). 
De diagnose GH-deficiëntie dient gebaseerd te zijn op resultaten van een 
stimulatietest, daar basale plasma GH- en IGF-I-concentraties kunnen overlappen bij 
hypofysaire dwergen en gezonde individuen (Gill et al., 1998; Kooistra et al., 2000). 
Aangezien toediening van ghreline bij jonge honden een sterkere stimulus voor GH-secretie 
bleek te zijn dan GHRH, zou dit peptide mogelijk ook gebruikt kunnen worden om GH- 
deficiëntie vast te stellen. In hoofdstuk 6 worden de effecten van intraveneuze toediening van 
ghreline op de plasma GH-concentratie beschreven bij Duitse herders met een aangeboren 
tekort van meerdere hypofysevoorkwabhormonen en bij gezonde honden van vergelijkbare 
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leeftijd. Ghreline-toediening leidde bij geen enkele hypofysaire dwerg tot een toename van de 
plasma GH-concentratie boven de 5 µg/l. Dit is in overeenstemming met waarnemingen bij de 
mens waar geïsoleerde GH-deficiëntie bij kinderen ook gekenmerkt wordt door een sterk 
verminderde GH-respons op ghreline (Aimaretti et al., 2002). Echter, bij enkele gezonde 
honden bleef de plasma GH-concentratie ook laag na toediening van ghreline. Dus, terwijl 
een ghreline-geïnduceerde plasma GH-waarde hoger dan 5 µg/l GH deficiëntie blijkt uit te 
sluiten kunnen fout-negatieve resultaten voorkomen.  
Ghreline veroorzaakt, via andere wegen dan die betrokken bij GH-secretie, ook 
gewichtstoename door stimulatie van de eetlust en vermindering van vetafbraak. Bij 
verscheidene zoogdieren blijkt dit peptide ook een rol te spelen bij de initiatie van 
voedselopname (Kamegai et al., 2000; Tschop et al., 2000; Wren et al., 2000; Wren et al., 
2001). In hoofdstuk 7 is het onderzoek bij gezonde honden beschreven naar de effecten van 
voedselopname en vasten. Hiertoe werden de plasmaconcentraties van ghreline, GH, IGF-I, 
glucose en insuline bepaald na voedselopname op het gebruikelijke voedertijdstip, na 1 dag 
vasten, na 3 dagen vasten, en na hervatting van de voedselverstrekking op het gebruikelijke 
voedertijdstip de volgende dag. Onze bevindingen waren vergelijkbaar met 
onderzoeksresultaten bij knaagdieren (Tschop et al., 2000; Asakawa et al., 2001) en mensen 
(Cummings et al., 2001). Toediening van een maaltijd resulteerde in lagere plasma 
ghrelineconcentraties en vasten leidde tot hogere plasma ghrelineconcentraties. De hogere 
plasma ghrelineconcentratie tijdens vasten zou de fysiologische rol van dit peptide bij de 
toename van eetlust en initiatie van voedselopname kunnen weerspiegelen. De hoogste 
plasma ghrelinewaarden werden bij onze honden waargenomen net voor de toediening van 
voedsel op de eerste dag. Het is mogelijk dat deze preprandiale toename van de plasma 
ghrelineconcentratie een anticiperende respons is op voedselopname, aangezien de honden 
gedurende jaren het voeder kregen toegediend op hetzelfde moment van de dag. Sugino et al. 
(2002) toonden aan dat emotionele factoren, en vooral de verwachting dat voedsel zal worden 
verstrekt, bij schapen ghrelinesecretie stimuleert. Deze tijdelijke toename van de 
ghrelinesecretie zou het gevolg kunnen zijn van een geconditioneerde emotionele respons. 
Het is bekend dat secretie van speeksel en maagzuur vlak voor voederopname op gang komt 
doordat een dergelijke geconditioneerde emotionele respons leidt tot stimulatie van de nervus 
vagus (Harding en Leek, 1973).  
Overeenkomstig de bevindingen bij knaagdieren en mensen, namen bij onze honden 
de plasma ghrelineconcentraties ook af vlak na inname van voedsel, maar deze afname was 
niet significant. Zeer recent hebben Yokoyama et al. (2005) bij honden een significante daling 
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van de circulerende ghrelineconcentraties vlak na voederopname gerapporteerd. Het 
mechanisme dat hiervoor verantwoordelijk is begint stilaan duidelijk te worden: 
veranderingen in de plasma insulineconcentratie, intestinale osmolariteit, en intestinale 
neurale signalen lijken een rol te spelen, terwijl uitzetting van de maag, vagale activiteit en 
glucagon-achtig peptide geen rol lijken te spelen (Williams et al., 2003; Gelling et al., 2004). 
In overeenstemming met de resultaten van een onderzoek bij koeien (Miura et al., 
2004) werd bij onze honden geen GH-stijging gezien parallel aan de preprandiale toename 
van de plasma ghrelineconcentratie. Dit is in tegenstelling met bevindingen bij de mens en bij 
schapen (Cummings et al., 2001; Sugino et al., 2002), waarbij de anticipatie van 
voedselverstrekking wel leidt tot een stijging van de plasma ghrelineconcentratie.  
Evenals bij de mens (Cummings et al., 2001), waren de veranderingen in het 
plasmaprofiel van ghreline tijdens voedselopname en vasten tegengesteld aan de 
veranderingen in het circulerend profiel van glucose en insuline. De vraag is dan of insuline 
de vrijstelling van ghreline negatief beïnvloedt of omgekeerd. De eerste hypothese werd 
onderzocht door verscheidene onderzoeksgroepen (Saad et al., 2002; Flanagan et al., 2003; 
Kamegai et al., 2004). Deze onderzoeken toonden aan dat insuline de plasmaconcentraties van 
ghreline kan onderdrukken als het wordt toegediend in supra-fysiologische doses of hoog-
normale doses worden gegeven gedurende een lange periode. Fysiologische 
insulineconcentraties blijken de vrijstelling van ghreline niet te reguleren (Caixas et al., 2002; 
Schaller, et al., 2003; Soriano-Guillen et al., 2004). Er is ook gesuggereerd dat ghreline de 
secretie en de werking van insuline zou kunnen blokkeren om zo het bloedglucosegehalte te 
handhaven (Broglio et al., 2001; Cummings et al., 2005). Verscheidene studies hebben 
aangetoond dat ghreline de glucose-gemedieerde insulinesecretie kan remmen, zowel in vivo 
als in vitro (Egido, et al., 2002; Colombo, et al., 2003; Reimer, et al., 2003). Ook exogeen 
toegediend ghreline verlaagt circulerende insulineconcentraties bij muizen (Reimer, et al., 
2003) en mensen (Broglio et al., 2003). 
De aanmaak en vrijstelling van GH is aangetoond in diverse humane extra-hypofysaire 
weefsels zoals het centrale zenuwstelsel (Render et al., 1995) en het immuunsysteem (Clark, 
1997; Van Buul-Offers en Kooijman, 1998). Expressie van mRNA coderend voor GH is ook 
gevonden in het beenmerg (Kooijman et al., 1997) en de testis (Untergasser et al., 1997). 
Een prachtig voorbeeld van extra-hypofysaire GH-synthese bij de hond is de 
progesteron-geïnduceerde aanmaak in melkklierweefsel. De productie van GH in de melkklier 
kan worden geïnduceerd door endogeen progesteron en door de toediening van progestativa. 
Activatie van de progesteronreceptor door progesteron of progestativa wordt dan ook 
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beschouwd als de eerste stap in dit proces (Selman et al., 1994a; Mol et al., 1995 a,b; Mol et 
al., 1996; van Garderen et al., 1997). Bij de hond bereikt het mammaire GH de systemische 
circulatie, waardoor het beeld van hypersomatotropisme of acromegalie kan ontstaan (Selman 
et al., 1994b). Het plasma GH-profiel bij teven met progesteron-geïnduceerde acromegalie 
heeft geen pulsatiel karakter (Watson et al., 1987). Bovendien kunnen de plasma GH-
concentraties bij deze honden niet gestimuleerd worden met GHRH noch geremd worden met 
SS (Watson et al., 1987; Selman et al., 1991). Endogeen progesteron en synthetische 
progestativa zoals medroxyprogesteron acetaat (MPA) induceren de expressie van GH 
voornamelijk in het epitheel van de ductale, knopvormig uitgroeiende structuren van de 
melkklier tijdens de proliferatiefase. Dit suggereert dat lokaal geproduceerd GH de 
proliferatie van epitheel bevordert op een autocriene en/of paracriene wijze (van Garderen et 
al., 1997). Het lokaal gevormde GH speelt dus waarschijnlijk een rol bij de proliferatie en 
differentiatie van ductale structuren, waaruit uiteindelijk alveolair, secernerend klierepitheel 
ontstaat.  
Expressie van GH is ook aangetoond in goed- en kwaadaardige melkkliertumoren bij 
de hond (Mol et al., 1995a). GH-genexpressie is ook gevonden in fibroadenomateuze 
melkklierhyperplasie bij katten die behandeld waren met progestativa (Mol et al., 1995a). Bij 
deze diersoort lijkt het mammaire GH de algemene circulatie echter niet te bereiken. Ook in 
humaan onaangetast melkklierweefsel en in melkkliertumoren werd GH-expressie aangetoond 
(Mol et al., 1995a). Het GH-gen in melkklierweefsel en melkkliertumoren van mens en hond 
is identiek aan het gen coderend voor GH in de hypofysevoorkwab (Mol et al., 1995 a,b). 
Voor een overzicht van de effecten van progesteron en synthetische progestativa bij de teef, 
wordt de lezer verwezen naar hoofdstuk 2 van dit proefschrift. 
In overeenstemming met eerdere publicaties (Takahashi et al., 1981; French et al., 
1987; Kooistra et al., 2000) laten de in hoofdstuk 8 beschreven bevindingen zien dat bij de 
gezonde teef GH pulsatiel wordt afgegeven. Toediening van MPA gedurende 1 jaar 
resulteerde bij gezonde controlehonden in hogere basale plasma GH- en IGF-I-concentraties, 
hogere oppervlaktes onder de curve (AUCs) boven het nulniveau voor GH, en lagere AUCs 
boven de basaallijn voor GH (= minder GH afgegeven in pulsen) dan bij honden die een 
volledige mastectomie hadden ondergaan. De bevindingen bij de controlehonden zijn te 
verklaren door een negatieve terugkoppeling van progesteron-geïnduceerd mammair GH en 
de toegenomen plasma IGF-I-concentraties op de pulsatiele afgifte van hypofysair GH.  
In de anoestrusfase van de ovariële cyclus en vóór MPA-behandeling was het 
melkklierweefsel bij histologisch onderzoek inactief. Na 1 jaar MPA-behandeling was het 
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grootste deel van het mammaweefsel gedifferentieerd tot alveolair melk-secernerend 
klierepitheel, behalve bij één hond waarbij melkklierweefsel in de proliferatiefase werd 
gevonden. Het epitheel bij deze hond bestond uit ductale, knopvormig uitgroeiende 
structuren. Deze bevindingen zijn vergelijkbaar met de bevindingen in een eerder onderzoek 
bij honden (van Garderen et al.,1997). 
In de hondenmelkklier worden immunoreactief GH (iGH) en GH-genexpressie 
voornamelijk gevonden in ductale, knopvormig uitgroeiende structuren in de vroege en 
midluteale fase van de ovariële cyclus. GH-genexpressie neemt sterk af in gedifferentieerd 
alveolair secernerend klierepitheel en in de anoestrusfase van de ovariële cyclus (van 
Garderen et al., 1997). Ook in onze studie was geen iGH aantoonbaar in de melkklier van de 
honden in anoestrus vóór behandeling met MPA. Bij de controlehonden die gedurende 1 jaar 
zijn behandeld met MPA werd bij één hond iGH gevonden in het epitheel van ductale, 
knopvormig uitgroeiende structuren. 
RT-PCR-analyse, een veel gevoeliger techniek dan immuunhistochemie, liet zien dat 
onder invloed van de MPA-behandeling in het melkklierweefsel van de controlehonden de 
GH-genexpressie toenam en de GH-receptor (GHR)-genexpressie afnam. Ook in een andere 
studie werd een toegenomen concentratie GH-mRNA gevonden in de hondenmelkklier na 
langdurige toediening van progestativa (Mol et al., 1995a). Passend bij onze bevindingen is 
ook met immunohistochemisch onderzoek aangetoond dat de expressie van de GHR 
vermindert in gedifferentieerd alveolair secernerend klierepitheel op het einde van de luteale 
fase (van Garderen et al., 1999). 
Naast de effecten in de melkklieren, heeft het door progesteron-geïnduceerde 
mammaire GH mogelijk ook een endocrien effect op het baarmoederslijmvlies. Zo is door ons 
gepostuleerd dat het mammaire GH een rol speelt bij de ontwikkeling van cysteuze 
endometriumhyperplasie (CEH). Cysteuze endometriumhyperplasie wordt frequent 
waargenomen bij teven die herhaaldelijk zijn behandeld met progestativa ter preventie van de 
loopsheid (Capel-Edwards et al., 1973; Sokolowski en Zimbelman, 1973; Goyings et al., 
1977). CEH kan zich echter ook spontaan ontwikkelen gedurende de luteale fase van de 
ovariële cyclus bij teven van middelbare en hoge leeftijd. (Dow, 1958). Gezien de gelijkenis 
tussen de progesteron-geïnduceerde epitheliale veranderingen in de melkklier en de 
baarmoeder, kan de vraag gesteld worden of mammair GH ook betrokken is bij de 
ontwikkeling van progesteron-geïnduceerde CEH. Met immunohistochemie werd reeds GH 
aangetoond in uterusepitheel van honden die behandeld werden met progestativa. Echter de 
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afwezigheid van mRNA coderend voor GH suggereerde dat dit niet wordt aangemaakt in de 
uterus zelf (Kooistra et al., 1997).  
De bevindingen van het onderzoek beschreven in hoofdstuk 8 tonen aan dat bij beide 
groepen honden (controlehonden en gemastectomeerde honden) MPA-behandeling leidt tot 
uteriene veranderingen met macroscopische als microscopische kenmerken van CEH. In het 
uterusepitheel van beide groepen honden was ná MPA-behandeling immunoreactiviteit voor 
GH aanwezig, terwijl er vóór behandeling geen iGH was. Deze bevindingen tonen aan dat 
progesteron-geïnduceerd mammair GH geen essentiële rol speelt bij de ontwikkeling van 
CEH. Echter, de aanwezigheid van iGH in het cytoplasma van hyperplastisch uterusepitheel 
bij honden met CEH suggereert dat GH mogelijk wel betrokken is bij het ontstaan van CEH. 
Bij onderzoek met RT-PCR bleek dat na MPA-behandeling GH-mRNA alleen was 
toegenomen in het uterusepitheel van gemastectomeerde honden en niet bij de gezonde 
controlehonden. Vergelijkbaar met de progesteron-geïnduceerde GH genexpressie in de 
hondenmelkklier (van Garderen et al., 1997), leidde MPA-behandeling ook tot meer GH 
genexpressie in het uterusepitheel. Waarschijnlijk leidde bij de controlehonden de toename 
van de plasmaconcentraties van mammair GH en de daaruit voortkomende toename van 
plasma IGF-I-concentraties tot een onderdrukking van de GH-genexpressie, op eenzelfde 
manier als reeds aangetoond voor de hypofyse (Hartman et al., 1993). MPA-behandeling 
resulteerde ook in een toegenomen expressie van het IGF-I-gen in de baarmoeder, maar dit 
was alleen significant bij de controlehonden. Een verklaring hiervoor zou het stimulerend 
effect van de toegenomen plasmaconcentraties van mammair GH op de IGF-I-genexpressie 
kunnen zijn. MPA-behandeling stimuleerde de expressie van GHRn in uterusepitheel bij onze 
honden niet, waardoor het niet waarschijnlijk lijkt dat toename van de GHRn de aanwezigheid 
van iGH in uterusepitheel, zoals eerder gesuggereerd door Kooistra et al. (1997), zou kunnen 
verklaren 
In hoofdstuk 9 worden de effecten van MPA op de functie van de hypofysevoorkwab 
bij de teef beschreven. De effecten van supra-hypofysaire stimulatie, waarbij gebruik gemaakt 
werd van een gecombineerde functietest voor de hypofysevoorkwab (Meij et al., 1996), op de 
vrijstelling van zeven hypofysevoorkwabhormonen werd bestudeerd vóór MPA-toediening en 
op diverse tijdstippen tijdens een 1 jaar durende MPA-behandeling. Oestruspreventie door 
middel van MPA bij onze honden kon niet worden toegeschreven aan een significante afname 
van de plasmaconcentraties van follikelstimulerend hormoon (FSH) of LH. Sterker nog, 
MPA-behandeling werd zelfs gekenmerkt door een toename van de basale plasma FSH-
concentratie, zonder verandering van de basale plasma LH-concentratie gedurende de eerste 
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maanden van MPA-behandeling. Deze toegenomen basale FSH-concentratie zou het gevolg 
kunnen zijn van een direct remmend effect van MPA op het niveau van het ovarium, 
resulterend in een vermindering van de ovariële oestradiol- en/of inhibinesecretie of stimulatie 
van de activinevrijstelling (Couzinet en Schaison, 1993; Poindexter et al., 1993; Shupnik, 
1996; Heikinheimo et al., 1996). Bij voortgaande MPA-behandeling namen de basale FSH-
concentraties weer af tot hun niveau vóór MPA-behandeling, terwijl de hypofysaire FSH-
respons op supra-hypofysaire stimulatie daalde. Onderdrukking van de hypofysaire GnRH-
receptoren door continue GnRH-stimulatie zou hiervoor een verklaring kunnen zijn (Belchetz 
et al., 1978). 
Eerdere bevindingen toonden aan dat progestativa de GH-IGF-I-as (Eigenmann et al., 
1983; Selman et al., 1994b) bij de teef beïnvloeden, en dit werd bevestigd bij het onderzoek 
vermeld in hoofdstuk 9. Basale plasma GH-concentraties stegen geleidelijk gedurende de 1 
jaar durende MPA-behandeling, echter de stijging was niet statistisch significant. Concannon 
et al. (1980) vonden eerder dat plasma GH-concentraties niet significant stegen bij 27 van de 
36 MPA-behandelde honden. Echter, de significante stijging van circulerend IGF-I gedurende 
MPA-behandeling in ons onderzoek impliceert indirect de overmatige blootstelling aan GH 
(Selman et al., 1994b). Plasma IGF-I-concentraties lijken dus een meer gevoelige indicator te 
zijn dan plasma GH-concentraties voor het documenteren van de effecten van progestativa op 
de GH-IGF-I-as. 
Naast een interactie met de progesteronreceptor heeft MPA ook een relatief hoge 
affiniteit voor de glucocorticoïdreceptor (Selman et al., 1996). Onderdrukking van de 
hypothalamus-hypofyse-bijnierschors-as gedurende MPA-behandeling werd verwacht, 
aangezien dit eerder al aangetoond was bij de mens (Willemse et al., 1990) en de hond 
(Selman et al., 1994c, Selman et al., 1996). Echter, de resultaten van de studie beschreven in 
hoofdstuk 9 laten zien dat de effecten op de ACTH-secretie gedurende MPA-behandeling 
beperkt bleven. Aangezien de supra-hypofysaire stimulatie uitgevoerd werd ongeveer 4 
weken na injectie van MPA is het mogelijk dat de ACTH-synthese zich intussen had hersteld. 
De onderdrukking van de cortisolsecretie was evenwel meer uitgesproken en vergelijkbaar 
met resultaten in vorige studies (Selman et al., 1996). Blijkbaar was de onderdrukking van de 
ACTH-secretie sterk genoeg om aanleiding te geven tot atrofie van de zona fasciculata van de 
bijnierschors. 
De basale plasma TSH-concentraties waren 8 maanden na MPA-behandeling 
gestegen, maar ze bleven toch binnen de referentiegrenzen van ons laboratorium. Frank et al. 
(1979) vonden geen effect van MPA-behandeling op de circulerende TSH-concentratie. Men 
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zou kunnen veronderstellen dat MPA door de inherente glucocorticoïde werking een direct 
effect heeft op de schildklier (Kemppainen et al., 1983). Via terugkoppeling op de hypofyse 
zou dit een (lichte) stijging van de plasma TSH-concentraties tot gevolg kunnen hebben. 
MPA-behandeling veroorzaakte geen veranderingen in de secretie van PRL of α-
melanocyt-stimulerend hormoon. Een verklaring voor het uitblijven van een effect op de 
PRL-secretie gedurende MPA-behandeling zou de afwezigheid van een duidelijke afname van 
progestagene activiteit kunnen zijn. Van dergelijke abrupte dalingen is bekend dat ze leiden 
tot verhoogde afgifte van PRL (Galac et al., 2000). 
De aanwezigheid van progesteronreceptoren in de hondenmelkklier maakt het 
mogelijk om honden met progesteron-geïnduceerde mammaire GH-hypersecretie doelgericht 
te behandelen met progesteronreceptor-blokkers. De resultaten van het onderzoek beschreven 
in hoofdstuk 10 tonen aan dat toediening van de progesteronreceptor-blokker aglépristone 
aan honden met progesteron-geïnduceerd hypersomatotropisme leidt tot een significante 
daling van de plasma GH- en IGF-I-concentraties. Dit stemt overeen met de bevindingen van 
Watson et al. (1987) die bij honden met progesteron-geïnduceerde acromegalie vonden dat 
met de toediening van de progesteronreceptor-antagonist mifepristone de plasma GH-
concentratie significant daalde en de plasma IGF-I-concentratie normaliseerde. Bij analyse 
van het plasma GH-profiel bleek dat de gemiddelde basale GH-concentratie en de AUC boven 
het nulniveau voor GH bij onze honden met GH-overmaat op het einde van de behandeling 
met aglépristone gering waren afgenomen, vergeleken met deze waarden vóór 
aglépristonebehandeling. De AUC boven de basaallijn voor GH, dat is de hoeveelheid GH 
geproduceerd in pulsen, was aan het einde van de aglépristonebehandeling gestegen, hoewel 
niet significant. Dus, behandeling met aglépristone resulteerde in gedeeltelijk herstel van de 
normale pulsatiele GH-secretie. Een hogere dosis aglépristone zou mogelijk kunnen leiden tot 
complete normalisatie van het pulsatiele GH patroon.  
Drie en een half en 5,5 week na de laatste toediening van aglépristone namen de 
plasma IGF-I-concentraties weer toe; een teken van toegenomen blootstelling aan GH. De 
terugkeer van IGF-I hypersecretie na het stoppen van aglépristone-toediening was niet 
verbazingwekkend aangezien alle honden een depot-progesteronpreparaat toegediend hadden 
gekregen gedurende een periode van 1 jaar, en aangezien het progesteroneffect van dit 
preparaat veel langer is dan de duur van de aglépristone-behandeling in deze studie. Dit 
impliceert dat behandeling met een progesteronreceptor-antagonist zo lang moet duren als het 
te verwachten effect van het progestageen. 
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De volgende conclusies kunnen worden getrokken voor de hond: 
• Hypofyse-afhankelijk hyperadrenocorticisme gaat niet alleen gepaard met een afname van 
de afgifte van GH in pulsen, maar ook met een verminderde respons op GH-stimulantia. 
• Bij jonge honden is ghreline een potentere stimulus voor GH-afgifte dan GHRH en 
GHRP-6. Bij oude honden leidt GHRH-toediening tot hogere plasma GH-concentraties dan 
de toediening van ghreline of GHRP-6.  
• De ghreline-geïnduceerde GH-secretie neemt af met toenemende leeftijd; deze 
leeftijdsafhankelijke afname is veel lager bij toediening van GHRP-6 of GHRH.  
• Ghreline en GHRP-6 stimuleren specifiek de vrijstelling van GH en veroorzaken geen 
toename van de secretie van ACTH, cortisol, TSH, LH, of PRL. 
• Een ghreline-stimulatietest is een bruikbaar alternatief voor stimulatie met GHRH bij de 
diagnostiek van hypofysaire dwerggroei. 
• Vasten en voedselopname gaan gepaard met, respectievelijk, hogere en lagere 
circulerende ghrelineconcentraties. 
• De veranderingen in plasma ghrelineconcentraties gedurende voedselopname en vasten 
gaan niet gepaard met vergelijkbare veranderingen in de plasma GH-concentraties.  
• Gedurende vasten en voedselopname zijn de veranderingen in de circulerende insuline- en 
glucoseconcentraties omgekeerd aan de veranderingen in de plasma ghrelineconcentraties. 
• Bij gezonde controlehonden leidt toediening van medroxyprogesteron acetaat (MPA) tot 
een hogere basale plasma GH-concentratie en minder GH afgegeven in pulsen dan bij honden 
zonder melkklieren. Bij gemastectomeerde honden leidt behandeling met MPA niet tot een 
verandering van de basale plasma GH-concentratie, de AUC boven het nulniveau en boven de 
basaallijn voor GH, en de frequentie van de GH pulsen. 
• Zowel bij gezonde honden als bij gemastectomeerde honden ontwikkelt zich na 
behandeling met MPA cysteuze endometriumhyperplasie (CEH). Dus, progesteron-
geïnduceerd mammair GH speelt geen essentiële rol bij de ontwikkeling van CEH.  
• De aanwezigheid van immunoreactief GH in het cytoplasma van hyperplastisch 
baarmoederepitheel suggereert echter een rol van GH in de pathogenese van CEH. 
• Het effect van MPA op de secretie van gonadotrope hormonen blijft beperkt tot de FSH- 
secretie. Gedurende de eerste maanden leidt MPA-behandeling tot een toename van de basale 
plasma FSH-concentratie, terwijl de FSH respons op supra-hypofysaire stimulatie afneemt.  
•  Progesteron-geïnduceerd hypersomatotropisme kan met de progesteronreceptor-
antagonist aglépristone worden behandeld. 
Samenvatting en conclusies 
 
 
 285
Referenties 
Aimaretti G, Baffoni C, Broglio F, Janssen JA, Corneli G, Deghenghi R, Van Der Lely AJ, Ghigo E, 
Arvat E. Endocrine responses to ghrelin in adult patients with isolated childhood-onset growth hormone 
deficiency. Clin Endocrinol 2002;56:765-771. 
Aloi JA, Gertz BJ, Hartman ML, Huhn WC, Pezzoli SS, Wittreich JM, Krupa DA, Thorner MO. 
Neuroendocrine responses to a novel growth hormone secretagogue, L-692, 429, in healthy older subjects. J Clin 
Endocrinol Metab 1994;8:4249-4257. 
Arce V, Cella SG, Loche S, Ghigo E, Devesa J, Muller EE. Synergistic effect of growth hormone-
releasing hormone (GHRH) and clonidine in stimulating GH release in young and old dogs. Brain Res 
1990;537:359-362.  
Arvat E, Maccario M, Di Vito L, Broglio F, Benso A, Gottero C, Papotti M, Muccioli G, Dieguez C, 
Casanueva FF. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: 
comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. J Clin 
Endocrinol Metab 2001;86:1169-1174. 
Asakawa A, Inui A, Kaga T, Yuzuriha H, Nagata T, Ueno N, Makino S, Fujimiya M, Niijima A, Fujino 
MA, Kasuga M. Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin. 
Gastroenterology 2001;120:337-345.  
Belchetz PE, Plant TM, Nakai Y, Keogh EJ, Knobil E. Hypophysial responses to continuous and 
intermittent delivery of hypopthalamic gonadotropin-releasing hormone. Science 1978;202:631-633. 
Bowers CY, Newell D, Granda-Alaya R, Garcia M, Barrera C. Comparative studies on growth hormone 
release in younger and older men and women. In: Proceedings of the 74th Annual Meeting of the Endocrine 
Society 1992; p. 172. 
Bowers CY. Editorial: A new dimension on the induced release of growth hormone in obese subjects. J 
Clin Endocrinol Metab 1993;76:817-818. 
Broglio F, Arvat E, Benso A, Gottero C, Muccioli G, Papotti M, van der Lely AJ, Deghenghi R, Ghigo 
E. Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin 
secretion in humans. J Clin Endocrinol Metab 2001;86:5083-5086. 
Broglio F, Benso A, Castiglioni C, Gottero C, Prodam F, Destefanis S, GaunaC, Van der Lely AJ, 
Deghengi R, Bo M, Arvat E, Ghigo E. The endocrine response to ghrelin as function of gender in humans in 
young and elderly subjects. J Clin Endocrinol Metab 2003;88:1537-1542. 
Broglio F, Gottero C, Benso A, Prodam F, Destefanis S, Gauna C, Maccario M, Deghenghi R, van der 
Lely AJ, Ghigo E. Effects of ghrelin on the insulin and glycemic responses to glucose, arginine, or free fatty 
acids load in humans. J Clin Endocrinol Metab 2003;88:4268-4272.  
Burguera B, Muruais C, Penalva A, Dieguez C, Casanueva FF. Dual and selective actions of 
glucocorticoids upon basal and stimulated growth hormone release in man. Neuroendocrinology 1990;51:51-58. 
Caixas A, Bashore C, Nash W, Pi-Sunyer F, Laferrere B. Insulin, unlike food intake, does not suppress ghrelin in 
human subjects. J Clin Endocrinol Metab 2002;87:1902.  
Capel-Edwards K, Hall DE, Fellowes KP, Vallance DK, Davies MJ, Lamb D, Robertson WB. Long-
term administration of progesterone to the female beagle dog. Toxicol Appl Pharmacol 1973;24:474-488. 
Chaper 12 
 
 
286 
Casanueva FF. Physiology of growth hormone secretion and action. Endocrinol Metab Clin North Am 
1992;21:483-517. 
Ceda GP, Valenti G, Butturini U, Hoffman AR. Diminished pituitary responsiveness to GH-releasing 
factor in aging male rats. Endocrinology 1986;118:2109-2114. 
Cella SG, Moiraghi V, Minuto F, Barreca A, Cocchi D, De Gennaro Colona V, Reina G, Muller EE. 
Prolonged fasting or clonidine can restore the defective growth hormone secretion in old dogs. Acta Endocrinol 
1989;121:177-184. 
Cella SG, Arce VM, Pieretti F, Locatelli V, Settembrini BP, Müller EE. Combined administration of 
growth hormone-releasing hormone and clonidine restores defective growth hormone secretion in old dogs. 
Neuroendocrinol 1993;57:432-438. 
Cella SG, Locatelli V, Poratelli M, De Gennaro Colonna V, Imbimbo BP, Deghenghi R, Muller EE. 
Hexarelin, a potent GHRP analogue: interactions with GHRH and clonidine in young and aged dogs. Peptides 
1995;16:81-86. 
Chapman IM, Bach MA, Van Cauter E, Farmer M, Krupa D, Taylor AM, Schilling LM, Cole KY, 
Skiles EH, Pezzoli SS. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral 
administration of a GH secretogogue (MK-677) in healthy elderly subjects. J Clin Endocrinol Metab 
1996;81:4249-4257. 
Clark R. The somatogenic hormones and insulin-like growth factor-1: stimulators of lymphopoiesis and 
immune function. Endocr Rev 1997;18:157-179. 
Colombo M, Gregersen S, Xiao J, Hermansen K. Effects of ghrelin and other neuropeptides (CART, 
MCH, orexin A and B, and GLP-1) on the release of insulin from isolated rat islets. Pancreas 2003;27:161-166.  
Concannon PW, Altszuler N, Hampshire J, Butler WR, Hansel W. Growth hormone, prolactin, and 
cortisol in dogs developing mammary nodules and an acromegaly-like appearance during treatment with 
medroxyprogesterone acetate. Endocrinology 1980;106:1173-7.  
Conway S, McCann SM, Krulich L. On the mechanism of growth hormone autofeedback regulation: 
possible role of somatostatin and growth hormone-releasing factor. Endocrinology 1985;117:2284-2292.  
Corpas E, Harman SM, Pineyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing 
hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin 
Endocrinol Metab 1992;75:530-535. 
Couzinet B and Schaison G. The control of gonadotrophin secretion by ovarian steroids. Hum Reprod 
1993;8:97-101. 
Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS. A preprandial rise in 
plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001;50:1714-1719.  
Cummings DE, Foster-Schubert KE, Overduin J. Ghrelin and energy balance: focus on current 
controversies. Curr Drug Targets 2005;6:153-169.   
Dow C. The cystic hyperplasia-pyometra complex in the bitch. Vet Rec 1958;70:1102-1110. 
Egido EM, Rodriguez-Gallardo J, Silvestre RA, Marco J. Inhibitory effect of ghrelin on insulin and 
pancreatic somatostatin secretion. Eur J Endocrinol 2002;146:241-244. 
Samenvatting en conclusies 
 
 
 287
Eigenmann JE, Eigenmann RY, Rijnberk A, van der Gaag I, Zapf J, Froesch ER. Progesterone-
controlled growth hormone overproduction and naturally occurring canine diabetes and acromegaly. Acta 
Endocrinol (Copenh) 1983;104:167-176. 
Finkelstein JW, Roffwarg HP, Boyar RM, Kream J, Hellman L. Age-related change in the 24-hour 
spontaneous secretion of growth hormone. J Clin Endocrinol Metab 1972;35:665-670. 
Flanagan DE, Evans ML, Monsod TP, Rife F, Heptulla RA, Tamborlane WV, Sherwin RS. The 
influence of insulin on circulating ghrelin. Am J Physiol Endocrinol Metab 2003;284:313-316. 
Frank DW, Kirton KT, Murchison TE, Quinlan WJ, Coleman ME, Gilbertson TJ, Feenstra ES, Kimball 
FA. Mammary tumors and serum hormones in the bitch treated with medroxyprogesterone acetate or 
progesterone for four years. Fertil Steril 1979;31:340-346.  
French MB, Vaitkus P, Cukerman E, Sirek A, Sirek OV. Secretory pattern of canine growth hormone. 
Am J Physiol 1987;252:E268-E272. 
Galac S, Kooistra HS, Butinar J, Bevers MM, Dieleman SJ, Voorhout G and Okkens AC. Termination 
of mid-gestation pregnancy in bitches with aglepristone, a progesterone receptor antagonist. Theriogenology 
2000;53:941-950. 
Gelling RW, Overduin J, Morrison CD, Morton GJ, Frayo RS, Cummings DE, Schwartz MW. Effect of 
uncontrolled diabetes on plasma ghrelin concentrations and ghrelin-induced feeding. Endocrinology 
2004;145:4575-4582.   
Ghigo E, Arvat E, Gianotti L, Maccario M, Camanni F (1999) The regulation of growth hormone 
secretion. In: The endocrine response to acute illness, pp 152-175. Eds. RC Jenkins, RJM Ross. Karger, Basel: 
Frontiers of Hormone Research.  
Gill MS, Toogood AA, O'Neill PA, Thorner MO, Shalet SM, Clayton PE. Urinary growth hormone 
(GH), insulin-like growth factor I (IGF-I), and IGF-binding protein-3 measurements in the diagnosis of adult GH 
deficiency. J Clin Endocrinol Metab 1998;83:2562-2565. 
Giustina A and Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in 
experimental animals and the human. Endocr Rev 1998;19:717-797.  
Goyings LS, Sokolowski JH, Zimbelman RG, Geng S. Clinical, morphologic, and clinicopathologic 
findings in Beagles treated for two years with melengestrol acetate. Am J Vet Res 1977;38:1923-1931.  
Harding R, Leek BF. Central projections of gastric afferent vagal inputs. J Physiol 1973;228:73-90.  
Hartman ML, Clayton PE, Johnson ML, Celniker A, Perlman AJ, Alberti KG, Thorner MO. A low dose 
euglycemic infusion of recombinant human insulin-like growth factor I rapidly suppresses fasting-enhanced 
pulsatile growth hormone secretion in humans. J Clin Invest 1993;91:2453-2462.  
Hartman ML. Physiological regulators of growth hormone secretion. In: Growth hormone in adults. Eds 
A Juul and JOL Jorgensen. Cambridge University Press, UK, pp 3-53. 
Heikinheimo O, Gordon K, Williams RF, Hodgen GD. Inhibition of ovulation by progestin analogs 
(agonists vs antagonists): preliminary evidence for different sites and mechanisms of actions. Contraception 
1996;53:55-64. 
Hotta M, Shibasaki T, Masuda A, Imaki T, Sugino N, Demura H, Ling N, Shizume K. Effect of human 
growth hormone-releasing hormone on GH secretion in Cushing's syndrome and non-endocrine disease patients 
treated with glucocorticoids. Life Sci 1988;42:979-984. 
Chaper 12 
 
 
288 
Kamegai J, Wakabayashi I, Kineman RD, Frohman LA. Growth hormone-releasing hormone receptor 
(GHRH-R) and growth hormone secretagogue receptor (GHS-R) mRNA levels during postnatal development in 
male and female rats. J Neuroendocrinol 1999;11:299-306.  
Kamegai J, Tamura H, Shimizu T, Ishii S, Sugihara H, Wakabayashi I. Central effect of ghrelin, an 
endogenous growth hormone secretagogue, on hypothalamic peptide gene expression. Endocrinology 
2000;141:4797-4800.  
Kamegai J, Tamura H, Shimizu T, Ishii S, Sugihara H, Oikawa S. Effects of insulin, leptin, and 
glucagon on ghrelin secretion from isolated perfused rat stomach. Regul Pept 2004;119:77-81.  
Kelijman M. Age-related alterations of the growth-hormone/insulin-like growth factor-I axis. J Am 
Geriatr Soc 1991;39:295-307. 
Kemppainen RJ, Thompson FN, Lorenz MD, Munnell JF, Chakraborty PK. Effects of prednisone on 
thyroid and gonadal endocrine function in dogs. J Endocrinol 1983;96:293-302. 
Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-
releasing acylated peptide from stomach. Nature 1999;402:656-660. 
Kooijman R, Malur A, Van Buul-Offers SC, Hooghe-Peters EL. Growth hormone expression in murine 
bone marrow cells is independent of the pituitary transcription factor Pit-1. Endocrinology 1997;138:3949-3955. 
Kooistra HS, Okkens AC, Mol JA, van Garderen E, Kirpensteijn J, Rijnberk A. Lack of association of 
progestin-induced cystic endometrial hyperplasia with GH gene expression in the canine uterus. J Reprod Fertil 
Suppl 1997;51:355-361. 
Kooistra HS, Voorhout G, Mol JA, Rijnberk A. Combined pituitary hormone deficiency in German 
shepherd dogs with dwarfism. Domest Anim Endocrinol 2000;19:177-190. 
Lanzi R, Tannenbaum GS. Time course and mechanism of growth hormone's negative feedback effect 
on its own spontaneous release. Endocrinology 1992;130:780-788. 
Leal-Cerro A, Pumar A, Garcia-Garcia E, Dieguez C, Casanueva FF. Inhibition of growth hormone 
release after the combined administration of GHRH and GHRP-6 in patients with Cushing's syndrome. Clin 
Endocrinol 1994;41:649-654. 
Leal-Cerro A, Venegas E, Garcia-Pesquera F, Jimenez LM, Astorga R, Casanueva FF, Dieguez C. 
Enhanced growth hormone (GH) responsiveness to GH-releasing hormone after dietary restriction in patients 
with Cushing's syndrome. Clin Endocrinol 1998;48:117-121.  
Lee WM (2004). Growth hormone secretion in healthy and diseased dogs. Thesis Universiteit Utrecht. 
Lima L, Arce V, Diaz MJ, Tresguerres JA, Devesa J. Glucocorticoids may inhibit growth hormone 
release by enhancing beta-adrenergic responsiveness in hypothalamic somatostatin neurons. J Clin Endocrinol 
Metab 1993;76:439-444. 
Meij BP (1997). Transsphenoidal hypophysectomy for treatment of pituitary-dependent 
hyperadrenocorticism in dogs. Thesis Universiteit Utrecht. 
Meij BP, Mol JA, Hazewinkel HA, Bevers MM, Rijnberk A. Assessment of a combined anterior 
pituitary function test in beagle dogs: rapid sequential intravenous administration of four hypothalamic releasing 
hormones. Domest Anim Endocrinol 1996;13:161-170. 
Samenvatting en conclusies 
 
 
 289
Miell J, Corder R, Miell PJ, McClean C, Gaillard RC. Effects of glucocorticoid treatment and acute 
passive immunization with growth hormone-releasing hormone and somatostatin antibodies on endogenous and 
stimulated growth hormone secretion in the male rat. J Endocrinol 1991;131:75-86. 
Miura H, Tsuchiya N, Sasaki I, Kikuchi M, Kojima M, Kangawa K, Hasegawa Y, Ohnami Y. Changes 
in plasma ghrelin and growth hormone concentrations in mature Holstein cows and three-month-old calves. J 
Anim Sci 2004;82:1329-1333. 
Mol JA, van Garderen E, Selman PJ, Wolfswinkel J, Rijnberk A, Rutteman GR. Growth hormone 
mRNA in mammary gland tumors of dogs and cats. J Clin Invest 1995a; 95:2028-2034. 
Mol JA, Henzen-Logmans SC, Hageman P, Misdorp W, Blankenstein MA, Rijnberk A. Expression of 
the gene encoding growth hormone in the human mammary gland. J Clin Endocrinol Metab 1995b;80:3094-
3096.  
Mol JA, van Garderen E, Rutteman GR, Rijnberk A. New insights in the molecular mechanism of 
progestin-induced proliferation of mammary epithelium: induction of the local biosynthesis of growth hormone 
(GH) in the mammary glands of dogs, cats and humans. J Steroid Biochem Mol Biol 1996;57:67-71.   
Momany FA, Bowers CY, Reynolds GA, Chang D, Hong A, Newlander K. Design, synthesis, and 
biological activity of peptides which release growth hormone in vitro. Endocrinology 1981;108:31-39. 
Momany FA, Bowers CY, Reynolds GA, Hong A, Newlander K. Conformational energy studies and in 
vitro and in vivo activity data on growth hormone-releasing peptides. 
Muccioli G, Tschop, M, Papotti M, Deghenghi R, Heiman M, Ghigo E. Neuroendocrine and peripheral 
activities of ghrelin: implications in metabolism and obesity. Eur J Pharmacol 2002;440:235-254. 
Muller EE, Locatelli V, Cocchi D. Neuroendocrine control of growth hormone secretion. Physiol Rev 
1999;79:511-607.  
Nakamura S, Mizuno M, Katakami H, Gore AC, Terasawa E. Aging-related changes in in vivo release 
of growth hormone-releasing hormone and somatostatin from the stalk-median eminence in female rhesus 
monkeys (Macaca mulatta). J Clin Endocrinol Metab 2003;88:827-833. 
Nicolas V, Prewett A, Bettica P, Mohan S, Finkelman RD, Baylink DJ, Farley JR. Age-related decrease 
in insulin-like growth factor-I and transforming growth factor-B in femoral cortical bone from both men and 
women: Implications for bone loss with aging. J Clin Endocrinol Metab 1994;78:1011-1016.  
Niimi K, Krieg RJ Jr, Hanna JD, Santos F, Chan JC. Glucocorticoid-induced changes in the quantity 
and secretory capacity of individual rat somatotropes. J Am Soc Nephrol 1993;3:1428-1433. 
Ohyama T, Sato M, Niimi M, Hizuka N, Takahara J. Effects of short- and long-term dexamethasone 
treatment on growth and growth hormone (GH)-releasing hormone (GHRH)-insulin-like growth factor-1 axis in 
conscious rats. Endocr J 1997;44:827-835. 
Pavlov EP, Harman SM, Merriam GR, Gelato MC, Blackman MR. Responses of growth hormone (GH) 
and somatomedin-C to GH-releasing hormone in healthy aging men. J Clin Endocrinol Metab 1986;62:595-600. 
Peterson ME and Altszuler N. Suppression of growth hormone secretion in spontaneous canine 
hyperadrenocorticism and its reversal after treatment. Am J Vet Res 1981;42:1881-1883.  
Poindexter AN, Dildy GA, Brody SA, Snabes MC, Brodyand SA. The effects of a long-acting progestin 
on the hypothalamic-pituitary-ovarian axis in women with normal menstrual cycles. Contraception 1993;48:37-
45. 
Chaper 12 
 
 
290 
Reimer MK, Pacini G, Ahren B. Dose-dependent inhibition by ghrelin of insulin secretion in the mouse. 
Endocrinology 2003;144:916-921.  
Rijnberk A (1996). Hypothalamus-pituitary system. In: Clinical Endocrinology of Dogs and Cats, pp 
11-34. Ed. A Rijnberk. Dordrecht: Kluwer Academic Publishers. 
Render CL, Hull KL, Harvey S. Neural expression of the pituitary GH gene. J Endocrinol 
1995;147:413-422. 
Rudman D. Growth hormone, body composition and aging. J Am Geriatr Soc 1985;33:800-807. 
Rutteman GR, Stolp R, Rijnberk A, Loeffler S, Bakker JA, Bevers MM, Meulenberg PM, Eigenmann 
JE. Medroxy-progesterone acetate administration to ovariohysterectomized, oestradiol-primed Beagle bitches. 
Effect on secretion of growth hormone, prolactin and cortisol. Acta Endocrinol 1987;114:275-282.  
Saad MF, Bernaba B, Hwu CM, Jinagouda S, Fahmi S, Kogosov E, Boyadjian R. Insulin regulates 
plasma ghrelin concentration. J Clin Endocrinol Metab 2002;87:3997-4000. 
Schaller G, Schmidt A, Pleiner J, Woloszczuk W, Wolzt M, Luger A. Plasma ghrelin concentrations are 
not regulated by glucose or insulin: a double-blind, placebo-controlled crossover clamp study. Diabetes 
2003;52:16-20.  
Selman PJ, Mol JA, Rutteman GR, Rijnberk A. Progestins and growth hormone excess in the dog. Acta 
Endocrinol 1991;125(Suppl):42-47. 
Selman PJ, Mol JA, Rutteman GR, van Garderen E, Rijnberk A. Progestin-induced growth hormone 
excess in the dog originates in the mammary gland. Endocrinology 1994a;134:287-92. 
Selman PJ, Mol JA, Rutteman GR, Rijnberk A. Progestin treatment in the dog: I. Effects on growth 
hormone, IGF-I, and glucose homeostasis. Eur J Endocrinol 1994b;131:413-421. 
Selman PJ, Mol JA, Rutteman GR, Rijnberk A. Progestin treatment in the dog: II. Effects on the 
hypothalamic-pituitary-adrenal axis. Eur J Endocrinol 1994c;131:422-430. 
Selman PJ, Wolfswinkel J, Mol JA. Binding specificity of medroxyprogesterone acetate and 
proligestone for the progesterone and glucocorticoid receptor in the dog. Steroids 1996;61:133-7. 
Senaris RM, Lago F, Coya R, Pineda J, Dieguez C. Regulation of hypothalamic somatostatin, growth 
hormone-releasing hormone, and growth hormone receptor messenger ribonucleic acid by glucocorticoids. 
Endocrinology 1996;137:5236-5241. 
Shupnik MA. Gonadotropin gene modulation by steroids and gonadotropin-releasing hormone. Biol 
Reprod 1996;54:279-286.  
Sokolowski JH, Zimbelman RG. Canine reproduction: effects of a single injection of 
medroxyprogesterone acetate on the reproductive organs of the bitch. Am J Vet Res 1973;34:1493-1499. 
Sonntag et al., 1980 Sonntag WE, Steger RW, Forman LJ, Meites J. Decreased pulsatile release of 
growth hormone in old male rats. Endocrinology 1980;107:1875-1879. 
Sonntag WE, Steger RW, Forman LJ, Meites J. Decreased pulsatile release of growth hormone in old 
male rats. Endocrinology 1980;107:1875-1879. 
Soriano-Guillen L, Barrios V, Lechuga-Sancho A, Chowen JA, Argente J. Response of circulating 
ghrelin levels to insulin therapy in children with newly diagnosed type 1 diabetes mellitus. Pediatr Res 
2004;55:830-835. 
Samenvatting en conclusies 
 
 
 291
Sugino T, Hasegawa Y, Kikkawa Y, Yamaura J, Yamagishi M, Kurose Y, Kojima M, Kangawa K, 
Terashima Y. A transient ghrelin surge occurs just before feeding in a scheduled meal-fed sheep. Biochem 
Biophys Res Commun 2002;295:255-260.  
Sun YK, Xi YP, Fenoglio CM, Pushparaj N, O'Toole KM, Kledizik GS, Nette EG, King DW. The 
effect of age on the number of pituitary cells immunoreactive to growth hormone and prolactin. Hum Pathol 
1984;15:169-180.  
Takahashi Y, Ebihara S, Nakamura Y, Takahashi K. A model of human sleep-related growth hormone 
secretion in dogs: effects of 3, 6, and 12 hours of forced wakefulness on plasma growth hormone, cortisol, and 
sleep stages. Endocrinology 1981;109:262-272. 
Takahashi S, Kawashima S, Seo H, Matsui N. Age-related changes in growth hormone and prolactin 
messenger RNA levels in the rat. Endocrinol Jpn 1990;37:827-840. 
Takaya K, Ariyasu H, Kanamoto N, Iwakura H, Yoshimoto A, Harada M, Mori K, Komatsu Y, Usui T, 
Shimatsu A. Ghrelin strongly stimulates growth hormone release in humans. J Clin Endocrinol Metab 
2000;85:4908-4911. 
Tannenbaum GS, Ling N. The interrelationship of growth hormone releasing factor and somatostatin in 
generation of the ultradian rhythm of growth hormone secretion. Endocrinology 1984;115:1952-1957. 
Terzolo M, Bossoni S, Ali A, Doga M, Reimonda G, Milani G, Peretti P, Manelli F, Angeli A, Giustina 
A. Growth hormone (GH) response to GH-releasing hormone alone or combined with arginine in patients with 
adrenal incidentaloma: evidence for enhanced somatostatinergic tone. J Clin Endocriol Metab 2000;85:1310-
1315. 
Thakore JH and Dinan TG. Growth hormone secretion: the role of glucocorticoids. Life Sci 
1994;55:1083-1099. 
Thomas GB, Fairhall KM, Robinson ICAF. Activation of the hypothalamo-pituitary-adrenal axis by the 
Growth-Hormone (GH) Secretagogue, GH-Releasing Peptide-6, in rats. Endocrinology 1997;138:1585-1591. 
Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature 2000;407:908-913. 
Untergasser G, Kranewitter W, Schwarzler P, Madersbacher S, Dirnhofer S, Berger P. Organ-specific expression 
pattern of the human growth hormone/placental lactogen gene-cluster in the testis. Mol Cell Endocrinol 
1997;130:53-60.  
van Buul-Offers SC and Kooijman R. The role of growth hormone and insulin-like growth factors in the 
immune system. Cell Mol Life Sci 1998;54:1083-1094. 
van Garderen E, De Wit M, Voorhout WF, Rutteman GR, Mol JA, Nederbragt H, Misdorp W. 
Expression of growth hormone in canine mammary tissue and mammary tumors: Evidence for a potential 
autocrine/ paracrine stimulatory loop. Am J Pathol 1997;150:1037-47. 
van Garderen E, van der Poel HJ, Swennenhuis JF, Wissink EH, Rutteman GR, Hellmen E, Mol JA, 
Schalken JA. Expression and molecular characterization of the growth hormone receptor in canine mammary 
tissue and mammary tumors. Endocrinology 1999;140:5907-5914. 
Voss TC, Mangin TM, Hurley DL. Insulin-like growth factor-1 causes a switch-like reduction of 
endogenous growth hormone mRNA in rat MtT/S somatotroph cells. Endocrine 2000;13:71-79. 
Chaper 12 
 
 
292 
Wajchenberg BL, Liberman B, Gianella Neto D, Morozimato MY, Semer M, Bracco LO, Salgado LR, 
Knoepfelmacher M, Borges MHS, Pinto ACAR, Kater CE, Lengyel AMJ. Growth hormone axis in Cushing's 
syndrome. Horm Res 1996;45:99-107. 
Walker RF, Codd EE, Barone FC, Nelson AH, Goodwin T, Campbell SA. Oral activity of the growth 
hormone releasing peptide His-DTrp-Ala-trp-Dphe-Lys-NH2 in rat, dogs, monkeys. Life Sci 1990;47:29-36. 
Walker RF, Yang S-W, Bercu BB. Robust growth hormone (GH) secretion in aged female rats co-
administered GH-releasing hexapeptide (GHRP-6) and GH-releasing hormone (GHRH). Life Sci 1991;49:1499-
1504. 
Watson ADJ, Rutteman GR, Rijnberk A, Mol JA. Effects of somatostatin analogue SMS 201-995 and 
antiprogestin agent RU486 in canine acromegaly. Front Horm Res 1987;17:193-198. 
Watson S, Porter RJ, Young AH. Effect of hydrocortisone on the pituitary response to growth hormone 
releasing hormone. Psychopharmacology 2000;152:40-46. 
Wehrenberg WB, Baird A, Ling N. Potent interaction between glucocorticoids and growth hormone-
releasing factor in vivo. Science 1983;221:556-558. 
Wehrenberg WB, Bergman PJ, Stagg L, Ndon J, Giustina A. Glucocorticoid inhibition of growth in 
rats: partial reversal with somatostatin antibodies. Endocrinology 1990;127:2705-2708. 
Willemse PHB, Dikkeschei LD, Tjabbes T, Vanveelen H, Sleijfer DT. Adrenal steroids as parameters of 
the bioavailability of MA and MPA. Eur J Cancer 1990;26:359-62. 
Williams DL, Grill HJ, Cummings DE, Kaplan JM. Vagotomy dissociates short- and long-term controls 
of circulating ghrelin. Endocrinology 2003;144:5184-5187.   
Wilshire GB, Loughlin JS, Brown JR, Adel TE, Santoro N. Diminished function of the somatotropic 
axis in older reproductive-aged women. J Endocrinol Metab 1995;80:608-613. 
Wren AM, Small CJ, Ward HL, Murphy KG, Dakin CL, Taheri S, Kennedy AR, Roberts GH, Morgan 
DG, Ghatei MA, Bloom SR. The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone 
secretion. Endocrinology 2000;141:4325-4328.  
Wren AM, Seal LJ, Cohen MA, Brynes AE, Frost GS, Murphy KG, Dhillo WS, Ghatei MA, Bloom SR. 
Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 2001;86:5992.  
Yokoyama M, Nakahara K, Kojima M, Hosoda H, Kangawa K, Murakami N. Influencing the between-
feeding and endocrine responses of plasma ghrelin in healthy dogs. Eur J Endocrinol 2005;152:155-160.  
Zadik Z, Chalew SA, Mc Carter RJ Jr, Meistas M, Kowarski AA. The influence of age on the 24-hour 
integrated concentration of growth hormone in normal individuals. J Endocrinol Metab 1985;60:513-516. 
  

 295 
Dankwoord 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dankwoord 
 
 
296 
Dankwoord 
 
 
 297
 Het is me gelukt… Heel gelukkig ben ik en ook fier dat ‘mijn boekje’ nu naast dat van 
Sarne kan komen te staan in onze boekenkast. Een heleboel mensen - het is een onbegonnen 
taak om deze allen bij naam te noemen - hebben de voorbije jaren hun rechtstreekse of 
onrechtstreekse bijdrage geleverd aan het tot stand komen van dit proefschrift. Hierbij wil ik 
hen van harte danken. Tot een aantal personen wil ik graag een persoonlijk woordje van dank 
richten omdat ze één voor één, op hun eigen specifieke manier, voor mij heel wat hebben 
betekend. 
Dr. Hans Kooistra. Beste Hans, wat ben ik blij dat ik jou ontmoet heb en dat Luc en ik, 
zeven jaar geleden, naar Utrecht zijn ‘gereisd’ om samen op zoek te gaan naar een geschikt 
doctoraatsonderwerp. Ja, toen leek Utrecht nog ‘zo veraf’, ondertussen is het afleggen van de 
reis voor mij routine geworden. Het schrijven van een artikel werd me niet aangeleerd tijdens 
de opleiding tot dierenarts maar toch gaf je al erg positieve commentaar bij de eerste versie 
van mijn eerste manuscript. Je bent dit blijven doen en je bent me blijven stimuleren. Ook op 
momenten dat het wat minder goed ging, kon je me via een e-mail of een telefoongesprek 
weer volledig opbeuren! Hans, je bent op professioneel vlak echt te bewonderen en daarnaast 
maak je ook tijd voor Hilde, David en Roselinde. Met dit proefschrift wordt de goede 
samenwerking tussen Utrecht en Gent bevestigd. Ik ben ervan overtuigd dat we in de 
toekomst samen nog interessant wetenschappelijk werk kunnen verrichten!  
Prof. Dr. Rijnberk. Beste Ad, vanaf onze eerste gesprekken vertelde u mij dat ik u met 
uw voornaam mocht aanspreken maar ik heb het daar nog steeds moeilijk mee omdat ik 
enorm veel bewondering en respect voor u heb. U hebt me laten zien hoe boeiend 
endocrinologie is. Ik heb vele poliklinieken met u gevolgd en u hebt me ongelooflijk veel 
geleerd! U bent ondertussen op emeritaat, maar dit staat voor u niet gelijk aan het nemen van 
rust. Mijn manuscripten hebt u steeds heel nauwgezet gelezen en u gaf steeds opbouwende 
kritiek. Hartelijk dank daarvoor. Ik ben buitengewoon fier dat ik met zo een ‘groot man’, 
letterlijk en figuurlijk, heb mogen samenwerken. Ik wens u verder nog veel mooie momenten 
toe met uw echtgenote Carla en ik weet dat u uw taak als grootvader ook ter harte neemt. 
Geniet ervan! 
Prof. Dr. Van Ham. Beste Luc, een groot deel van mijn ‘diergeneeskundige carrière’ 
werd, in positieve zin, door jou beïnvloed. Als student had ik steeds veel ontzag voor het werk 
dat je deed in de neurologie en door jou werd mijn interesse voor deze discipline opgewekt. Je 
hebt me veel geleerd op professioneel vlak maar daarnaast heb je me ook veel levenswijsheid 
meegegeven en ben ik er zeker van dat je dat in de toekomst zult blijven doen. Sorry dat ik de 
laatste maanden niet meer kon bijspringen tijdens de consultaties. Je hebt daar eigenlijk nooit 
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een probleem van gemaakt omdat voor jou het afwerken van mijn doctoraat prioritair was. 
Dankjewel daarvoor! Het was niet altijd makkelijk voor jou om mijn manuscripten te lezen en 
te begrijpen omdat het niet echt jouw ‘ding’ was maar toch ben ik heel blij dat je mijn co-
promotor bent geweest. Ik wens je veel succes met je toekomstige taak als vakgroepvoorzitter 
maar ik ben ervan overtuigd dat je dit met enorm veel overgave zal doen. Ik hoop dat ik je 
hierbij kan helpen door opnieuw mijn taken in de kliniek op te nemen en je daardoor extra tijd 
te gunnen. 
Dr. ir. Mol. Beste Jan, op het gebied van de mammaire groeihormoonsecretie bij de 
hond bent jij zeker de expert. Bedankt dat je me in dit boeiende onderwerp wou begeleiden. 
Als clinicus was het niet altijd even makkelijk om je te begrijpen als je het had over 
‘GAPDH’, ‘cloneren en muteren’, ‘sequencen’, een ‘expressievector’, een ‘leesraam’ en 
dergelijke, toch heb je me samen met Frank in deze materie ingewijd. 
Prof. Dr. De Rick, ik wil u hierbij bedanken voor het vertrouwen dat u in mij stelde. 
Telkens weer was u enthousiast over de studies die ik uitvoerde met mijn Beagles en telkens 
weer heeft u me daarin de volledige vrijheid gegeven. U heeft me ook, samen met Luc, de 
mogelijkheid gegeven om mij het laatste jaar van mijn assistentschap zo goed als volledig 
terug te trekken uit de kliniek zodat ik mij voltijds kon bezighouden met het afwerken van 
mijn proefschrift. Uw taak als vakgroepvoorzitter is bijna volbracht en ik wens u alvast veel 
mooie momenten toe tijdens uw emeritaat.  
Prof. Dr. Duchateau. Beste Luc, de resultaten van een artikel kunnen pas goed 
geïnterpreteerd worden als ze ook statistisch geanalyseerd worden. Jij hebt me daarin op een 
voortreffelijke manier bijgestaan. Ook naar het einde toe, als het tempo wat hoger kwam te 
liggen, heb je mijn vele datasets snel verwerkt en als ik vragen had, en vaak waren dat er 
nogal veel…, kon ik ook onmiddellijk bij je terecht. Statistiek zal nooit mijn stokpaardje 
worden maar jij hebt me laten inzien dat het meer is dan alleen maar een P-waarde 
beoordelen. Ik vond het heel fijn om met jou samen te werken! 
Dr. Mulenda Tshamala. Beste Clément, uren heb je aan de operatietafel gestaan voor 
mijn onderzoek. Voornamelijk voor de mastectomieoperaties was er veel tijd en geduld nodig, 
iets wat ik aan niemand anders wou toevertrouwen dan aan jou. Merci beaucoup! 
Prof. Dr. Ducatelle, bedankt voor de professionele beoordeling van de histologische en 
immunohistochemische preparaatjes van de melkklieren en baarmoeders. Wat we onder de 
microscoop zagen was niet altijd wat ik verwacht had, maar dat hoort nu eenmaal bij 
wetenschappelijk onderzoek. Bedankt ook voor het filosoferen over bepaalde hypothesen. 
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Dr. Auke Schaefers-Okkens. Beste Auke, bedankt voor jouw professionele 
begeleiding van mijn proefschrift in de hoofdstukken die handelen over de voortplanting. Ook 
dank voor de gezellige sfeer op jullie kamer met lekkere thee en klassieke muziek op de 
achtergrond. 
Harry van Engelen. Beste Harry, ik weet echt niet wat ik moet zeggen om jou te 
bedanken! Jij hebt voor mij ongelooflijk veel werk verzet en je deed dit steeds met een 
enorme deskundigheid en enthousiasme, niets was jou teveel. Desondanks we bijna steeds 
tegen de klok werkten, bleef je altijd ijzig kalm, ook als het eens niet lukte om bloed te 
prikken of een intraveneuze katheter te plaatsen. Duizenden buisjes hebben we gevuld met 
bloed en die hebben we dan samen gepipetteerd. Ik had nooit gedacht dat ik dit zou schrijven 
maar eerlijk gezegd mis ik die tijd wel. Ook wil ik van de gelegenheid gebruik maken om 
jouw vrouw Henriëtte en jouw knappe dochters, Myrna en Birthe, te bedanken voor hun 
gastvrijheid! Als we in ons nieuw huis wonen dan moeten jullie zeker eens langskomen! En, 
… die Culemborgse Tompoezen wil ik toch graag nog eens proeven want die waren echt het 
einde! 
Mijn collega’s en goede vriendinnen van de dienst neurologie. Iris en Sofie, jullie ben 
ik ook enorm veel verschuldigd… Bedankt dat jullie van mij alle consultaties hebben 
overgenomen de laatste maanden. Vaak benijdde ik jullie als ik hier boven ‘opgesloten’ zat in 
mijn bureau en wou ik veel liever samen met jullie beneden het kliniekwerk doen. Misschien 
beseffen jullie dat niet maar jullie zijn onmisbaar geweest in de kliniek! Jullie werken met een 
enorme toewijding en dat wordt enorm geapprecieerd. Ook de vele babbeluurtjes die we 
hebben gehad en de etentjes samen hebben me enorm deugd gedaan. Iris, nu is het jouw beurt. 
Het is een moeilijke weg maar achteraf geeft het je enorm veel voldoening. Mijn hulp en 
steun krijg je zeker al! Valentine, ik ben blij dat je nu ook tot ‘onze groep’ behoort. Ik ben 
ervan overtuigd dat je het leuk zal vinden en dat je veel zal bijleren. 
Mijn collega’s van de dienst interne geneeskunde, wil ik hierbij ook zeker niet 
vergeten. Bedankt voor het overnemen van de patiënten endocrinologie. Jullie hebben me ook 
vaak uit de nood geholpen als enkele van mijn patiënten dringend deskundige hulp nodig 
hadden als ik weer geen tijd had om de hond of kat te onderzoeken.  
Beste Greet, we hebben elkaar vaak gebeld of gemaild en meestal beurden we elkaar 
dan op. Ik heb echt heel veel gehad aan onze gesprekken en aan jouw lieve oppeppende 
mailtjes. Bedankt daarvoor! Greet, voor mij ben je altijd een supergoede interniste geweest, ik 
ben ontzettend blij voor jou dat je jouw diploma hebt behaald en dat je nu "specialist" mag 
genoemd worden! Proficiat, ik wist dat het je zou lukken!  
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Beste Karin en Frank, wat een geluk heb ik gehad om jullie te ontmoeten. Bedankt 
voor jullie enorme gastvrijheid. Sarne en ikzelf hebben dat enorm geapprecieerd. Bedankt 
voor de lekkere maaltijden, de lekkere ‘koffie’s verkeerd’, de leuke gesprekken. Nu zijn jullie 
beiden aan de beurt en ik wens jullie alvast veel sterkte en succes toe.  
De medewerkers van de diverse laboratoria. Jeanette, Frank, Adri, Elpetra, Thea, wil 
ik van harte bedanken voor alle hormoonbepalingen. En het zijn er een hele hoop geworden! 
Ik was al blij dat Harry telkens de ganse lading met plasmastaaltjes bij jullie binnenbracht 
zodat ik dit niet zelf hoefde te doen… Frank, jij hebt me ook op sleeptouw genomen en me 
kennis laten maken met het cloneren. Ook over PCR analyse heb je me veel bijgebracht. Je 
hebt dit steeds met veel geduld en deskundigheid gedaan. Je bleef steeds vriendelijk, ook toen 
ik voor de zoveelste maal vergeten was het deksel op de centrifuge te plaatsen… Ik vond het 
erg fijn om met jullie samen te werken. 
De medewerkers van het labo pathologie. Isabelle, Christian, Delphine, Sara, jullie 
hebben met een enorme vakkundigheid van alle melkklier- en baarmoederstaaltjes 
histologische en immunohistochemische coupes gemaakt. Bedankt daarvoor! 
Niek, onze samenwerking was kort, maar wel krachtig. Je hebt met mijn data op korte 
termijn een mooi manuscript geschreven en in de toekomst zal je nog data van mij kunnen 
gebruiken voor het maken van een nieuw manuscript. Ik wens je veel succes met jouw 
onderzoek en kijk uit naar jouw promotie! 
De dierverzorgers. Geneviève, Stefaan en Eveline, ik zal nooit vergeten hoeveel hulp 
ik van jullie kreeg bij het verzamelen van de bloedstalen. Ook het verzorgen van mijn hondjes 
deden jullie heel nauwgezet, bedankt! 
Het zal waarschijnlijk vreemd lijken, maar toch wil ik al mijn Beagles bedanken: 
Pinschie, Wittie, Cherry, Droopy, Noesja, Kia, Dickie, Wiske, Angel, Jana, Kiki, Senta, 
Moussa, Magic, Mabish, Gini, Samba, Mango en Steffi. Zonder jullie was dit proefschrift er 
nooit gekomen. Ik had het er vaak moeilijk mee dat ik jullie ‘nodig’ had voor mijn onderzoek 
en er zijn vaak discussies geweest met de studenten over het feit dat ik jullie ‘gebruikte’. Mijn 
grootste voldoening haal ik uit het feit dat ik voor elk van jullie een mooie thuis heb kunnen 
vinden!  
Bedankt ook aan alle farmaceutische firma’s die mijn onderzoek en/of het drukken 
van dit proefschrift financieel ondersteund hebben. 
Mijn ouders en broer. Beste mama, papa en Karim, niemand kan een proefschrift 
schrijven zonder de steun van zijn of haar dichtstbijzijnde familie. En die steun heb ik van 
jullie gekregen. Het was altijd erg ontspannend om bij jullie thuis te komen. Ik ben er zeker 
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van dat jullie heel fier op me zijn. Ik hoop jullie leven nog rijker en boeiender te maken nu 
jullie oma, opa en oom zijn geworden en ik weet dat jullie enorm zullen genieten van dit 
kleine wonder! Mijn liefste Pablo, je bent er niet meer, maar jouw aanwezigheid en 
vriendschap zal ik nooit vergeten! Onze Sien heeft jouw taak nu gedeeltelijk overgenomen en 
dat doet me deugd.  
Mijn schoonouders. Beste Boelie en Paly, bedankt dat we altijd welkom waren bij 
jullie. Boelie, zelfs op onverwachte of onaangekondigde momenten wist je iets lekkers op 
tafel te toveren. Paly, bedankt voor de mooie cover van mijn proefschrift, ik wens je nog vele 
en inspiratievolle schilderuurtjes toe. 
Mijn schoonfamilie. Beste Petro, Raf, Rune en Mendel, bedankt voor alle gezellige 
momenten die we samen al beleefd hebben. Bedankt om ons op andere gedachten te brengen 
als we weer eens na een lange vermoeiende dag bij jullie binnensprongen.  
Liefste Sarne, dit proefschrift is aan jou opgedragen. Het beste wat me in mijn leven is 
overkomen is dat ik jou heb mogen ontmoeten. We zijn nu al meer dan 10 jaar samen en we 
hebben, samen met onze zoon Tuur, nog mooie jaren voor ons liggen. Het motto van jouw 
proefschrift was: “de weg om te slagen is moed houden en geduld, en stevig doorwerken” en 
dit heb ik steeds in gedachten gehouden. Sarne, ik zie je heel erg graag, bedankt voor jouw 
onvoorwaardelijke liefde. Ik ben blij dat ik je vrouw mag zijn. 
 
Sofie 
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Curriculum vitae 
Sofie Bhatti werd op 24 november 1973 geboren te Luik. Na het behalen van het 
diploma van hoger secundair onderwijs aan het Nieuwen-Bosch college te Gent, startte zij 
met de studies Diergeneeskunde te Gent. Het diploma van Dierenarts werd in 1998 behaald 
met grote onderscheiding. 
In juli 1998 trad de schrijfster in dienst bij de Vakgroep Geneeskunde en Klinische 
Biologie van de Kleine Huisdieren van de Faculteit Diergeneeskunde te Merelbeke. Zij 
werkte eerst als wetenschappelijk medewerker in de afdeling anesthesiologie en interne 
geneeskunde (1998-1999). Vanaf 1999 werd ze assistent bij de Vakgroep en ontwikkelde een 
bijzondere interesse in de endocrinologie en neurologie. In het jaar 2000 werden, in 
samenwerking met Prof. Dr. A. Rijnberk, Dr. H.S. Kooistra en Dr. J.A. Mol van het 
Departement Geneeskunde van Gezelschapsdieren van de Faculteit der Diergeneeskunde te 
Utrecht en Dr. L.M.L. Van Ham van de Vakgroep Geneeskunde en Klinische Biologie van de 
Kleine Huisdieren van de Faculteit Diergeneeskunde te Merelbeke, de eerste stappen gezet die 
geleid hebben tot dit proefschrift. In januari 2004 werd het getuigschrift van de 
Doctoraatsopleiding van de Faculteit Diergeneeskunde te Merelbeke verkregen.  
Sofie Bhatti was meerdere malen spreker op postuniversitaire studiedagen zowel in 
België als in Nederland. Zij is (co-)auteur van verscheidene publicaties in internationale en 
nationale tijdschriften en nam deel aan verscheidene nationale en internationale congressen. 
In het najaar van 2001 ontving ze de “Intervet Award” voor de beste wetenschappelijke orale 
presentatie op het 11de “ESVIM (European Society of Veterinary Internal Medicine) 
congress” te Dublin. In juni 2002 werd de auteur uitgenodigd om te spreken op het jaarlijks 
congres van de “ACVIM (American College of Veterinary Internal Medicine)” in Dallas, 
Verenigde Staten.  
De schrijfster is in 2003 getrouwd met Sarne De Vliegher en in 2006 moeder 
geworden van Tuur. 
 
Sofie Bhatti was born in Liége, Belgium, on November 24, 1973. After finishing her 
secondary school education (Nieuwen-Bosch college, Ghent), she started to study veterinary 
medicine at the Faculty of Veterinary Medicine at Ghent University (1992-1998).  
After graduation the author started to work at the Department of Small Animal 
Medicine and Clinical Biology at the Faculty of Veterinary Medicine in Merelbeke as full 
time scientific contributor in anaesthesiology and internal medicine (1998-1999). In 1999 the 
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author became assistant at the same department and developed a special interest in 
endocrinology and neurology. In the year 2000 the author started with the studies described in 
this PhD thesis, in collaboration with Prof. Dr. A. Rijnberk, Dr. H.S. Kooistra, and Dr. J.A. 
Mol from the Department of Clinical Sciences of Companion animals, Utrecht University, 
and Dr. L.M.L. Van Ham from the Department of Small Animal Medicine and Clinical 
Biology, Ghent University. 
Sofie Bhatti has been invited to speak on post university lectures in Belgium and The 
Netherlands. She is (co-)author of a number of publications in national and international peer-
reviewed journals and participated in several different national and international congresses. 
In 2001 the author received the “Intervet Award” for the best oral presentation at the 11th 
“ESVIM (European Society of Veterinary Internal Medicine) congress” in Dublin. In June 
2002 she was invited speaker at the annual congress of the “ACVIM (American College of 
Veterinary Internal Medicine)” in Dallas, United States.  
In 2003 the author married to Sarne De Vliegher and in 2006 she became mother of 
Tuur. 
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